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Breast cancer is a disease that has plagued many women globally. As the level of 
awareness for this mammary gland disorder is raised globally, more women are stepping 
forward to go for routine mammogram screening, implying a foreseeable surge in the 
number of breast cancer cases detected. Although the outcome need not be fatal, the 
physical, psychological and financial impacts inflicted extend beyond the patient. While 
advances in treatment are evolving at a rapid pace, mortality remains high. The rapid rise 
in incidence rate has prompted the rigorous search to understand its etiology and find 
better management strategies for this dreaded disease. Biomedical research has pointed 
towards a genetic origin in carcinogenesis, leading to a surge in experimental effort to 
uncover oncogenes responsible for this life threatening disease. 
Metallothioneins (MTs) belong to a superfamily of metal-binding proteins. In 
human, four classes of MTs are represented by 10 function isoforms, viz. MT-1A, 1B, 1E, 
1F, 1G, 1H, 1X, 2A, 3 and 4. Averaging 7 kDa in size, a single mammalian polypeptide is 
capable of binding 7 divalent cations through the 20 cysteine residues present and 
forming thiolate clusters. Inherently, MT binds to trace elements such as zinc and copper, 
as well as, cadmium and mercury toxic heavy metals. Dysregulation of MT has been 
associated with many diseases, including neurological disorders, cardiopathy, liver 
diseases and cancers. Previously, MT over-expression has been reported in many cases of 
breast cancers and the MT-2A gene, the most abundantly expressed isoform, has been 
implicated in tumourigenesis of the mammary glands. However, there is a paucity of 
information on the pathways regulated by this MT isoform in breast cancer. In this study, 
expression level of MT has been successfully silenced and up-regulated in MCF-7 breast 
 2 
cancer cells through RNA interference and stable transfected cell models respectively. 
These in vitro models demonstrated that over-expressing MT enhanced proliferative and 
migratory/invasive potentials of breast cancer cells, promoting a more aggressive 
phenotype. On the other hand, silencing the MT-2A isoform also induced a subset of 
MCF-7 cells to undergo entosis, manifesting a cell-within-cell feature. Internalized cells 
often underwent lysosomal degradation, supporting the notion that MT plays important 
role in the regulation of cell growth in breast cancers. 
  Through genomic analysis, candidate genes associated with MT manipulated 
expression were identified and the involvement of follistatin (FST), one of the candidate 
genes, was explored. Transwell and matrigel assays confirmed that MCF-7 cell displayed 
increased migratory and invasive capabilities after FST silencing. Along with other MT-
associated genes, namely KLK12, BCAT1, CXCL12, MEK5, MAOB, BCHE and COL3A1, 
these results previewed plausible interactions between MTs and their molecular partners 
that could impact tumour development in luminal epithelial cells.  
Moreover, evaluation conducted on clinical samples confirmed high levels of MT-
2A transcript observed in invasive ductal carcinoma correlated with the percentage of 
tumourigenic cells within the lesion and cancer staging. Furthermore, increased MT 
immuno-expression was separately found to be positively associated with histological 
grade and lymph node metastasis in tissue samples from female patients diagnosed with 
invasive ductal carcinoma. These results corroborate some of the in vitro findings and 
could substantiate the potential of MT to be a biomarker of tumour development and 



















































1.1 Gross anatomy of the breast and its development 
 
 The female breast is a highly complex and dynamic organ that undergoes 
numerous developmental stages throughout a woman‟s life. As a woman ages, her 
mammary glands are constantly subjected to different physiological factors during 
puberty, menstrual cycle, pregnancy and menopause. As such, its structural component 
such as glandular, fibrous and adipose tissues constantly changes from time to time, 
adapting to hormonal stimulus accompanying these developmental milestones. An 
anatomical representation of the female breast is depicted in Figure 1.1.  
 
Figure 1.1 Structure of the mammary gland 
Situated on the anterior portion of the chest wall, the mammary glands play the 
important role of providing nourishment for newborns. External features of the female 
breast comprises of the nipple, tubercles and a circular areola (Drake et al, 2005). The 
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nipple is mainly made up of skin and smooth muscle tissue, while the encircling areola 
contains numerous sebaceous and sweat glands. Internally, the breast parenchyma 
structure consists of approximately 20 lobes, each containing a milk duct that connects to 
the lobules adjoining the openings on the nipple. These lobules are surrounded by 
fibrovascular and adipose tissues for nutrition (Bland & Copeland, 2004; O'Malley et al, 
2006).  
Histologically, the lactiferous duct consists of a bilayered structure formed by an 
inner ring of cuboidal epithelial cells fenced by an outer layer of myoepithelial cells 
which was enclosed within a basement membrane. Contractility of myoepithelial cells 
facilitates the transport of milk to the nipple. These ducts terminate in the lobules, 
forming a terminal-ductal-lobular unit (TDLU) with associated acinar glands responsible 
for milk production (Dimri et al, 2005). The TDLUs in turn are embedded within a 
network of connective tissue, including fibrous and adipose tissue, nerves, blood, and 
lymphatic vessels for support and nutrients.  
Development of the mammary glands begins with the formation of milk ridges on 
the ventral surface of the fetus as early as 4th week of gestation. This is followed by the 
accumulation of epithelial cells at centre of the mammary ridge, forming the mammary 
bud. By the 6
th
 week, the fetus would have developed milk lines extending from the axilla 
to the both sides of the groin (Dawson, 1954). However, development of the milk line 
regresses except in the chest region whereby continuous growth is accompanied by the 
aggregation of mesenchymal cells around the bud, stimulating its outgrowth and 
sprouting to give rise to lobes. Subsequently the lobules by week 16 of gestation of the 
fetal mammary gland have the ability to secrete colostrum in response to maternal 
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hormones and prolactin in the final stage of mammary gland development (Howard & 
Gusterson, 2000; Mikkola & Millar, 2006). However, this capability is terminated with 
the post natal breast tissue reverting to its rudimentary state following withdrawal of 
maternal hormones after birth (Russo & Russo, 2004).  
As the female approaches puberty, the onset of circulating estrogen and 
progesterone will trigger changes in the previously quiescence mammary glands. As the 
breast enlarges, fat begin to accumulate and ductal elongation coupled with thickening 
occurred under the influence of estrogen and insulin-like growth factor 1 (Knight & 
Sorensen, 2001). Complex branching occurs in the ductal system, giving rise to TDLUs 
and smaller ductules (Russo & Russo, 2004). Small groups of cells will also form at the 
TDLUs to give rise to alveolar acini, responsible for colostrum secretion during lactation. 
Differentiation of the mammary gland takes course over the next few years as with each 
menstrual cycle until pregnancy, where the breast tissue will attain its full development 
(Russo et al, 2001).        
The breasts are considered fully developed after a woman has given birth and 
produced milk (Drife, 1986). During pregnancy, extensive glandular expansion occurs 
through terminal ducts and lobules undergoing further differentiation. The mammary 
glands grows rapidly in size with alveologenesis taking place, causing the lobules to 
enlarge and milk production begins (Lochter, 1998). This is a concerted effort of elevated 
estrogen and progesterone to promote ductal and lobule synthesis in conjunction with 
other hormones such as follicle stimulating hormones, prolactin, oxytocin, luteinizing 
hormone and human placental lactogen to induce the production of milk for breast 
feeding.    
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On the other hand, the dramatic decrease in estrogen production experienced 
during menopause lead to the gradual involution of lobules and subsequent replacement 
by adipose tissue. Eventually, shrinkage of the breast occurs with a loss in elasticity and 
shape.     
1.2 Breast cancer  
1.2.1 Classification of breast disorders 
As the mammary glands adapt to continuously changing microenvironment 
throughout a woman‟s life, abnormality occurs when hormones are dysregulated. 
Diseases associated with the breast are common and can be classified into many 
categories according to histological assessments, enabling proper treatment(s) to be 
administered to patients. Lesions of the mammary glands include benign disorders, in situ 
carcinoma and invasive carcinoma (Polyak, 2001; Seow et al, 2004).    
Benign breast disorders, such as fibrocytic disease, encompasses a collection of 
breast lesions typified by abnormal growth of cells. Harris et al have classified them into 
1) non-proliferative lesion, 2) proliferative lesions without atypical hyperplasia and 3) 
proliferative lesion with atypical hyperplasia according to the degree of cellular 
proliferation (Harris et al, 2004). Non-proliferative epithelial lesions include cysts, 
fibroadenomas, intraductal papilloma, fibrosis, and mastitis. These conditions generally 
do not associate with an increased risk of mammary gland tumour. While excessive 
proliferation of the luminal epithelium is the main cause of hyperplasia, this is a common 
breast disease found in women due to aging and hormonal fluctuation. Hence, 
proliferative lesions without atypia such as complex fibroadenoma, sclerosing adenosis, 
or solitary papilloma which are largely non-cancerous, do not significantly increase the 
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risk of these subsets of female patients developing carcinoma of the breast (Dupont & 
Page, 1985). Conversely, women suffering from proliferative atypical hyperplasia in the 
milk duct and lobules are at high risk of developing malignancy. Cytological and 
histopathological analyses of atypia usually demonstrate both elements of hyperplasia as 
well as carcinoma in situ and therefore heighten the probability of a cancerous outcome 
(Rosens, 2008 ). 
  
1.2.2 Non-invasive breast cancer 
    Breast cancer is a worldwide disease that plagues many women and is one of the 
leading causes of mortality (American Cancer Society, 2009). Most cases of breast cancer 
originate from epithelial cells, where they undergone transformation and grow 
uncontrollably into lump of cells. Some breast tumours are non-invasive in nature, where 
they are still kept within the confines of their origins. Commonly known as breast 
carcinoma in situ, two such forms of cancer exist in clinical setting, namely ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS, believed to be the 
precursor of invasive breast cancers, contains a mass of rogue luminal epithelial cells 
proliferating into hollow of the milk ducts. Cells of this pre-invasive form of breast 
malignancy do not penetrate the basement membrane and are usually contained within 
the tubular ductal system (Rosens, 2008 ). Although DCIS may originate from a single 
glandular unit, it is capable of spreading through the milk duct throughout the mammary 
gland. If left untreated, DCIS may give rise to invasive breast cancer when it infiltrates 
the surrounding tissues. DCIS represents a range of diseases and can be categorized into 
3 grades viz. low, intermediate and high. This grading system, based on morphological 
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growth pattern and cytological abnormalities, allows clinicians to predict the likelihood 
of disease recurrence and deterioration after local excision (Schwartz et al, 2000; Pinder, 
2010). With proper treatment, DCIS could be prevented from progressing to invasive 
ductal carcinoma. 
1.2.3 Invasive ductal carcinoma   
 Invasive ductal carcinoma (IDC) is the commonest form of breast cancer reported, 
accounting for 60-80% of all cases diagnosed (Rosens, 2008 ). It is typified by malignant 
cells invading into the surrounding breast stroma from the ducts and lobules that they 
derived from. Figure 1.2 illustrates the sequential oncogenic transformation of epithelial 
cells from the lumen of lactiferous duct into IDC.  
 
Figure 1.2 Oncogenic transformation of epithelium of the milk duct to ductal 
carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). (A) Cross-sectional 
representation of normal milk duct showing a bilayered orientation of luminal and 
myoepitheial cells. (B) Transformed luminal epithelial cells shed milk production duties 
and occupy the lumen. In DCIS, myoepithelial cells have altered expression of proto-
oncogenes that in turn propagate tumour cells (in grey). (C) A subset of cancerous cells 
which acquire invasive potential begin infiltrating through the basement membrane 
barrier and into surrounding breast stroma (in red).  Abbreviations: MEPC- myoepithelial 
cells; LEPC- luminal epithelial cells; TLEPC- transformed luminal epithelial cells; BM- 
basement membrane.   
Physically, the gross appearance of the cancerous lesion is usually fibrous, 
forming a solid lump. In certain instances, the carcinomas may have considerable degree 
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of elastosis demarcated by yellow streaks. Phenotypically, IDC are highly variable as 
aggressive tumour cells usually invade the stromal region in an irregular fashion with 
occasional traces of lymphoplasmacytic infiltrate detected.     
Heterogeneity of breast cancer has contributed to the complexity of this life 
threatening ailment as different patients demonstrate varying stages of neoplasia growth, 
infiltration and angiogenicity. Usually, the seriousness of this form of invasive breast 
cancer is examined clinically by pathologists to have a better understanding of state of 
disease within each patient according to histological parameters such as tumour size, 
tumour stage, histological grade, nuclear grade, hormonal receptors and proliferative 
capacity (Harris et al, 2004). Breast cancers are classified accordingly to the standards set 
by International Union against Cancer (UICC) and American Joint Committee on Cancer 
(AJCC). Based on the tumour-node-metastasis (TNM) system devised by French 
physician Pierre Denoix, this categorizing system takes into account the size of the 
primary tumour (T), the extent of axilary nodal metastases (N) and eventual distant 
metastases to other organs. Mammographic screening advances in molecular and 
immunohistological detection and neoadjuvant chemotherapy has greatly reshaped the 
methodology used in breast cancer staging and constant revisions were made to cater to 
evolving needs of breast cancer stricken individuals (Escobar et al, 2007; Jeruss et al, 
2008). The outcome of this stratification exercise will determine the treatment modality 
that the patient undergoes and prognosis from the disease. Principally, TNM staging can 
be classified as follow: 
Stage 0- Earliest form of breast cancer, where they are still localized within the lumen of 
the milk ducts and lobules without any signs of invasion. 
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Stage I- Cancer cells begin to infiltrate the normal neighbouring tissue, whereby tumour 
size does not exceed 2 centimeters and does not involve the lymph node. 
Stage II- Breast cancers are sub-categorized into IIA and IIB: 
 For IIA, i) cancerous cells are found in the axillary lymph node instead of the 
mammary gland OR ii) tumour measures ≤ 2 cm with ipsilateral nodal metastasis 
OR iii) size of the tumour is 2cm< x< 5cm without lymph node involvement.  
 For IIB, i) tumour size is 2cm< x< 5cm with lymph node metastasis OR ii) >5 cm 
without lymph node involvement.  
Stage III- Breast tumours are further divided into three sub-classes: 
 For IIIA, malignant cells are found clumped together or adhered to surrounding 
structures in the auxiliary lymph node or lymph node near to the breast bone 
instead of the mammary gland, OR ii) tumour measures ≥ 5 cm with ipsilateral 
nodal metastasis and found clumped together or attached to other structures. 
 For IIIB, i) tumour can be larger than 5 cm with cancerous cells metastasis to 
axillary lymph node and found clumped together or adhered to surrounding 
structures. In most cases, spread of cancer cells has extended to the chest wall 
and skin of the breast OR ii) identification of inflammatory breast cancer 
 For IIIC, i) tumour can be of any dimension showing concurrent metastases in 
lymph nodes above and below the collar bones, near the breast bones, axillary  
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lymph nodes, as well as chest wall and skin of the mammary gland even without 
being detected at the site of origin.  
Stage IV- Cancer cells has affected other organs, including the lungs, brain, bone and 
liver. 
 To better manage the disease, enhancement of the predictive capability of clinical 
and pathological staging is necessary. Hence, AJCC has recommended the grading of all 
invasive carcinomas to further delineate the subtypes that existed within invasive breast 
cancer category after staging (Thor, 2004). Histological grading estimates the extent of 
differentiation within the neoplastic establishments, looking out for microscopic growth 
and cytological traits. The Nottingham Combined Histological Grading system was 
adopted to measure the 1) degree of tubule formation, 2) the mitotic index and 3) nuclear 
pleomorphism of transformed cells (Elston, 2005). Each factor was ranked between 1 to 
3; 1-best whereas 3- worst of outcomes. The summation of the three scores would 
generate a Bloom-Richardson scoring criteria, where a low grade, well differentiated 
tumour (Grade I) would have a score between 3 to 5; intermediate grade breast tumour 
(Grade II) would be represented by a score between 6 to 7 and a score of 8 to 9 will 
accompany a poorly differentiated tumour (Grade III). The incorporation of a histological 
grading into diagnostic evaluation would assist the pathologist in predicting disease 
prognosis, recurrence, survival and patient assignment into appropriate treatment 
modality.      
 In addition to ductal carcinomas, special and less common classes of breast cancer 
constitute the remaining cases of breast neoplasm reported, namely Paget‟s disease, 
 13 
phyllodes tumour and inflammatory breast cancer (Karim et al, 2009; Roodman, 2010; 
Van Laere et al, 2010). As they represent a different etiology from ductal carcinoma 
examined in this study, they shall not be discussed in further detail.   
1.2.4 Epidemiology of breast cancers 
 According to the American Cancer Society, breast cancer is the second leading 
cause of cancer related death in female Americans (2009) after lung and bronchial 
cancers. Its annual report also estimated that approximately 192,370 and 62,280 new 
cases of female invasive breast cancers (IBC) and carcinoma in situ to be diagnosed 
respectively in the United States. These figures was ensued by the death tolls attributed to 
breast cancer forecasted to be 40,170 within the same year with IBS the major contributor 
of this high mortality rate. From 1975 to 2006, breast cancer incidence rate showed an 
increasing trend reflected by more women going for mammographic screenings coupled 
with a sharp decline in hormone replacement therapy (HRT) after the Women‟s Health 
Initiative citing prolonged usage as a possible risk factor for oncogenesis in the mammary 
glands for peri and postmenopausal women (50 to 69 years old) on HRT regime (Cui et 
al, 2009). Early detection and advances in breast cancer treatments has led to a steady 
decline in death rate in developed countries, from 36.2 per 100,000 in 1991 to 25.2 per 
100,000 cases reported in United States alone (Jemal et al, 2007).      
 In Singapore, breast cancer the most prevalent type of cancer reported in the 
female population (Seow et al, 2004). An interim report from the Singapore Cancer 
Registry also highlighted a similar scenario, where mammary gland tumours constituted 
29.3 % of all female cancer for the period between years 2003-2007 (Fig 1.3). It has an 
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age standardized incidence rate of 58.5 per 100,000 cases screened and its fatality was 
highest amongst all cancer related deaths registered in female Singaporeans (Singapore 
Cancer Registry, 2009). In general, an upward trend was observed with number of breast 
cancer cases detected within the duration from 1968 to 2002 (Seow et al, 2004). This was 
largely attributed to the increased awareness of the disease that led to the concomitant 
surge in mammography screening. Other underlying factors include rapid urbanization, 
where females adopt Western diet and lifestyle, as well as low and late parity (Rastogi et 
al, 2008; Verkooijen et al, 2009).     
 
Figure 1.3 Distribution of the top ten female cancers reported in Singapore. Data 
adopted from Singapore Cancer Registry Report Interim Report, trends in cancer 
incidence in Singapore, 2003-2007.  
1.2.5 Risk factors of breast cancers            
Given the widespread of breast cancer, the task to identify risk factors associated 
with tumourigenesis in the mammary gland has become of upmost importance. Research 
has revealed complex interplay of factors such as hormonal, reproductive, genetic, dietary 
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and other modifiable factors to culminate in the pathological outcome. Some of the 
known risk factors are as such:  
 Gender: Although not exclusive to women, gender difference does contribute to 
breast cancer susceptibility (American Cancer Society, 2009). The rare 
occurrence constitutes 1 % of all breast cancer detected, indicative that the male 
population is still susceptible to this disease as a result of structural similarity in 
breast tissue make-up in both males and females (Borgen et al, 1992; Fentiman et 
al, 2006). 
 Age: Women above the age of 50 years old constitute 45 % of the total breast 
cancer cases detected in Singapore and the risk of developing breast tumour 
heightens profoundly once they surpass 55 years old (Seow et al, 2004). While 
incidence rate remains low in women below 25 years of age, the risk doubles 
with every 10 years gained (McPherson et al, 2000).  
 Family history: Likelihood to develop breast cancer increase in females where 
there is a positive family history of the disease, particularly if they are first 
degree relatives of the patient(s) (Petrucelli et al, 2010). 
 Genetic predisposition: With reference to familiar breast cancers, inheritance of 
gene mutations was postulated to underlie the susceptibility. Mutation to the 
tumour suppressor BRCA gene is well studied in hereditary breast cancers, where 
women carrying the BRCA 1 mutation developed the disease before the age of 35 
while BRCA 2 deletion enhances the risk of breast neoplastic development by 45 
% (Ferla et al, 2007; Machackova et al, 2008). Other genes that are commonly 
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mutated in breast cancers include p53 tumour suppressor gene, phosphatase and 
tensin homologue (PTEN) and ataxia telangiectasia mutated (ATM).       
 Nulliparity and delayed child birth: A younger woman delivers her firstborn 
earlier is at a lower risk of developing breast cancer compared to her counterparts 
who has never given birth (Hahn & Moolgavkar, 1989). 
 Early menarche and delayed menopause: Women who experienced early 
menarche and late menopause are more prone to develop breast cancer due to 
prolong exposure to estrogen and progesterone ( Singletary, 2003; Dumitrescu & 
Cotarla, 2005).  
 Hormone usage: Breast cancer risk is elevated with the exposure to exogenous 
hormone practice. The use of contraceptives pills and HRT has been implicated 
to promote breast tumourigenesis (Alberg et al, 2000; Boyle, 2005). 
 Lifestyle: A woman‟s habitual inclination has a huge impact on the probability of 
developing breast cancer. Several risk factors such as diet, alcohol consumption, 
obesity and cigarette smoking have been linked to mammary gland tumuors. 
While a high fat diet laden with excessive alcohol intake has been proposed to 
promote breast cancer risk, this assumptions remained controversial due to the 
lack mechanistic explanation for their causative effects. ( Singletary & Gapstur, 
2001; Mazhar & Waxman, 2006). Obesity and accumulation of body fat in post 
menopausal women was believed to increase estrogen level in circulation and 
adopting a physically active lifestyle could counter this effect by attenuating 
body adiposity, bringing estrogen back to normal level ( Colditz et al, 2003; 
Boyle, 2005).       
 17 
1.2.6 Detection of breast cancer  
 No apparent symptoms can be derived from early stage breast cancer, where 
treatment has been proven to be most therapeutic. For this reason, women are advised to 
follow the recommendation to undergo breast examination and screening on a regular 
basis. Mammogram, self and clinical examination, ultrasound, biopsy, positron emission 
tomographgy (PET) and magnetic resonance imaging (MRI) are commonly employed for 
the detection of breast cancers. 
1.2.6.1 Mammography  
Mammographic screening has been proven to reduce mortality related to breast 
cancers (Smith et al, 2004). Due to its non-invasiveness and relative ease of use, it is 
routinely performed and has effectively diagnosed 64 % of breast carcinoma in its early 
stages (Ng et al, 1998; Tan et al, 1999). It was also found to be most beneficial to women 
with family histories of breast cancer (Kerlikowske et al, 1993). 
1.2.6.2 Self and clinical examination    
 Women are highly encouraged to perform regular self-examinations to detect any 
breast irregularity (Yip et al, 2008). They should be taught to look out for salient tell-tale 
features and apply the correct technique before they attempt this self-assessment method. 
If in doubt, they should always revert to clinical breast examinations performed by 
professional healthcare practitioners, usually paired with a mammographic screening to 






 Ultrasonography is a highly sensitive and widely used method in screening 
patients with palpable breast lesion. This diagnostic methodology is commonly used to 
guide fine needle aspiration and paired with mammography to enhance sensitivity of the 
detection (Benson et al, 2004). Ultrasound screening is more prevalently conducted for 
young women with high breast cancer risk as their mammary gland tissues are denser 
compared to older counterparts (Irwig et al, 2004).       
1.2.6.4 Biopsy 
 Biopsy and cytopathological examination, still considered “gold standards” in 
beast cancer diagnosis, are carried out using fine needle aspiration or core needle biopsy 
and evaluated for histopathologic and cytologic features associated with breast neoplasia 
(Ellis, 2010). Guided by ultrasound and mammography, needle-based biopsy has 
emerged an important detection tool for women with suspicious but non-palpable mass.    
1.2.6.5 Positron emission tomography 
  PET scanning is a visualization tool that exploits the glucose uptake by cancerous 
cells to generate 3 dimensional images after metabolizing the radioactive homologue of 
glucose, fluorodeoxyglucose (FDG) (Wahl et al, 1991). PET scanning was found to be 
remarkably sensitive and specific for detecting neoplastic breast lesions (Wahl et al, 
2004). 
1.2.6.6 Magnetic resonance imaging 
 Since the introduction of MRI for breast cancer screening in 1980s, it has been 
demonstrated to be more sensitive than mammography. The MRI was also effective in 
ruling out breast cancers in women with genetic predisposition and was recommended by 
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the American Cancer Society for women in the high risk group as an adjunct to annual 
mammographic screening after the age of 30 (Saslow et al, 2007).     
 
1.2.7 Treatments for breast cancers  
Typically, breast cancers are usually painless initially and the first tell tale sign 
occurs when a lump is felt in the chest region (Klein, 2005). Thickening in the breast 
areas could soon follow along with changes in size and shape of the breast as well as the 
nipple. Dimpling of the skin, rash and abnormal discharge from the nipple and sighting of 
lumps in the armpit region are other symptoms associated with carcinoma of the 
mammary glands (Barton et al, 1999).  
Current treatments for breast cancer include surgery, chemotherapy, radiotherapy, 
hormonal and targeted therapy. Depending on the clinical status of the patient, these 
treatment modalities would be used in combination to achieve maximum efficacy to 
combat this disease.   
 
1.2.7.1 Surgery 
 Surgery is the mainstream treatment for breast cancers and it encompasses 
lumpectomy and mastectomy. The type of surgical procedure to be performed largely 
depends on the size and distribution of the tumour, as well as the patient‟s wish. 
Lumpectomy involves the partial removal of breast containing tumour cells together with 
a rim of healthy cells surrounding the lesion (Khan & Eladoumikdachi, 2010). This 
procedure is suited for patients diagnosed with non-invasive ductal carcinoma and DCIS. 
On the other hand, mastectomy can be sub-classified into total and modified radical 
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mastectomies which are commonly practiced (Khan & Eladoumikdachi, 2010). While the 
former requires the whole breast tissue to be surgically removed, modified radical 
mastectomy involves axillary lymph node excision along with the whole mammary gland 
removal. Both regimes are followed on by post surgical radiation therapy.  
 
1.2.7.2 Radiotherapy 
 High beams of ionizing radiation are used to destroy cancerous cells by targeting 
their DNA and inhibiting cell division. As these transformed cells are defective in their 
DNA repair mechanism, they are less likely to recover from high energy beam treatment 
and cell death ensues. Radiation or radio-therapy is usually administered before surgery 
to limit tumour growth and post surgically to eradicate remnant cancerous cells. It is 
commonly used in combination after breast conserving lumpectomy and several studies 
have also reported on its effectiveness as a prophylaxis against local recurrence after 
surgery, thereby improving patients‟ survival (Clarke et al, 2005; Whelan & Levine, 
2005). Patients that do not qualify for surgical treatment are also placed on radio-therapy 
regimes. Technological advancement has improved the accuracy and specificity of 
radiation therapy, thus minimizing undesired side effects associated with previous radio 
therapeutic procedures such as drying, itching and blistering of skin at the affected site 
(Levin et al, 2005).  
 
1.2.7.3 Chemotherapy 
 Systemic therapy is generic term commonly used to describe biological, chemo 
and hormonal therapeutics used in breast cancer treatment. These agents can be 
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administered prior and post surgery and their efficacies has been demonstrated by Mauri 
and colleagues to be equally effective in limiting disease progression in spite of their 
point of introduction (Mauri et al, 2005).  
Chemotherapy can be administered intravenously or orally, depending on the 
nature of the drug and it is commonly use to target cancers that have metastasized from 
its site of origin (Findlay et al, 2008; O'Neill & Twelves, 2002). Personalization of the 
drugs regimens instituted must be considered due to the heterogeneous nature of breast 
cancers and patients‟ variable health conditions (McArthur & Hudis, 2007).  
Adjuvant chemotherapy given after surgical excision has been demonstrated to 
lower the risk of relapse in females suffering from breast cancers (Kelly & Hortobagyi, 
2010). These chemotherapeutics, when used in combination, has been validated to be 
more effective when used alone in breast cancer treatment (Hortobagyi, 1998; Kelly & 
Hortobagyi, 2010). In spite of this, the strategy of combining chemotherapeutic agents 
has yielded limited success such as cyclophosphamide-methotrexate-5-fluorouracil 
(CMF), doxorubicin and cyclophosphamide (DC) and 5-fluorouracil-adriamycin-
cyclophosphamide (FAC) combinations (Brennan et al, 2005).  
 
1.2.7.4 Endocrine therapy 
 Hormonal therapy can be considered for a sub-population of breast cancer 
stricken females if the tumours tested are estrogen/progesterone receptors positive. It is a 
form of systemic therapy and is well-established in treating this subset of breast cancers 
by interrupting hormonal activity and inhibiting its synthesis. Until recently, Tamoxifen 
is the most widely used drug in endocrine therapy, antagonizes estrogen binding to its 
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receptor that was responsible for inducing growth in ducts and lobules in the mammary 
glands (Weinberg et al, 2005). When given as neo-adjuvant or adjuvant therapeutics, it 
was proven to shrink the tumour and reduce recurrence in some cases of DCIS (Yuyama 
et al, 2000). 
The use of aromatase inhibitor to disrupt conversion of androgen to estrogen was 
an alternative approach to down regulate estrogen availability. Unlike Tamoxifen, this 
strategy is only applicable to post-menopausal women when active estrogen production 
ceases in the ovaries and various reports have confirmed its superiority over the gold 
standard Tamoxifen treatment (Bonneterre et al, 2000; Milla-Santos et al, 2003; 
Mouridsen et al, 2003).    
Other hormone directed therapies include the use of alternative selective estrogen 
receptor modulator (SERMs) like raloxifene and toremifene, estrogen down regulators 
(EDRs) and ovarian shut-down/ removals are available for clinical consideration 
(Weinberg et al, 2005). However, clinicopathological parameters should be evaluated 
before recommendation for endocrine therapy is made to breast cancer patients. 
 
1.2.7.5 Biological therapy    
 With improved understanding of breast cancer biology, novel therapeutics has 
been developed to combat breast cancers. The human epidermal growth factor receptor 2 
(HER2/neu) oncoprotein was found to be prevalently over-expressed and amplified in 20-
25% of breast cancers (Slamon et al, 1987; Slamon et al, 1989). This led to the inception 
of Trastuzumab or Herceptin, a humanized monoclonal antibody raised against HER2 
receptor, which was approved by Food and Drug Administration (FDA) for treatment of 
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HER2 over-expressing breast cancers (Chang, 2010). Trastuzumab binds to the 
extracellular domain of the HER2, thus limiting cell proliferation regulated this receptor-
linked PI3K/Akt activation. A large clinical trial conducted revealed benefits of 
Herceptin usage, including lowering risk of recurrence, cancer mortality and incidence of 
metastatic cancers (Viani et al, 2007). Bevacizumab or Avastin is another type of 
humanized antibody therapeutics that has gained FDA approval (Alvarez et al, 2010). 
Unlike Herceptin, Avastin recognizes vascular and endothelial growth factor (VEGF), 
responsible for angiogenesis in tumours. This acts to deprive the tumour mass of oxygen 
and nutrients needed to survive and proliferate. Both Herceptin and Avastin have been 
used in combination with other chemotherapeutics to improve remission from breast 
cancers.  
 Despite advances made in cancer treatment modalities, mortality remains high 
(Jemal et al, 2007). Given the heterogenous origins of breast carcinomas, there is a 
pressing need to look for novel target(s) or pathway(s) for therapeutic consideration to 
improve breast cancer management and overcome this dreaded disease. One such 
candidate might be metallothionein, where this family of metalloproteins was 
demonstrated to be consistently up-regulated in malignant ductal cells in previous studies 
(Ioachim et al, 2003; Jin et al, 2002; Sens et al, 2001).     
 
1.3 Metallothioneins             
1.3.1 Biology of Metallothioneins (MTs) 
 Since Margoshes and Vallee (1957) isolated MT from equine kidney more than 
50 years ago, this metal binding protein has been characterized as a low molecular 
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weight, water soluble and cysteine rich (30% cysteine residues by composition) 
polypeptide ( Margoshes & Vallee, 1957; Kagi & Valee, 1960). MT has the tendency to 
bind metallic cations such as zinc (Zn) and copper (Cu) in vivo, but it was its affinity 
towards cadmium that led to its discovery and its role as a metal detoxifying mediator 
when elevated level of this protein was found to accumulate in liver and kidneys of 
animals challenged with this heavy metal (Kagi & Vallee, 1961; Piotrowski et al, 1973). 
In addition, exogenous introduction of Cu and Zn can also induce the expression of MT, 
leading to the suggestion of its physiological responsibility to regulate the homeostasis of 
these trace elements (Davis & Cousins, 2000; Sato & Kondoh, 2002). Cellular expression 
of MT is intricately linked to cytosolic Zn concentration. Researchers have shown that a 
surge in cellular Zn has resulted in the up-regulation of MT at the transcript and protein 
levels in Rattus hepatocytes (Davis & Cousins, 2000). MT was also determined to be 
differentially regulated in respond to stress conditions associated with profound Zn 
fluctuations. These include events such as hypothermia and exercise, fasting and bacterial 
infections respectively (Yoshida et al, 2005; Ferencz & Hermesz, 2008; Emeny et al, 
2009; Ni et al, 2010). Glucocorticoids were found to be another potent inducer of MT, 
particularly dexamethasone. After binding to its receptor in the nucleus, dexamethasone 
is capable of promoting MT mRNA transcription, thereby increasing the formation of 
zinc-thionein and in turn triggering Zn uptake into the cell (Failla & Cousins, 1978; Karin 
et al, 1980; Karin & Herschman, 1981; Petering et al, 2006). Other glucocorticoids such 
as progesterone and aldosterone also bind to the same dexamethasone target site with 
different affinities to induce MT synthesis (Hernandez et al, 2000). 
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1.3.2 Structure of MT 
Structural analysis of MT demonstrated the existence of independent metal 
binding sites comprising cysteinyl residues responsible for cation binding ( Kagi & 
Schaffer, 1988; Carpene et al, 2007) Kojima and his co-workers first deduced the 
primary amino sequence of MT back in 1976, revealing an interesting feature of 20 
cysteine (Cys) residues arranged into 7 groups to accommodate metal ions in horse 
kidney (Kojima et al, 1976).  Within each group or thiolate clusters, these functionally 
important Cys molecules are arranged conspicuously in Cys-Cys, Cys-X-Cys and Cys-X-
X-Cys motifs, where X represent any other amino acids except Cys (Kagi & Schaffer, 
1988). Such a formation of Cys residues predisposes MT to bind metal ions and this 
feature is evolutionary conserved in mammalian MT. Besides having a high content of 
Cys, MT was found to be lysine rich while aromatic and histidine molecules were clearly 
absent from nuclear magnetic resonance spectrometry (Boulanger et al, 1982). Circular 
dichroism spectrometry showed that 1 MT molecule is capable of ligating up to 7 metal 
ions and has preferential affinities for cations in the following order Cu>Cd>Zn (Rupp & 
Weser, 1978). Conformation stability is conferred through Zn and Cu ligand binding 
while Winge and Miklossy uncovered the distribution of 3 and 4 thiolate clusters in 
respective N and C terminals of MT (Winge & Miklossy, 1982). A reconstructed figure 




Figure 1.4 A cartoon showing the 3-D representation of rat MT-2 isoform generated 
by Rasmol using 4mt2 Protein Data Bank entry. Each MT-2 polypeptide has a α–
domain and β–domain and is capable to bind up to 7 divalent cations through its Cys 
residues, forming the thiolate clusters. Cadmium ions are represented by white spheres 
whereas Zn ions are colored in grey.  
 
1.3.3 Metallothionein and cancers 
Since cancer is ultimately a disease of altered gene expression, researchers have 
also turned their attention to screening the entire human genome to identify candidate 
oncogenes that are responsible for neoplasm of the mammary gland. Biomarkers are 
molecules whose presence, absence and dysregulation are indicative of physiological 
abnormalities such as injuries and disease. Several potential biomarkers of breast cancers 
identified includes estrogen and progesterone hormonal receptors, B-cell lymphoma 2 
oncoprotein, cell-junction protein E-cadherin and MT (Cherian et al, 2003; Esteva & 
Hortobagyi, 2004; Giancotti, 2006; Nicolini et al, 2006).  
MTs are ubiquitous, low molecular weight (6-7 kDa) metal binding proteins. In 
humans, 10 functional MT isoforms are coded by genes located on chromosome 16q13, 
namely MT-1A, 1B, 1E, 1F, 1G, 1H, 1X, 2A, 3 and 4 respectively (West et al, 1990; 
Stennard et al, 1994; Mididoddi et al, 1996). Averaging 61-68 amino acids in length, this 
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group of highly conserved polypeptides binds to heavy metal such as zinc, copper and 
cadmium by virtue of the unique clusters of cysteine residues located within their equally 
sized globular domains (Kagi, 1991). Before 1987, most research were focused on the 
metallo-regulatory roles of MTs until Cherian and co-workers reported the expression of 
MT in thyroid cancer (Nartey et al, 1987). Since then, there has been extensive interest in 
the contribution of MT to processes linked to carcinogenesis, such as cell proliferation, 
differentiation, apoptosis and radio-chemoresistance (Kelley et al, 1988; Kagi, 1991; 
Satoh et al, 1994; Nagel & Vallee, 1995; Jayasurya et al, 2000a; Jayasurya et al, 2000b; 
Kling & Olsson, 2000; Cai & Cherian, 2003).  To date, over-expression of MTs has been 
well documented in tumours of the breast, prostate and colon (Nagel & Vallee, 1995; Jin 
et al, 1999; Sens et al, 2000; Yamasaki et al, 2007; Eckschlager et al, 2009; 
Gomulkiewicz et al, 2010).   
 
1.3.4 Expression of MT isoforms in breast tumours 
The majority of breast cancer research has centred on luminal epithelial cells as 
these are believe to be the progenitors of most carcinomas of the breast (Ronnov-Jessen 
et al, 1996; Wiechmann & Kuerer, 2008).  In healthy and non-neoplastic human breast 
tissue, MT expression is chiefly limited to myoepithelial cells that border their luminal 
neighbours within the bilayered milk duct (Fresno et al, 1993; Bier et al, 1994; Jin et al, 
2001b). Conversely, MT positivity and up-regulation were annotated in invasive ductal 
carcinomas and their stromal components, as opposed to other classes of breast 
malignancies, where either weak or negative MT staining was recorded (Fresno et al, 
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1993; Schmid et al, 1993; Bier et al, 1994; Dutsch-Wicherek et al, 2005; Gurel et al, 
2005). 
Due to the lack of a good antibody, studies pertaining to specific MT isoforms are 
usually carried out by quantifying the respective mRNA level via Reverse Transcription 
Polymerase Chain Reaction (RT-PCR), as well as in situ hybridization using gene 
specific primers and probes.  Studies employing these strategies showed that various MT 
isoforms were diversely and variably expressed in invasive ductal carcinoma (Sens et al, 
2001; Jin et al, 2002; Tai et al, 2003).  Although both MCF-7 and MDA-MB-231 breast 
cancer cell lines are of adenocarcinoma lineage, they have demonstrated distinct 
expression profiles for various MT isoforms.  This could suggest  the possibility of breast 
cancer cells altering their expression signatures for various isoforms of MT during 
tumour development and, in the case of MDA-MB-231, acquisition of invasive potential 
(Cherian et al, 2003). 
 Tissue specific isoforms such as MT-1B and MT-4 were notably absent in human 
breast cancer while low levels of MT-1A and 1H transcripts were detected in the breast 
cancer cell lines and tissue samples. A recent finding by Piotrowski and colleagues 
showed that hypermethylation of CpG islets was responsible for MT-1A down-regulation 
while PLU-1/JARID1B transcription repressor negatively regulated MT-1H (Piotrowski et 
al, 2006; Scibetta et al, 2007). Expression of MT-1G was exclusive to cancerous tissue in 
a study conducted by Tai et al in which they surmised that its expression was due to the 
presence of myoepithelial cells in the stroma, the only cell type known to react 
immunopositively to MT staining in normal breast ductal tissue ( Jin et al, 2001b; Tai et 
al, 2003; Gurel et al, 2005). MT-1E was found to be highly expressed in estrogen 
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receptor (ER) negative subset of invasive ductal cancer (Friedline et al, 1998; Jin et al, 
2000). Interestingly, MT-1F, 1X and 2A expression were detected in breast cancer cell 
lines and tissues, with MT-2A having the highest expression amongst all MT isoforms. 
Higher expression level of MT-2A was positively associated with aggressiveness of breast 
cancer, suggesting a role for MT-2A in breast cancer progression (Jin et al, 2002). MT-1F 
was up-regulated in advanced breast cancer whilst MT-1X expression was increased in 
breast cancer compared to prostate cancer (Jasani & Schmid, 1997; Jin et al, 2001a). MT-
3 was reported to be over-expressed in ductal carcinoma in situ (DCIS) and confirmed via 
RT-PCR and immunohistochemistry with a MT-3 specific antibody (Sens et al, 2001).  
 
1.3.5 Roles of MT isoforms in breast carcinogenesis 
Carcinogenesis is a multi-step process. Hanahan and Weinberg proposed that 
transformed somatic cells would require essential modifications to their cellular 
physiology coined as “hallmarks of cancers,” in order to achieve immortality and 
malignancy (Hanahan & Weinberg, 2000). In that review paper, alterations to pathways 
governing apoptosis and cell proliferation were described as common targets of most 
cancers in the quest to fulfill their tumourigenic agenda. MTs are well known to influence 
tumour growth by affecting key processes such as cell proliferation and apoptosis in 
cancer development (Kagi, 1991). The contributions of proto-oncogenic MTs to the 
manifestation of cancerous lesions of the breast are discussed below.  
Breast cancer exhibits differential expression of MT isoforms. As previously 
suggested by Cherian and colleagues, changes in expression profile of various isoforms 
may be attributed to alteration in proliferation or differentiation in the event of tumour 
A 
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progression (Cherian et al, 2003). Based on their findings, Jasani and Schmid also 
postulated that the differential expression of specific MT isoforms may hold the key to 
functional significance to of MT up-regulation in tumour tissue (Jasani & Schmid, 1997).  
Table 1 summarises the validated function(s) of individual isoforms in the context of 
breast cancer. 
In 2002, Jin et al observed the association of MT-2A with enhanced cell 
proliferation. Using double immuno-labelling and co-localization studies with Ki-67, a 
marker of cell proliferative activity, the investigators showed a positive correlation 
between increased MT-2A mRNA transcripts and cell growth. Conversely, a reciprocal 
study employing antisense oligonucleotide mediated MT-2A silencing performed by 
Abdel-Mageed and Agrawal led to growth arrest and apoptosis (Abdel-Mageed & 
Agrawal, 1997).  The same investigators also proposed that MT-2A interacted with NF-
kB, a transcriptional activator to bring about the cell proliferative effect (Abdel-Mageed 
& Agrawal, 1998). Other breast cancer related binding partners of MT include protein 
kinase Cµ and Rab3A GTPase (Knipp et al, 2005; Rao et al, 2003). 
As MT is a metallo-protein, other hypotheses on its cancer promoting effects, 
revolve around the affinity that MTs have for zinc. MTs could potentially disrupt p53 
function by chelating zinc, which is required for p53 structural stability (Fan & Cherian, 
2002). Regarded as the guardian of the genome, the anti-cancer apoptotic and 
transcriptional activities regulated by p53 could be impaired due to the formation of MT-
p53 complex (Ostrakhovitch et al, 2006). A downstream product of p53 regulation, it 
would seem rather contradictory of MT to destabilize p53 but the over-expression of MT 
as observed in breast cancers was found to be independent of p53 induction 
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(Ostrakhovitch et al, 2007). More studies are required to understand the mechanism and 
rationale underlying the dysregulation of MTs and provide further insights on neoplastic 
transformation of breast tissues. 





Level in Cells 
Expression 




MT-1A Low Low Down-regulated 
(Piotrowski et al., 2006) 
 
N/A 
MT-1B Absent Absent Unknown 
 
N/A 
MT-1E High and only in 
ER-/- cell line 
High Replace ER function 
(Jin et al., 2000) 
 
Poor 
(Jin et al., 2000) 
MT-1F Moderate Moderate Tumour Differentiation 
(Jin et al., 2001a) 
 
Poor 
(Jin et al., 2001a) 
MT-1G Only in 
myoepithelial cells 
 
Low Unknown N/A 
MT-1H Low Low Down-regulated 
(Scibetta et al., 2007) 
 
N/A 
MT-1X Low Low Unknown 
 
N/A 
MT-2A Highest Highest Cell proliferation, Interact with 
NFkB (Jin et al., 2002), 
 
Disrupts p53 
(Fan and Cherian, 2002) 
 
Poor 
(Jin et al., 2002) 
MT-3 Absent High Disrupts p53 
(Sens et al., 2001) 
 
Poor 







(Jin et al, 2001a) 
N/A 
 
Expression levels of MT isoforms were semi-quantitated via Reverse Transcription 
Polymerase Chain Reaction. References are represented by numbers in brackets. All 
expression data were derived from Tai et al (2003) unless otherwise stated.  
Abbreviation: ER-estrogen-receptor, N/A- not applicable. 
 
On the other hand, MT-Zn could also function as an intracellular reservoir for Zn 
proteins that regulate cell proliferation, which include ER and transcription factor IIIa 
(Cano-Gauci & Sarkar, 1996; Jacob et al, 1998; Huang et al, 2004). There is a strong 
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association between ER status and MT-1E expression in breast carcinoma, with a high 
proportion of ER negative cancers displaying higher MT-1E transcript expression 
(Friedline et al, 1998; Jin et al, 2000). It has been suggested that MT-1E may serve as a 
replacement to carry out functions of ER in the ER-null state (McKenzie & Sukumar, 1996; 
Yaziji et al, 2000).  
Even though the majority of available literature appears to associate MT over-
expression with less favourable outcomes in invasive ductal breast cancers, Gurel et al 
reported that over-expression of MT-3 in selective breast cancer cell lines devoid of this 
isoform showed growth inhibition (Gurel et al, 2003). This counter-proliferative trait is 
unique to MT-3 despite sharing 70% homology with MT-1/MT-2 and is most probably 
linked to the growth inhibitory property of MT-3 previously established in murine neural 
cells ( Uchida et al, 1991; Tsuji et al, 1992; Amoureux et al, 1995; Sewell et al, 1995).  
Preventive measures have also been incorporated within the micro-environment 
of acinar milk ducts to deter epithelial cells from undergoing oncogenic transformation. 
Myoepithelial cells (as shown earlier in Figure 1.2) , the effector cells responsible for this 
mechanism, may be the first line of defence to keep luminal cells in check in addition to 
their milk ejection role (Hamperl, 1970). Tumour suppressing capabilities of these cells 
including perturbation to key processes such as angiogenesis and cell invasion, as well as 
induction of G2/M growth arrest, have been shown in vitro (Sternlicht et al, 1996 Shao et 
al, 1998; Nguyen et al, 2000). During the course of carcinogenesis, micro-evolution in 
cancerous breast tissue could result in adenocarcinoma cells assuming a myoepithelial 
phenotype, evident by anomalous MT expression, and subsequently overwhelming their 
myoepithelial counterparts (Jin et al, 2001b; Adriance et al, 2005). Loss of myopeithelial 
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cells, particularly their tumour suppressive functions, coupled to the mimicry to secrete 
myoepithelial- related onco-proteins may provide a competitive edge for these rogue 
epithelial cells to thrive and metastasize (Weaver et al, 2002).  
 
1.3.6 Association of MT isoforms with pathological parameters and prognostication  
Higher MT expression in breast cancers has generally been shown to predict 
worse survival for patients (Vazquez-Ramirez et al, 2000; Zhang et al, 2000; Ioachim et 
al, 2003). This implies that MT may have putative prognostic utility in breast tumors. 
Early studies conducted in pT2 invasive ductal breast carcinoma indicated that increased 
MT expression is associated with poorer prognosis and shorter disease-free survival 
period (Schmid et al, 1993; Goulding et al, 1995).  
Conventionally, histological grade has always been an essential criterion in 
pathological assessment of invasive ductal carcinoma. Bay and his co-workers have 
established the association between high expression of MT-1F and MT-2A isoforms with 
histological grade 3 invasive ductal carcinoma, indicating a poorer survival rate (Jin et al, 
2001b; Jin et al, 2002). The poor patient outcome is not surprising given the ability of 
MT to promote metastasis and cell proliferation (Schmid et al, 1993; Vazquez-Ramirez et 
al, 2000; Jin et al, 2002). Similarly, over-expression of MT-3 isoform was strongly 
associated with poor prognosis in DCIS (Sens et al, 2000). On the contrary, several 
investigations have shown that MT expression does not correlate with clinico-
pathological parameters such as age, tumour size or lymph node metastasis significantly 
(Fresno et al, 1993; Goulding et al, 1995; Oyama et al, 1996; Jin et al, 2002;).  
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In breast cancer therapy, the hormonal status of the cancerous tissue is critical in 
chemo-therapeutic assignment. ER-positive cancers receiving adjuvant tamoxifen 
treatment is less likely to suffer a relapse compared to ER-negative counterparts (Duffy, 
2001). Since high MT-1E expression is inversely related to ER positivity, screening for 
MT-1E could potentially strengthen the prediction of tamoxifen responsiveness in breast 
cancer treatment now that MTs have been proven to mediate tamoxifen resistance 
(Surowiak et al, 2005).  
Radio and chemo- resistance are major factors contributing to poor prognosis and 
MTs are believed to be key mediators. High levels of MTs were cited to confer resistance 
to radiation and anti-neoplastic drugs by sequestration of free-radicals, drugs and their 
metabolites, thereby reducing the efficacy of these therapeutic regimes (Yang et al, 1994; 
Cherian et al, 2003). Genomic analysis has singled out MT-2A as the culprit mediating 
resistance towards the novel anti-cancer drug, gallium nitrate, in lymphoma (Yang et al., 
2007).  In a separate study, Yang and his co-workers verified the involvement of MT-2A 
in cisplatin resistance (Yang et al, 1994). Given that its expression is the highest in most 
invasive ductal carcinoma, MT-2A‟s role in chemoresistance remains to be elucidated and 
reinforces its candidature as a biomarker of prognosis in breast tumour.   
 
1.4 Scope of Study 
 Previous studies have documented the relationship of dysregulated MT expression 
in breast cancers. While its roles in breast tumourigenesis remain unclear, MT over-
expression has been reported to promote cell proliferation, disrupt p53 stability and 
predict drug resistance in breast cancers (Fan & Cherian, 2002; Jin et al, 2002; Yap et al, 
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2009). Up-regulation of MT was also postulated to be responsible for an aggressive 
phenotype and poor prognosis in breast cancer (Bay et al, 2006; Jin et al, 2002; Sens et 
al, 2001). Given the importance of aberrant MT expression towards tumour progression 
in the mammary gland, there is a paucity of information on the mechanisms underlying 
MT‟s contribution.  
The hypothesis of this study is that MT expression in breast cancer cells is 
associated with breast carcinogenesis, particularly cell proliferation and metastasis. A 
double prong approach of over-expressing and silencing of the MT-2A isoform, the most 
abundantly expressed isoform in breast cancer, was performed in MCF-7 cells to verify 
its influence on growth rate, migration and invasion in vitro. Genomic analysis was also 
performed to screen for gene associated with MT expression and elucidate their 
contributions towards oncogenic transformation in luminal epithelial cells in conjunction 
with MT. These relationships would be further validated with clinocopathological 
parameters in tissue samples of invasive ductal carcinoma origin to demonstrate their 
clinical relevance.  
Therefore, the objectives for this present study are as follow: 
1. To generate a stable-transfected cell line that constitutively over-expresses the 
MT-2A isoform in MCF-7 breast cancer cells for studying phenotypic and 
functional effects related to elevated level of this MT isoform. 
2. Down-regulate MT-2A expression in the corresponding MC-7 cells via RNAi 
pathway for observation of reciprocal effects. 
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3. cDNA microarray screening for MT related genes in breast cancer cells after MT 
silencing and over-expression respectively and validating their expressions via 
real-time PCR and Western blot.   
4. Immunohistological examination of MT expression in breast cancer with 
associated clinicopathological parameters using tissue microarray panels from 







































































2. Materials and Methods 
 
2.1 Antibodies and Reagents 
 
 Monoclonal E9 mouse antibody recognizing the common epitope between MT-1 
and MT-2 isoforms was purchased from Dako Corporation Carpinteria (Carpentaria, CA, 
USA). Anti-human FST antibody raised in goat was obtained from R&D Systems 
(Minneapolis, MN, USA) while antibodies targeting β-catenin, MEK1, MEK2, ERK1, 
ERK2, ERK (pan) and MEK5 were obtained from BD Transduction Laboratories 
(Franklin Lakes, NJ, USA). Horse Radish Peroxidase conjugated secondary antibodies 
with affinity towards murine and goat antibodies for Western Blot application were 
purchased from GE Ambersham (Piscataway, NJ, USA) and Abcam (Cambridge, MA, 
USA) respectively whereas TRITC conjugated to Phalloidin from Amanita phalloides 
(Sigma Aldrich, Saint Louis, MO, USA) was used to aid visualization of filamentous 
actins under fluorescence microscopy. FITC-conjugated-CD24 and PE- conjugated-CD44 
specific antibodies from purified from mouse hosts were purchased from BD Pharmigen 
(Franklin Lakes, NJ, USA).  
 To test cell viability, alamarBlue cell viability reagent (Invitrogen, Carlsbad, CA, 
USA) and a MTT based assay using CellTiter 96 Non-radioactive Cell Proliferation 
Assay (Promega, Madison, WI, USA). Transfection reagent Lipofectamine 2000 was 
purchased from Invitrogen and 4‟, 6-diamidino-2-phenylindole (DAPI) used to illuminate 
the nucleus under fluorescence microscopy was obtained from Invitrogen. All other 




2.2 Cell Culture 
2.2.1 Maintenance of cell culture  
Cell lines of breast luminal origins MCF-12A (CRL-10782), MCF-7 (HTB-22), 
ZR-75 (CRL 1500), MDA-MB231 (HTB-26), T47D (HTB-133) were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, USA). MCF-12A is a cell 
line isolated from a nulliporous patient diagnosed with fibrocystic breast tissues after 
reduction mammoplasty (Paine et al, 1992; Pauley et al, 1993) These spontaneously 
immortalized, non-tumorigenic cells were cultured in a 1:1 mixture of Dulbecco‟s 
modified Eagle medium (DMEM) and Ham‟s F12 medium supplemented with 5% fetal 
calf serum (Hyclone, Logan, UT, USA), 20ng/ml Human epidermal growth factor, 100 
ng/ml cholera toxin, 0.01 mg/ml bovine insulin, 500 ng/ml hydrocortisone and 40µg/ml 
gentamicin (Invitrogen). The main breast cancer cell line used in this study, MCF-7, was 
isolated from the pleural effusion of a Caucasian woman who had two mastectomies in a 
five year span (Dickson et al, 1986). The woman was found to be suffering from benign 
tumour in the first mastectomy, malignant adenocarcinoma in the second mastectomy and 
pleural fluid of the patient eventually (Dickson et al, 1986). Highly invasive MDA-
MB231 cells were derived from adenocarcinoma of the breast from another 51-year old 
woman of Caucasian origin whereas ZR-75 and T47D are epithelial cells isolated from 
ductal carcinoma of the lactiferous ducts (Cailleau et al, 1978; Engel et al, 1978; Keydar 
et al, 1979). MCF-7 cells were routinely maintained in DMEM culture medium 
supplemented with 10% fetal bovine serum (FBS) without antibiotics. T47D, MDA-
MB231 and ZR -75 were cultured in RPMI medium supplemented with 10% FBS. The 
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cells were routinely inspected under light microscope to check for morphological changes 
during maintenance.  
Cell were constantly passaged at subconfluency and kept at 5% carbon dioxide 
environment within an incubator maintained 37
o
C. Cell monolayer was dislodged using 
0.25% trypsin in 1X PBS. For seeding, cells were centrifuged at 125 g before 
resuspension in complete medium and counted with the haemacytomer to determine 
concentration before seeding.  
 
2.2.2 Cryopreservation of Cells 
 To ensure a constant supply of cells for experimental usage and as a counter- 
measure to microbial contamination, cells were cryopreserved in nitrogen freezer for 
storage purpose. Briefly, trypsinized cells were centrifuged at 125 g for 5 min at 4
 o
C to 
remove traces of enzymatic protein. Cell pellet was subsequently resuspended with 
medium containing 20% FBS and 10% DMSO and counted before ampules (Nagle Nunc, 
Roskilde, Denmark)  containing 5 X 10
5
 cells/ml were transferred to 5100 Cryo 1
 o
C 
(Nagle Nunc) freezing container at -70 overnight before they were immersed in liquid 
nitrogen at -196
 o
C for long term storage.  
 
2.3 Manipulation of MT-2A gene expression 
2.3.1 Down regulation of MT-2A gene using siRNA 
For silencing of MT-2A gene, optimization of silencing efficiency was performed 
using a validated pair of siRNA duplex targeting the AC lamin gene (Qiagen, Hilden, 
Germany) and transfection efficiency was measured using a Cy3-labelled siRNA 
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containing a scrambled sequence that did not target any gene within the human genome 
for monitoring entry of siRNA into the cells.  
 Chemically synthesized siRNAs was customized to target the MT-2A isoform in 
MCF-7 breast cancer cells. They were seeded at a cell density of 6 X 10
4 
cells/well into a 
24-well plate format (Nagle Nunc) one day before transfection and allowed to grow to 
50% to 70% confluency. As recommended by the manufacturer, one microgram of 
respective siRNAs were diluted in opti-MEM I Reduced Serum (Invitrogen) to a final 
volume of 100µl before they were introduction into the wells. Intracellular delivery of 
siRNA was aided through the addition of 6 µl of RNAifect transfection reagent to the 
pre-diluted siRNA and mixed by pipetting. The silencing complexes were allowed to 
incubate for 15 min at room temperature. Spent medium was replaced with 300 µl of 
fresh culture medium before transfection complexes were introduced to the cells 
dropwise. Transfected cells were maintained at 37
o
C in a humidified incubator with 5% 
atmospheric CO2 up to 72h post transfection before analysis was performed. Sequences of 
siRNAs used to suppress the expression of MT-2A are listed in the Table 2.1.  
 
Table 2.1 Sequences of siRNAs used in MT-2A silencing. 
siRNA Manufacturer Target sequence Target gene 
siNegative Qiagen UUCUCCGAACGUGUCACGUUU  Non-silencing 
siAC Lamin Qiagen  CUGGACUUCCAGAAGAACAUU A/C Lamin 
siMT2A_1 Qiagen CCGGUUCCUGCAAAUGCAAUU MT-2A 
siMT2A_2 Qiagen  CUGGACUUCCAGAAGAACAUU MT-2A 





2.3.2 Cloning of MT-2A and over-expression  
2.3.2.1 Transient over-expression of MT-2A 
 Up-regulation of the MT-2A isoform in breast cancer cells conducted in this study 
were achieved through transient over-expression and the generation of a stably-
transfected cell line derived from parental MCF-7 cell line. For transient expression, total 
RNA isolated from MCF-7 cells using RNeasy Mini Kit (Qiagen) and mRNA was 
purified from the total RNA sample using Oligotex Mini Kit (Qiagen). Sensiscript two-
step reverse transcription polymerase chain reaction (RT-PCR) purchased from Qiagen 
was used to amplify the MT-2A isoform using the following pair of primers: Forward 5‟- 
GGA TCC GAT CCC AAC TGC GCC-3‟ and Reverse 5‟- CTC GAG TCA GGC GCA 
GCT GCA CTT- 3‟. The MT-2A gene was purified via QIAquick Gel Extraction Kit 
(Qiagen) and cloned into TOPO
®
 TA Cloning vector (Invitrogen) for DNA sequencing to 
check for point mutation. The MT-2A transgene was sub-cloned into the pXJ40 
expression vector (a generous gift from Dr Ed Manser from the Institute of Molecular and 
Cell Biology, Singapore) after a double digestion with BamH I and Xho I restriction 
enzymes (Promega). This 66-33 vector is capable of over-expressing a recombinant MT-
2A protein attached to a Green Fluorescent Protein (GFP) tag at the N-terminal driven by 
a strong CMV promoter when successfully transfected. Along with the null pXJ40 vector 
serving as a control, both vectors were transformed into DH5α competent cells 
(Invitrogen) for up-scale production of these plasmids via Endofree Maxi Kit (Qiagen). 
This application greatly reduced the amount contaminant endotoxin that co-eluted with 
plasmid DNA in conventional Maxi prep procedure, which might lower transfection 
efficiency. Intracellular delivery of plasmids were facilitated through the use of 
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Lipofectamine 2000 (Invitrogen) transfection reagent when 4 µg of plasmid were mixed 
in a 1:3 ratio [DNA (µg): Lipofectamine (µl)] for this lipofection process. Transfection 
efficiency was evaluated through GFP expression while MT-2A over-expression was 
determined at the transcript level using real-time PCR.   
  
2.3.2.2 Stable transfection of MT-2A 
Employing a similar strategy, total RNA isolated from MCF-7 cells were reverse 
transcribed and PCR amplified using the following pair of primers instead : Forward 5‟- 
GCT AGC CTC GCC ATG GAT CCC AAC -3‟ and Reverse 5‟- GAA TTC CCA GCA 
TCA GGC GCA GCA -3‟. This allowed the incorporation of a unique pair of Nhe I and 
EcoR I restriction enzymes sites onto the MT-2A construct to facilitate cloning into 
pIRES2-EGFP (Clontech Laboratories, Mountain View, CA, USA) after digestion. After 
ligation by T4 ligase (Promega), plasmids were sequenced to confirm the successful 
cloning of human MT-2A gene into the expression vector. Plasmids were transformed 
into competent cells and cultured for large scale preparation of plasmids for transfection. 
Driven by the CMV promoter, pIRES2-EGFP vector carrying the MT-2A sequence (MT-
2AO/E) allows both MT-2A protein and EGFP to be co-translated from a single 
bicistronic mRNA. To generate a clone of MCF-7 cells stably over-expressing MT-2A, 
G418 (Invitrogen) was added to medium (1200 µg/ml) to select for successful 
transfectants after lipofection as described in section 2.14.1. G418 resistant cells were 
passaged and maintained in antibiotic supplemented medium until all non-transfected 
cells die out before a stepwise reduction in geneticin concentration was introduced. 
Eventually, stable tranfectants were maintained in culture with G418 supplementation 
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(200 µg/ml) and their existence coincided with EGFP expression as view under 
fluorescence microscopy.   
 
2.4 Silencing of FST gene   
 Similarly, silencing of the FST gene was performed using Smart pool siRNAs 
(Dharmacon, Chicago, IL, USA) comprised of a mixture of four double-stranded RNA 
duplexes targeting the same gene. MCF-7 breast cancer cells were seeded at 3.0X 10
5
 
cells/well in a 6-well format plate and maintained in the incubator overnight. On the day 
of transfection, 6µl of Dharma-fect 1 (Dharmacon) transfection reagent was diluted in 
opti-MEM I reduced serum and incubated for 5 min at room temperature. This reaction 
mix was co-incubated with diluted FST targeting siRNAs in a 1:1 manner and allowed to 
stand for 20 min for the formation of silencing liposome complex before it was 
administered to the cells. Spent medium was aspirated from individual wells and replaced 
with 1.6 ml of fresh DMEM complete medium containing 10% FBS. MCF-7 cells were 
transfected with 400 µl of siRNA mixture (final concentration of 30 nM of siRNAs) and 
returned to water-jacketed CO2 incubator where they were maintained for up to 72 hr in a 
humidified 37
 o
C environment before quantification and validation. Spent medium was 
changed at 24 hr post transfection to remove unincorporated siRNA silencing complexes 
and cell debris. Sequences of siRNAs targeting FST gene used for this study were listed 
in the Table 2.2.  
Table 2.2 Sequences of siRNAs targeting FST. 
siRNA Manufacturer Target sequence Target gene 
siFST_05 Dharmacon GGACUACAGCUUUCCUAUA FST 
siFST_06 Dharmacon GUAAAGAAACGUGUGAGAA FST 
siFST_07 Dharmacon GGUAAACUCUCUAUAAGUG FST 
siFST_08 Dharmacon UGUGUGACCUGUAAUCGGA FST 
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2.5 Quantitative Real-Time Polymerase Chain Reaction 
2.5.1 Total RNA isolation  
 Cell monolayer was washed with 1X PBS twice to remove traces of medium 
before direct lysis was performed with cell scraper in 350 µl RLT buffer (Qiagen) 
containing 1% β-mercaptoethanol to provide a reducing condition during total RNA 
extraction. Cell lysate was homogenized by passing through a 22-guage needle fitted with 
a syringe eight times before an equal volume of 70% ethanol was added and to clarify the 
viscous mixture by pipetting. Subsequently, the mixture was loaded onto a RNeasy 
MiniElute spin column attached to a 2 ml collection tube and centrifuged at 8000 g for 
30s. The column was washed with 1 volume of RW1 buffer before genomic DNA 
removal by DNAse I (Qiagen) through in column digestion following 15 min incubation 
at ambient temperature. Further washing procedures were provided by the addition 
buffers RW1 and RPE respectively, whereby the flow-throughs were discarded after 
centrifugation. To prevent carry-over alcohol from affecting the final concentration of the 
RNA eluate, the columns were subjected to an open-cap centrifugation step for 5 min at 
maximum speed to dry its content following a final washing step with 80% ethanol. 
Purified total RNA was eluted into a 1.5ml collection tube with 30 µl and 14 µl of 
RNAse-free water for RNeasy Mini and RNeasy Micro kit respectively after 1 min final 
centrifugation at 16000 g. Isolated total RNA was quantified immediately or preserved at 
-80 
o
C for long term storage for further analysis to be performed. 
 Total RNA isolated from the cells was quantified by Nanodrop ND-1000 
spectrophotomer (Thermo Scientific, Lafayette, CO, USA) to determine the its quality 
and concentration. One microliter of sample was loaded on the lower measurement 
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pedestal and spectral measurement was electronically calculated by the ND-1000 
software. Purity and integrity of the RNA was then estimated by comparing the 
absorbance ratio of the sample 260nm and 280nm wavelengths. Typically, good quality 
RNA should give an output reading between 1.9 to 2.1.  
 
2.5.2 First strand cDNA synthesis  
 Complementary DNA was reverse transcribed using SuperScript III first strand 
synthesis kit from Invitrogen. One microgram of input total RNA was mixed with 1 µl of 
random hexamer (50ng/µl) and 1 µl of dNTPs (10mM) to a final volume of 10 µl with 
DEPC water. This RNA/primer sample was incubated at 65
 o
C for 5 min in a 
thermocycler (Thermo Hybaid, Middlesex, UK) and left on ice for at least 1 min to lower 
the temperature of its content prior to the addition cDNA synthesis mix prepared as 
follows: 
 2 µl of 10X RT buffer 
 4 µl of  25mM MgCl2 
 2 µl of 0.1 M DTT 
 
 1 µl of RNAseOUT (40 U/ µl) 
 
 1 µl of SuperScript III (200 U/ µl) 
 
The RNA/primer and cDNA synthesis mix were combined and placed in the 
thermocycler for 25
 o
C for 10 min, followed by 50
 o
C incubation for 50 min. Enzymatic 
activity from Moloney Murine Leukemia Virus (M-MLV) reverse transciptase was 
terminated by 5 min heating at 85
 o
C while residual template RNA was digested by the 
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action of RNAseH after 37
 o
C incubation for 20 min after its introduction. The resulting 




2.5.3 Real-time Ploymerase Chain Reaction  
 Quantitative PCR (qPCR) was performed on Roche LightCycler System (Roche, 
Indianapolis, IN, USA) using QuantiTect SYBR Green PCR Kit (Qiagen). Primers were 
designed using the PRIMER3 software (Rozen & Skaletsky, 2000) and specificity of the 
obtained primers was confirmed by the nucleotide blast program available on the Basic 
Local Alignment Search Tool (BLAST) database (version 2.2.22) from National Center 
for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/). Primers specific 
towards individual MT isoforms were adapted from Mididoddi et al whereas designs for 
primers specific towards MT-2A over-expression has been described in the section „MT-
2A cloning and over-expression‟ (Mididoddi et al, 1996). The details of the primers used 
for this study were illustrated in Table 2.3.  
   The real-time reaction mix is comprised of a final concentration of 1X 
QuantiTect SYBR Green PCR Master Mix (Qiagen), 0.3 µM of forward and reverse 
primers respectively and less or equal to 500 ng of template cDNA. A total reaction 
volume of 10 µl of the real-time reaction mix was loaded into lightcycler capillaries 
(Roche) after a brief centrifugation. The resulting capillaries were sealed and 
systematically placed into the carousel before they were subjected to a thermocyclic 




Table 2.3 Primers for quantitative real-time PCR 
Gene 
Symbol Forward Primer Reverse Primer 
Amplicon 
size 
G3PDH 5'-GAAGGTGAAGGTCGGAGTCAACG-3' 5'-TGCCATGGGTGGAATCATATTGG-3' 158 
MT-1A 5'-CTCGAAATGGACCCCAACT-3' 5'-ATATCTTCGAGCAGGGCTGTC-3' 219 
MT-1B 5'-GCTTGTCTTGGCTCCACA-3' 5'-AGCAAACCGGTCAGGTAGTTA-3' 289 
MT-1E 5'-GCTTGTTCGTCTCACTGGTG-3' 5'-CAGGTTGTGCAGGTTGTTCTA-3' 284 
MT-1F 5'-AGTCTCTCCTCGGCTTGC-3' 5'-ACATCTGGGAGAAAGGTTGTC-3' 232 
MT-1G 5'-CTTCTCGCTTGGGAACTCTA-3' 5'-AGGGGTCAAGATTGTAGCAAA-3' 309 
MT-1H 5'-CCTCTTCTCTTCTCGCTTGG-3' 5'-GCAAATGAGTCGGAGTTGTAG-3' 317 
MT-1X 5'-TCTCCTTGCCTCGAAATGGA-3' 5'-GGGCACACTTGGCACAGC-3' 151 
MT-2A 5'-GGATCCGATCCCAACTGCTCCTGCGCC-3' 5'-CTCGAGTCAGGCGCAGCAGCTGCACTT-3' 198 
MT-3 5'-CCGTTCACCGCCTCCAG-3' 5'-CACCAGCCACACTTCACCACA-3' 325 
MT-4 5'-CATGGACCCCAGGGAATGTGT-3' 5'-GGGGTGGGAACGATGGA-3' 213 
ROCK1 5'-GAAGCTCGAGAGAAGGCTGA-3' 5'-TTGTCTGCCTCAAATGCTTG-3' 224 
ROCK2 5'-GATGGTTTCTATGGGCGAGA-3' 5'-CCCATTTCTCCCAAGTCGTA-3' 231 
MAP1-LC3A 5’-ACAGCATGGTGAGTGTGTCC-3’ 5’–GCTCAGTTCAGGAACCAGGA–3’ 193 
MAP1-LC3B 5'-ATTCGAGAGCAGCATCCAAC-3' 5'-CTGTGTCCGTTCACCAACAG-3' 194 
ATG-5 5'-CTGTGTCCGTTCACCAACAG-3' 5'-ATGGTTCTGCTTCCCTTTCA-3' 170 
ATG-7 5'-TGGAACAAGCAGCAAATGAG-3' 5'-AGACAGAGGGCAGGATAGCA-3' 151 
ATG-12 5'-TTCCCCAGACCAAGAAGTTG-3' 5'-GTCTCTTGCCACAAGCATCA-3' 183 
MAOB 5'-GGCTTTGTGCTTGTTCTTCC-3' 5'-CACCTCTGTGGGCTTCAGTT-3' 158 
FST 5'-GTGGGAATGATGGAGTCACC-3' 5'-CGACTTACTGTCAGGGCACA-3' 218 
UGT2B15 5'-GCATGGAGGGTTTTAAATGG-3' 5'-TGCTGCATCCAGTAACTCGT-3' 220 
BCAT1 5'-GTCAAGACGAAGGCAAAACC-3' 5'-TTCCTGTGCTAGAGAGCATGG-3' 150 
CXCL12 5'-CGCTTTGAGTGACTGGGTTT-3' 5'-CACCAGGACCTTCTGTGGAT-3' 225 
IL1RAP 5'-CCGTAATGCCCAAATGTAGC-3' 5'-TTCAGGAAAAATTCCGAAAGTC-3' 246 
BCHE 5'-TGAAACAAAAATGCCAGAAGG-3' 5'-GAAATTGAACCAGGCCATTG-3' 167 
KLK12 5'-GGGAGAATCACGAGCAACAT-3' 5'-GGTGTAGACTCCAGGGATGC-3' 165 
COL3A1 5'-GGGAATGGAGCAAAACAGTC-3' 5'-CGTCCACACCAAATTCTTGA-3' 114 
ELF5 5'-GGACTGCCCCTAGGACTTCT-3' 5'-TCCACCTGGAAAACACATGA-3' 173 
NBEA 5'-TATTGGCACTTTGCACCAGA-3' 5'-TTGCTTACAGCCTGGTGATG-3' 183 
BMP7 5'-CATGGTGGCTTTCTTCAAGG-3' 5'-ACAGTAGTAGGCGGCGTAGC-3' 250 
BMPR1B 5'-CCCAGACACATAGCAGTGGA-3' 5'-ACTGGTTCCCCCAAAAGAAC-3' 184 
UGT1A 5'-TAAGTGGCTACCCCAAAACG-3' 5'-TCCAGCTCCCTTAGTCTCCA-3' 175 
 
Complementary DNA sample was subjected to 45 PCR cycles after an initial 
activation of Taq polymerase at 95°C for 15 min, denaturation at 94°C for 15 seconds, 
annealing of primer at 60°C for 25 seconds and elongation at 72°C for 18 seconds. To 
confirm the specificity of the amplification process, a melting curve analysis was 
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performed to examine for the presence of primer-dimers or non-specific amplification. 
This was achieved through a denaturation step at 95°C for 0s by a temperature transition 
rate of 20°C /s, incubation at 65°C for 15s and a final heating to 95°C with transition rate 
of 0.1°C /s. Melting curve was plotted as the first negative derivative of the fluorescence 
versus temperature [-d(F)/d(T)] by the Light Cycler data analysis software. A single, 
narrow and sharp peak represented a specific amplification. The amplicons were allowed 
to cool to 40°C for 30s before they were retrieved for agarose gel electrophoreisis. 
 
2.5.4 Agarose gel electrophoreisis 
 To further exclude the possibility of non-specific amplification, PCR amplified 
products were analyzed on 2% agarose gel electrophoreisis. Five microliters of qPCR 
products were mixed with 1 µl of DNA loading dye (Blue/Orange 6X Loading Dye- 15% 
Ficoll, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 0.4% orange G, 10 mM Tris-
HCl ph 7.5, 50mM EDTA) before loading into wells of the gel bathed in TAE buffer ( 40 
mM Tris-acetate, 1 mM EDTA, pH 8.0). Visualization of single banded amplicons was 
compared was aided through the addition of ethidium bromide and size of the DNA 
bands were determined by comparison with a molecular weight marker (Promega) 
following electrophoreisis for 50 min at 100V. The bands were documented using Gel 
Documentation Image Analysis System V6.03 (Chemigenius SynGene, Cambridge, UK) 





2.5.5 Gene expression analysis of qRT-PCR data 
 The relative quantification method, 2
-ΔΔCt
, whereby the relative expression of a 
target gene is calculated against a reference housekeeping gene (Livak & Schmittgen, 
2001) was employed to analyze the real-time PCR data. Threshold cycle (Ct) value was 
determined as the cycle number at which the SYBR fluorescent signal in the sample first 
exceeds the level of background noise and becomes exponential, mirroring the 
amplification copy number of the target gene using the second-derivative maximum 
method inherent in the LightCycler software.      
 Normalized gene expression (ΔCt) was derived by finding the difference in Ct 
values between target gene versus the reference gene. ΔΔCt was further computed by 
subtracting the ΔCt values of the treatment group compared with control. The overall 
calculation could be summarized into the following equation: ΔΔCt = [treatment (ΔCt 
target – ΔCt reference)] – [control (ΔCt target – ΔCt reference)]. Finally, the value of 2
-ΔΔCt
 is 
represented as relative fold change of a gene at the transcript level.   
 
2.6 Immunocytochemistry  
 Cells were seeded into 4-well chamber flasks (Nagle Nunc) and treated with 
respective siRNAs accordingly. After 72h post transfection, cells were washed with 1X 
PBS and fixed in 4% paraformaldehyde for 15 min prior to cell membrane 
permeabilization with 0.1% Triton-X in PBS (0.2% PBS-TX). To minimize non-specific 
staining, endogenous peroxidase activities were inhibited by incubating fixed cells with 
0.5% H2O2 diluted in methanol. The samples were subsequently blocked with 5% Horse 
serum for 1 h and incubated with E9 clone antibody (Dako Corporation) (1:200) in 0.2% 
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PBS-TX overnight at 4°C. For negative control, isotype antibody was substituted for the 
primary antibody instead. Cells were washed with 0.2% PBS-TX thrice prior to the 
addition of secondary anti-mouse antibody at a 1:200 dilution. This was followed by 
incubation with biotin and avidin-peroxidase complex (Vector Laboratories, Burlingame, 
CA, USA) for 1 h. Immunostaining was demonstrated after co-incubating samples with 
3,3‟-diaminobenzidine (DAB) and hydrogen peroxide for 10 min. Further washings were 
carried out to ensure complete removal of DAB before cell nuclei were counter-stained 
with haematoxylin. The immunostained samples were dehydrated in increasing 
concentration of ethanol and Histoclear before they were mounted onto glass slides for 
viewing under light microscope.  
To determine the intensity of staining, micrographs of five randomly chosen 
views were photo documented under 400X magnification and evaluated. Cells were 
assigned a immunoreactivity score of 1-for light staining or conversely 2- for intensified 
staining and the summated score was divided by the number of cells per view to derive at 
the immunopositivy score. Tabulated results were subjected to further analysis either 
through One-way ANOVA or Student‟s t-test to determine statistical siginificance of the 
staining evaluation.   
 
2.7 Immunofluoroscence staining  
 To improve cell adherence, coverslips were treated with an acid wash procedure 
with 1M HCl overnight at 60°C to remove impurities coated onto their glass surfaces. 
These coverslips were subsequently rinsed with de-ionized water and kept in 70% ethanol 
for storage. Upon usage, acid-washed coverslips were further rinsed with autoclaved 
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water and air-dried in the biosafety cabinet before they were placed at the bottom of the 
multi-well plate. 6 X 10
4
 MCF-7 cells were seeded onto the pre-treated coverslips and 
left overnight in the humidified incubator to grow to optimal 50%-70% confluency for 
transfection. After introduction of siRNA, cells were maintained for another 72 h before 
they were washed with 1X PBS and fixed with 4% paraformaldehyde. Fixed cells were 
permeabilized with 0.2% PBS-TX for 10 min and blocked with 1X PBS containing 10% 
FBS. Primary antibody targeting β–catenin (BD Transduction Laboratories) was diluted 
1:500 in 0.2% PBS-TX and left in 4
 o
C overnight. Cells were washed thrice with 0.2% 
PBS-TX before co-incubation of FITC conjugated anti-mouse antibody (1:500) 
(Molecular Probe, Carlsbad CA, USA) and TRIT-C conjugated phalloidin (Sigma) were 
introduced. Cells were allowed to stand at room temperature in the dark for 1 h before 
they were washed to remove unbound antibodies and cell nuclei were counter-stained 
with 4‟,6-diamidino-2-phenylindole (DAPI) diluted in 1X PBS for 5 min. After a final 
washing step with 1XPBS, the coverslips were mounted and viewed under fluorescence 
microscopy (Zeiss, Stuttgart, Germany).    
 
2.8 Transmission Electron Microscopy  
Cells grown on chamber flasks (Nagle Nunc) were treated with siMT2A_2 or 
siNeg were incubated for 72h before washing and fixation in 2.5% glutaraldehyde in 
phosphate buffered saline (PBS) for 30min. Fixed cells were subsequently washed with 
PBS and post-fixed with 1% osmium tetraoxide for 1h at pH 7.4. Samples were 
dehydrated in an ascending series of ethanol and infiltrated with absolute ethanol and 




overnight. For semi-thins section, ultra-microtome section were counterstained with 0.5% 
methylene blue diluted in 0.5% borax and  mounted onto glass slides for examination 
under light microscope. Ultra-thin samples were cut by an ultra-microtome, mounted on 
formvar-coated copper grids and doubly stained with uranyl acetate and lead citrate. The 
grids were viewed in a Philips CM120 BioTWIN transmission electron microscope 
(TEM) (FEI, Hillsboro, OR, USA).  
 
2.9 Cell viability assay  
 Cell viability was monitored using CellTiter 96® Aqueous Non-radioactive cell 
proliferation assay (Promega), a colourimetric based technique routinely performed to 
determine the number of viable cells in proliferation. This assay exploited the ability of 
cells to convert tetrazolium compound (MTT) into formazan through cellular 
mitochondrial activity upon incubation. The amount of formazan product formed in 
culture is directly proportional to the number of living cells. Cells with or without 
siRNAs treatment were counted and seeded into respective well at a density of 1 X 10
4
 
cells/well. These cells were serum starved for 24 h before 50 µl fresh medium containing 
10% FBS was re-introduced. Cell viability was examined at various time points, where 
15 µl of the Dye Solution was pipetted into the medium and allowed to incubate for 4 h 
within a 5% CO2 incubator at 37°C in the absence of light. To terminate the reaction, 100 
µl of the Solubilization Solution/ Stop Mix was added to solubilize the formazan crystals 
with additional 1 h incubation at 37 °C. Wells were thoroughly mixed by pipetting before 
absorbance readings representative of triplicate experiments were recorded at 570nm and 
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650 nm using SpectraMax M5 plate reader (Molecular Device, Sunnyvale, CA, USA), 
with the latter being used as a reference. 
 
2.10 Growth curve analysis 
 Assessment of cell proliferation rate in response to various treatments was 
routinely screened in the laboratory. Cells were cultured up to 72 h post siRNA silencing 
and cell viability assays were conducted using alamarBlue (Invitrogen) which allows 
continuous monitoring of the treated cells. The amount of alamarBlue to be added should 
constitute 10% (v/v) of the total volume of medium in which the cells were cultured in 
and allowed to incubate for 4 h in a 37°C, 5% atmospheric CO2 environment. Similar to 
MTT based proliferation assays, alamarBlue dye relied on the cellular metabolism to 
reduce non- fluorescent resazurin compound to the highly fluorescent resorufin without 
killing the cells. Fluorescence readings were taken with excitation and emission 
wavelengths at 570 nm and 585 nm respectively. After quantification, alamarBlue 
containing medium was aspirated before 100 µl of fresh complete medium was 
replenished. The non-cytotoxic nature of alamarBlue allows the same replicates to be 
repeatedly assayed at various time points (24 h, 48 h and 72 h post transfection) and a 
growth curve was plotted  to represent the cell proliferation profile for the duration.  
 
2.11 Transwell migration assay        
 Cell migratory capability was evaluated through the use of Transwell 
polycarbonate inserts with 8.0 µm. pore size (Corning Incorporated, Corning, NY, USA). 
These inserts were pre-hydrated by adding 200 µl and 500µl of DMEM medium without 
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FBS to the upper and lower chambers respectively in a 24-well plate (BD Falcon, 
Franklin Lakes, NJ, USA). The plate was incubated for 2 h inside an incubator prior to 
seeding and this equilibration procedure was carried out to aid cell attachment. Briefly, 
cells pre-treated with respective siRNAs up to 48 h post transfection were harvested by 
trysinization and pelleted as described in section 2.2.1. Medium was carefully removed 
from the equilibrated chamber and corresponding well before transfected cells were 
seeded at a concentration of 6 X 10
4
 in DMEM into the upper chamber while the 
Transwell was immersed into a surrounding filled with 500 µl of DMEM supplemented 
with 15% FBS as a chemoattractant. Cells were allowed to migrate for 18h under normal 
growth conditions before medium removal and the chambers were twice washed with 1X 
PBS. Methanol was added to fix the cells for 30 min before it was rinsed in 1X PBS and 
left to air dry. The Transwell inserts were stained with 0.5% (w/v) crystal violet 
reconstituted in PBS with 20% methanol for an additional 30 min before excess stain was 
washed out using deionised water. Non-migratory cells in the upper chamber were 
removed with a dampened cotton swap. Migrated cells found on the lower chamber were 
photo documented at 10X objective under stereo microscope (Nikon SMZ 1500, Melville 
NY, USA). For each insert, five random fields were taken and counted. The assay was 
performed in triplicates and repeated thrice independently to ensure reproducibility. Cell 
counts were subjected to further analysis either through One-way ANOVA to determine 
statistical siginificance of the staining evaluation.   




2.12 Cell invasion assay  
    To further validate the migratory and invasive potential of breast cancer cells 
after manipulation, in vitro cell invasion assay was conducted using Matrigel 
TM
 Invasion 
chambers (BD Biosciences, San Jose, CA, USA) fitted with PET membrane and a pore 
size limit of 8.0 µm. Likewise, the invasive chambers were equilibrated with 200 µl and 
500 µl of serum free DMEM overnight in a humidified 5% CO2 incubator at 37°C. Extra 
precaution was exercised to prevent disturbing the Matrigel Matrix during medium 
aspiration the following day. Treated cells (48 h post transfection) were dislodged using 
trypsin-EDTA method and cells were resuspended in serum-free DMEM to be counted 
with a haemacytomer. Two hundred microliters of serum-free DMEM containing 6 X 10
4 
breast cancer cells were carefully seeded into the hydrated upper chamber before it was 
slowly placed into a well (24-well format) containing 500 µl of DMEM containing 15 % 
FBS (v/v) with a pair of sterile forceps. This was done to prevent the trapping of air 
bubbles beneath the membrane that could impede cell invasion. Cells were allowed to 
further incubate for 24 h in the water-jacketed incubator at 37°C and 5% atmospheric 
CO2. Subsequently, cells were fixed and stained as described previously in section 2.11. 
Excess crystal violet solution was rinsed off with de-ionized water and non-migrated cells 
were swapped off the upper chamber with a damp cotton bud. Similarly, five independent 
views were captured for each Matrigel insert with the Nikon SMZ 1500 microscope 
under 10X magnification to determine the number of cells that successfully migrated 
across the physical barrier. The invasion assays were repeated on three separate occasions 
with the same experimental conditions to ensure reproducibility and results were further 
validated for statistical significance.     
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2.13 Genome wide expression analysis using GeneChip Microarray 
2.13.1 Preparation of RNA starting material 
 Genomic analysis was performed to evaluate MT-2A expression in breast cancer 
cells. For RNA preparation, MCF-7 cells were transfected with siNeg, siMT2A_1 and 
siMT2A_2 for 48 h before total RNA was extracted whereas MT-2AO/E transfected cells 
stably over-expressing MT-2A isoform provided RNA starting material representing the 
gene associated with MT-2A up-regulation in comparison to control treatment transfected 
with pIRES instead. Total RNA was isolated using RNeasy Mini Kit from Qiagen and 
determination of RNA purity and concentration was carried out as described in section 
2.5.2.  
 
2.13.2 RNA quality check 
For successful cDNA microarray screening, it is essential that input RNA must be 
of high quality before the commencement of sample preparation. RNA samples were 
analyzed using Agilent RNA 600 Nano chip on Agilent 2100 Bioanalyzer (Waldbronn, 
Germany) platform. Reagents were equilibrated to room temperature for 30 min prior to 
use and 550 µl of Nano gel matrix was filtered through the spin filter by centrifugation at 
1500 g at 10 min. An aliquot containing 65 µl of filtered gel was mixed with 1 µl of Nano 
dye and vortexed before solution was spun at 13000 g in Eppendorf 5415 D bench-top 
microfuge (Hamburg, Germany). To load the gel-dye mix, RNA 6000 Nano chip was 
placed onto the chip priming station attached to a syringe. Nine microliters of mixture 
was loaded into the first well marked “G” before the priming station was closed and the 
plunger was depressed until it was held by the clip. After 30 s, the clip was released and 
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the priming station was opened to allow 9.0 µl of gel-dye mix to be pipetted into two 
other wells with “G” labels respectively. The remaining wells were loaded with 5 µl of 
Nano marker followed by 1 µl of samples with the exception of the “ladder” well. To that 
well, 1 µl of RNA ladder was added and unused well(s) was incubated with a final 
volume of 6 µl of Nano marker instead. Nano chip was vortexed with a IKA vortexer for 
1 min at 2400 rpm. The chip was inserted into the Agilent 2100 Bioanalyzer and the 
RNA Nano assay programme was activated. Good quality RNA should register two sharp 
peaks corresponding to 18S and 28S ribosomal RNA on an electropheragram. In addition, 
the programme also assigned sample RNAs with a RNA integrity number ranging 
between 1 (totally degraded RNA) to 10 (intact RNA) Only RNA samples with a RIN ≥ 
9.0 and A260/A280 ratio within 1.9 to 2.1 were earmarked for microarray work.          
   
2.13.3 First strand cDNA synthesis 
 Three micrograms of total RNA was reverse transcribed into single-stranded 
cDNA using the one-cycle cDNA synthesis kit (Affymetrix, Santa Clara, CA, USA). A 
reaction mix was assembled in a 0.2 ml PCR tube as follows: 
 3.0 µg of total RNA 
 variable amount of RNase free water to make a final volume of 11 µl 
 2 µl of  50 µM  T7-Oligo(dT) primers  
 2 µl of  Diluted poly-A RNA control 
Reaction mixture was incubated at 70°C for 10 min within a PCR Express thermocycler 
(Thermo Hybaid) to allow primer hybridization before it was cooled at 4°C for 2 min and 
briefly centrifuged. The poly-A RNA controls (dap, lys, phe, thr, trp) were included to 
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monitor target labelling process. In a separate tube, a First-Strand Master Mix was 
concocted with the following constituents: 
 4 µl of 5X 1st Strand Reaction Mix 
 2 µl of 0.1 M DTT 
 1 µl of 10mM dNTP 
Seven microlitres of the First-Strand Master Mix was added to the hybridized sample and 
mixed by pipetting before returning the reaction mix back to the thermocycler for an 
additional 2 min at 42 °C. After the addition of 1 µl of SuperScript II reverse 
transcriptase, sample was spun down and further incubated for an hour at 42°C for first 
strand cDNA synthesis. Finally, the reaction tube was cooled at 4°C for at least 2 min 
before proceeding to Second-Strand cDNA Synthesis. 
 
2.13.4 Second-Strand cDNA Synthesis 
   A Second-Strand Master Mix was prepared with the following reagents: 
 91 µl of RNase-free water 
 30 µl of 5X 2nd Strand Reaction Mix 
 3 µl of 10mM dNTP 
 1 µl of E.coli DNA ligase  
 4 µl of E.coli DNA Polymerase I 
 1 µl of RNase H  
A total of 130 µl of Second-Strand Master Mix was incorporated into the sample tube 
from section 2.15.3 and mixed by pipetting. After a brief centrifugation, the PCR tube 
was incubated at 16°C for 2 h. Sample was incubated for another 5 min after the addition 
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of 2 µl of T4 DNA Polymerase at the same temperature. The reaction was terminated 
when 10 µl of 0.5M EDTA was added to the sample eventually.  
 
2.13.5 Clean up of double stranded cDNA   
 Complete removal of excess dNTP and carried over enzymes was necessary prior 
to in vitro transcription (IVT) of complementary RNA (cRNA) using the newly 
synthesized double stranded cDNA as template. Sample was transferred to a new 1.5 
microfuge tube before 600 µl of cDNA Binding Buffer was added and mixed thoroughly 
by vortexing for 3 s. Five hundred microlitres of this mixture was loaded into a cDNA 
Spin Column sitting in a 2 ml collection tube and spun at 8000 g for 1 min inside the 
bench-top centrifuge (Eppendorf). The flow through was discarded and remaining sample 
was pipetted into the same column before centrifugation. The column was transferred to a 
new collection tube and 750 µl of cDNA Wash Buffer was applied. Flow through was 
discarded after the sample containing column was spun down at the same condition. The 
membrane was air dried following an open cap centrifugation at maximum speed for 5 
min before the column was re-fitted into a new 1.5 ml collection tube. Sample was 
allowed to incubate for 1 min after 14 µl of cDNA Elution Buffer was emptied directly 
onto the membrane using a pipette. A maximum speed centrifugation step ensued for 1 
min before 12 µl of eluate was collected. 
 
2.13.6 Synthesis of Biotin-labelled cRNA 
 Purified double stranded cDNA from the preceding procedure was employed to 
generate biotinated cRNA for downstream microarray analysis. As the 10X IVT 
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Labelling Buffer contained spermidine, it is imperative not to assemble the reaction on 
ice that could result in the precipitation of template cDNA. Details of the IVT reaction 
mix were prepared in a RNase-free, 0.2 ml microfuge tube was as follow: 
 12 µl of template cDNA 
 8 µl of RNase-free water 
 4 µl of 10X IVT Labelling Buffer 
 12 µl of  IVT Labelling NTP Mix 
 4 µl of IVT Labelling Enzyme Mix 
All the reagents were carefully mixed and briefly centrifuged to collect the mix at the 
bottom before the sample was incubated for 16 h at 37°C using a thermocycler.  
 
2.13.7 Clean up of Biotin-Labelled cRNA 
 Following an overnight incubation, newly synthesized cRNA was transferred to a 
new RNase-free 1.5 ml centrifuge tube before 60 µl of RNase-free water was introduced 
and vortexed for 3 s. This was followed by the addition of 350 µl IVT cRNA Binding 
Buffer and the tube was vortexed for another for 3 s. A final addition of 250 µl of 
absolute alcohol was mixed by pipetting before 700 µl of lysate was applied to an IVT 
cRNA Cleanup Spin Column attached to a 2 ml collection tube. The column was spun at 
8000 g for 15 s before the collection was discarded along with the flow through. Spin 
column was transferred to a new 2.0 ml collection before 500 µl of IVT cRNA Wash 
Buffer was added and centrifuged under the same conditions. After the flow through was 
decanted, the column was washed with 500 µl of 80% (v/v) ethanol and centrifuged as 
described previously. To ensure complete removal of ethanol from the cRNA sample, cap 
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was opened before spin column was spun at maximum speed for duration of 5min. To 
elute the cRNA sample, 11 µl of RNase-free water was pipetted directly onto the column 
membrane and allowed to incubate for 1 min after it was transferred to a new 1.5 ml 
collection tube. The eluate was collected after spin column was spun at maximum speed 
for 1 min. A second elution was performed by adding additional 10 µl of RNase-free 
water to the same membrane and centrifuged after 1 min of incubation. As recommended 
by manufacturer, cRNA was stored at -70 °C if quantification was not intended 
immediately after elution. 
2.13.8 Quantification of Biotin-labelled cRNA  
 Using a spectrophotometer, 1 µl of biotinated cRNA was checked for absorbance 
at 260 nm and 280 nm to determine its concentration and purity. As total RNA was used 
as starting material, accurate quantification of labelled cRNA yield must be adjusted to 
reflect carried over unlabelled total RNA. The adjusted cRNA yield could be determined 
using the formula below:  
adjusted cRNA yield = RNAm – (total RNAi) (y) 
whereby  
RNAm = amount of cRNA measured after IVT (µg) 
total RNAi = starting amount of total RNA (µg) 
y = fraction of cDNA reaction used in IVT  
In this study, a total of 3.0 µg of total RNA was used initially and the complete fraction 




2.13.9 Fragmentation of cRNA 
 Human Genome U133 Plus 2.0 (Affymetrix) arrays were employed for this study, 
20 µg of adjusted cRNA was subjected to the fragmentation procedure according to 49/64 
Format described in GeneChip Expression Analysis technical manual. In a new tube, 8 µl 
of 5X Fragmentation Buffer was mixed with 20 µg of biotin-labelled cRNA before 
RNase-free water was added to make up a final reaction volume of 40µl. This reaction 
mix was subjected to 94°C incubation for 35 min and incubated on ice before an aliquot 
of the fragmented sample was retrieved for analysis on the Bioanalyzer as described in 
section 2.5.2. Typically, standard fragmentation procedure should generate RNA 
fragment sizes ranging from 35 to 200 bases to be confirmed after Bioanalyzer analysis. 
Meanwhile, fragmented cRNA was stored at – 70 °C until the samples were ready for 
hybridization.   
 
2.13.10 Target hybridization to Affymetrix GeneChip probe array  
 A hybridization cocktail was assembled with the following reagents: 
 15 µg of Fragmented cRNA 
 5 µl of Control Oligonucleotide B2 
 15 µl of 20X Eukaryotic Hybridization Controls (bioB, bioC, bioD, cre) 
 3 µl of Herring Sperm DNA (10ng/ml) 
 3 µl of BSA (50 g/ml) 
 150 µl of 2X Hybridization Buffer  
 30 µl of DMSO 
 RNase-free water to constitute final volume of 300 µl 
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Frozen stock of the 20X GeneChip Eukaryotic Hybridization Controls must be heated to 
65°C for 5 min for complete resuspension of cRNA before assembly of the hybridization 
mix. Probe array was allowed to equilibrate to ambient temperature to prevent septa 
cracking and eventual leaking during hybridization. Hybridization cocktail was heated to 
99°C for 5 min to denature the RNA contents while the array was filled with 200 µl of 
1X Hybridization Buffer at 45°C for 10 min with rotation (60 rpm) inside a GeneChip 
Hybridization Oven 640 (Affymetrix). After 5 min, pre-heated hybridization cocktail was 
transferred to a 45°C heat block and further incubated for another 5 min before it was 
centrifuged at maximum speed to pellet any insoluble material for removal. Hybridization 
buffer was duly aspirated from the probe array before it was replaced by 200 µl of 
clarified hybridization cocktail. Finally, GeneChip was re-introduced back into the 
Hybridization Oven to be incubated at 45°C with rotation (60 rpm) overnight (16 h). 
 
2.13.11 Washing and staining of probe array 
 The GeneChip Operating Software Version 1.2 (GCOS) was launched to prime 
the Fluidic Station 450 (Affymetrix) for post hybridization washing and staining of the 
GeneChip arrays. Priming ensured that the lines of the fluidic station were filled with 
appropriate buffers before specific fluidics station protocols were ran. Prior to priming, 
intake buffer reservoir A was filled with Non-Stringent Wash Buffer (Wash Buffer A, 6X 
SSPE, 0.01% Tween-20) while reservoir B was Stringent Wash Buffer (Wash Buffer B, 
100 mM MES, 0.1 M [Na
+
], 0.01% Tween-20) instead. During priming, hybridization 
cocktail was removed from probe array following 16 h of incubation and replaced with 
250 µl of Wash Buffer A instead to avoid bubble formation. When priming has 
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completed, probe array was loaded into the Fluidics Station 450 for washing and staining 
procedures. Fresh aliquots containing 600 µl of Stain Cocktail 1, 600 µl of Stain Cocktail 
2 and 800 µl of Array Holding Buffer were loaded onto sample holder 1, sample holder 2 
and sample holder 3 respectively. Fluidics Station 450 was programmed to run on 
FS450_0001 protocol as recommended by manufacturer and details of the process could 
be found in Table 2.4. The probe array was removed from the station module to check for 
presence of bubble after the run has completed. If there was no bubble detected, the probe 
array would be ready for scanning. 
 
Table 2.4 Wash and Stain Protocol for FS450_0001. 
Procedure FS450_0001 
Post Hybridization Wash 1 10 cycles of 2 mixes/cycle with Wash 
Buffer A at 30°C 
Post Hybridization Wash 2 6 cycles of 15 mixes/cycle with Wash 
Buffer B at 50°C 
1
st
 Stain Stain the probe array for 5 min with Stain 
Cocktail 1 at 35°C 
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash 
Buffer A at 30°C 
2
nd
 Stain Stain the probe array for 5 min with Stain 
Cocktail 2 at 35°C 
3
rd
 Stain Stain the probe array for 5 min with Stain 
Cocktail 1 at 35°C  
Final Wash 15 cycles of 4 mixes/cycle with Wash 
Buffer A at 35°C 
Array Holding Buffer Fill the probe array with Array Holding 
Buffer  
        
2.13.12 Probe array scanning and quality assessment 
 Before scanning, glass surface of the probe array was cleaned with non-abrasive 
tissue and rubber septa were sealed to prevent leakage. Probe arrays were scanned once 
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using Affymetrix GeneChip Scanner 3000 (Affymetrix) at 570 nm wavelength with a 
pixel value of 1.56µm. After scanning, the raw image file (.dat) was acquired for 
generating the cell intensity data (.cel) used for qualitative and quantitative analyses, 
including quality assessment of the entire microarray experiment. The GCOS software 
was employed to determine the quality of the scanned data, including grid alignment of 
the chip and staining intensities of poly-A RNA and hybridization controls. To ensure a 
successful hybridization was performed, the GeneChip arrays were screened for the 
following criteria: 
 3‟/5‟ ratio of housekeeping genes (GAPDH and β-actin) were 1≤ x ≤ 3, where x 
represents the ratio and the value is preferably closer to 1 
 Signal background ratio was below 100 
 Relative ratios amongst the GeneChips scanned was ≥ 3 
 Spike-in hybridization controls bioC, bioD and cre must be detected in every 
GeneChip probed 
 Spike-in hybridization control bioB  present in at least 50% of the arrays scanned  
 For expression data analysis, cell intensity data were exported to 3 different analytical 
algorithms, namely, GeneSpring (Silicon Genetics, Redwood City, CA, USA) software 
using Robust Multi-array Average (RMA) setting, Guanine Cytocine Robust Multi-array 
Average (GCRMA) (Irizarry et al, 2003a; Irizarry et al, 2003b) and Probe Logarithmic 
Intensity ERror (PLIER) (Affymetrix) to isolate genes associated with MT-2A over-
expression and silencing. Using different methodologies, these data were processed and 
normalized before they were summerized and filtered respectively.   
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2.13.13 GeneSpring-RMA Analysis 
Affymetrix cell intensity files were imported into GeneSpring 7.0 (Silicon 
Genetics) for analysis. Using the RMA algorithm, sample chips were subjected to Median 
Polishing normalization, whereby each chip was normalized against its median and each 
gene was normalized to its median based on staining intensity. This was performed to 
account for discrepancies in staining arose during experimental procedures. After 
normalization, differentially expressed genes were analyzed using One-way ANOVA for 
statistical relevance of these biological findings. Candidate genes were selected by 
filtering criteria described below:  
First Filter-Fold Change: Candidate gene must exhibit a fold change magnitude of at least 
2 to be considered. 
Second Filter-Statistical Significance: Genes with at least a 2 fold difference in 
expression must be accompanied by statistical significance (p<0.05) as analyzed by One-
way ANOVA.  
  
2.13.14 GCRMA analysis 
 Similarly, cell intensity files were exported and converted into expression set 
using GCRMA platform (Irizarry et al, 2003a; Irizarry et al, 2003b). This software 
allowed background correction contributed by noise, non-specific binding and GC-
contents within nucleotide sequence using Robust Multi-array Average (RMA) 
algorithm. This method relied heavily on probe sequence affinity, whereby only a perfect 
match (PM) or signal was considered for probe summarization compared to the mismatch 
(MM) normalized approach adopted by GCOS database. Following background 
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correction, quantile normalization and median polishing were introduced to ensure the 
PM values was consistent throughout all the arrays before they were log-transformed to 
reflect a genuine difference in expression profiles between treatment and control groups. 
Genes that demonstrated at least a 2 fold difference substantiated with p<0.05 were short-
listed for further validation. 
 
2.13.15 PLIER analysis 
 As an alternative to Affymetrix Microarray Suite 5.0 (Affymetrix), Affymetrix 
developed PLIER was capable of producing improved multiple-arrays gene expression 
analysis compared to its predecessor. Besides considering PM and PM/MM ratio for 
summarization, this algorithm featured an error estimation function to correctly represent 
error during summary value calculation. Raw cell intensity data was exported into PLIER 
software to be processed. Coupled with percentile normalization, probe set signal was 
determined and candidate genes were fished-out based on selection criteria described in 
Section 2.15.14. 
 
2.13.16 DAVID functional annotation 
 After filtering, probesets representing the candidate genes were uploaded to 
Database for Annotation, Visualization, and Integrated Discovery (DAVID) for 
functional clustering (Dennis et al, 2003). Genes were grouped according to functionality 
and physiological relevance according to the default setting of threshold count of 2.0 and 
EASE (modified Fisher exact p-value) score of 0.1 selection criteria. This provided leads 
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for further downstream validation of candidate genes associated with MT-2A 
manipulated expression.  
   
2.14 Immuno-blot analysis 
2.14.1 Protein extraction  
        Cell monolayer was carefully washed twice with 1XPBS to remove non-
adherent cells. Appropriate amount of M-PER Mammalian Protein Extraction Reagent 
(Thermo Scientific) supplemented with EDTA, Halt Protease Inhibitor Cocktail (Thermo 
Scientific) was added to the wells. Cells were incubated with the lysis mix for 10 min on 
ice before they were dislodged using a cell scraper. Cell lysate was transferred to a 1.5 ml 
microfuge tube and centrifuged at 16,000 g for 10 min at 4 °C to remove cell debris. The 
supernatant fraction was aliquoted and stored in -80 °C. Protein concentration was 
determined by the method of Bradford (Bradford, 1976), using bovine serum albumin 
(Bio-Rad, Hercules, CA, USA) as a standard. Protein Assay Dye Reagent (Bio-Rad) was 
diluted with de-ionised water (1:4) before it was filtered to remove any particulate that 
may interfere with absorbance reading. Five serial dilutions were made to the BSA stock 
(ranging from 0.05 to 0.5 mg/ml) for microtiter plate assay. Ten microlitres of diluted 
BSA and protein samples were pipetted into individual well before 200 µl of protein dye 
was added. The protein-dye mix was incubated for 5 min at room temperature away from 
light prior to absorbance reading at 595 nm in a GENios plate reader (Tecan Group Ltd, 




2.14.2 Preparation of sodium dodecyl sulphate polyacrylamide gel 
 The spacer and glass plates were wiped with 70% alcohol and air dried before 
they were assembled onto a casting frame and stand. Resolving gel was first prepared in 
sequential order according to Table 2.5.  
Table 2.5 Recipe for 2 pieces of SDS gels with 10 % Resolving and 5 % Stacking 
components.   
 
Reagents 10% Resolving Gel 5% Stacking Gel 
De-ionized Water 4000µl 3400 µl 
30% Polyacrylamide Mix 3300 µl 830 µl 
1.5 M Tris pH8.8 2500 µl - 
1.0 M Tris pH6.8 - 630 µl 
10 % SDS 100 µl 50 µl 
10 % APS 100 µl 50 µl 
TEMED 4 µl 5 µl 
Total Volume 10 ml 5 ml 
 
The gel mix was loaded into the space between spacer and glass plate to a height 
1 cm below the comb before de-ionized water was co-introduced immediately to layer the 
gel surface and prevent air bubble formation. Resolving gel was allowed to ploymerize 
for at least 20 min at ambient temperature. After the gel has completely polymerized, 
overlying water was drained by decanting and replaced by 5% Stacking gel prepared 
according to Table 2.5. A comb was inserted before polymerization of the 
polyacrylamide gel took place. Stacking gel was allowed to polymerize for an additional 
20 min before the comb was removed.  
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2.14.3 Sample preparation 
 Twenty micrograms of total cell lysate was mixed with 5X loading buffer 
containing 250 mM Tris-Cl (pH 6.8), 10% SDD, 30% glycerol, 5% dithiothretol and 
0.02% bromophenol blue (w/v) was boiled for 10 min before loading into the 
polyacrylamide gel for electrophoreisis.      
 
2.14.4 Protein separation on SDS-PAGE     
 Precision Plus Protein dual colour marker (Bio-rad) and twenty micrograms of 
denatured protein samples were loaded into the wells of the polymerized gels respectively 
before SDS-gel was resolved at 100V until the blue dye front reached the end of the gel 
in 1X Tris-glycine SDS electrophoreisis buffer. 
 
2.14.5 Transfer of protein 
 Polyvinyl difluoride (PVDF) membrane was activated in methanol for 15 s before 
it was equilibrated in 1X Transfer Buffer comprising of 20% (v/v) methanol, 25 mM Tris 
and 192 mM glycine. After electrophoreisis, a gel sandwich was assembled first with a 
filter pad at placed the bottom. This was succeeded by layering of the PVDF membrane 
followed by the SDS-gel before the sandwich was completed by the final addition of 
another filter pad. Extra caution should be exercised to prevent bubbles from forming in 
between the sandwich layers that could affect the transfer process. Protein transfer was 




2.14.6 Western Blot 
 Once the transfer of protein was completed, the PVDF membrane was blocked 
with Superblock reagent in TBS (Thermo Scientific) for an hour at room temperature 
with agitation. Subsequently, the protein bound membrane was incubated overnight at 4 
°C with primary antibodies solution. Blot was rinsed thrice in 1X TBS supplemented 
with 1% Tween-20 (1X TBST) with shaking on a platform shaker the following day prior 
to secondary antibody incubation for an addition 1 h. Post secondary antibody washing 
was performed thrice with 1X TBST for a interval of 10 min. Dilution of antibodies used 
to perform immunoblotting were summarized in Table 2.6.   
 For enhanced chemiluminescence (ECL) detection, Supersignal West Pico 
substrate (Thermo Scientific) was added to the immunoblots for visualization the protein 
bands. Equal volumes of stable peroxide solution and luminol solution were mixed and 
applied to the membrane. After 5 min incubation in the dark, excess substrate was 
drained off the membrane before it was transferred to a film cassette. CL-XPosure films 
(Thermo Scientific) were exposed according to sensitivity and developed using an 









Table 2.6 Antibody dilutions for Western Blot procedure. 
Primary Ab Antibody dilution Secondary Ab Antibody dilution 




ERK1 1:5000 Goat anti-mouse 
IgG HRP antibody 
1:1000 
 
ERK2 1:5000 Goat anti-mouse 
IgG HRP antibody 
1:1000 
 
MEK1 1: 1000 Goat anti-mouse 




MEK2 1: 2500 Goat anti-mouse 




MEK5 1:1000 Goat anti-mouse 
IgG HRP antibody 
1:1000 
 
ERK (pan) 1:5000 Goat anti-mouse 
IgG HRP antibody 
1:1000 
 
β-actin 1:1000 Goat anti-mouse 




2.14.7 Densitometric analysis of immuno-blot   
 Protein band intensities were analyzed using the GS-7000 Imaging Densitometer 
(Bio-rad). Images of Western blot captured on X-ray films were scanned and intensities 
of bands were measured using Quantity-One Image Analysis Software (Version 4.62) 
(Bio-rad). Protein expression was quantified when the ratio representing band intensities 
between target genes and loading controls [β-actin and ERK (pan)] were compared and 





2.15 Statistical Analysis 
 Values are presented as means ± standard error of the mean (SEM). Unpaired, 
two tailed, Student‟s t-test or One-way ANOVA followed by post hoc Tukey test was 
performed using GraphPad Prism version 5.00 for in vitro experiments. Only p <0.05 was 
considered to be statistically significant.   
 
2.16 Clinical patient samples 
2.16.1 Tissue Scan Array 
To profile the expression of MT-2A in human samples, real-time PCR analysis 
was performed on a 7500 HT Real-time PCR system (Applied Biosystems, Foster City, 
CA, USA) using cDNA extracted from surgical breast cancer tissue and biopsies. Briefly, 
archived tissue were retrieved from Cytomyx biorepositry and pre-normalized against β-
actin house-keeping gene after RNA intergirty was determined by Agilent Bioanalyzer 
and gel electrophoresis. Normalized samples from a cohort of 48 female patients of 
Caucasian heritage were seeded into a Tissuescan PCR plate (Origene, Rockville, MD, 
USA) before MT-2A specific primers reconstituted as a master mix with SYBR Green 
(Qiagen) was applied to the wells and sealed. After the run, MT-2A expression was 
calculated according to the method described in section before it was co-related with 
pathological indexes.    
 
2.16.2 Immunohistochemical staining of invasive ductal carcinomas 
 Tissue microarray (TMA) blocks of archival paraffin-embedded breast cancer 
specimens previously constructed by the Department of Pathology, Singapore General 
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Hospital (SGH) were used for this study with ethics approval from the hospital‟s 
Institutional Review Board. These TMA slides contained representative samples obtained 
from 99 female patients who were diagnosed with invasive ductal carcinoma (IDC) for 
the duration between years 2000 to 2006. Briefly, patient biopsies collected by 
pathologist were fixed in 10% formalin and embedded in paraffin. Using a 1 mm punch, 
cores of IDC were punched out from preselected and marked areas of the paraffin-fixed 
tissue and inserted sequentially into different recipient blocks using a microarrayer. Each 
recipient block contained 60 tissue punches and four blocks, namely, SP1-07, SP14A-06, 
TB1-04 and TB2-04, were used to construct the TMAs. Four micron thick sections cut 
from these blocks to be mounted onto silane (3-aminopropyltriethoxysilance; Sigma) 
coated glass slides and dried overnight at 37 
o
C for immunohistological staining 
Clinicopathological information of patients included their age, race, tumour size, 
staging, histological grade, steroid hormone receptors, namely estrogen receptors and 
progesterone receptors, epidermal growth factor receptor, lymph node status, and 
recurrence/metastasis status are depicted in Table 2.7. All information was retrieved from 
patients‟ record collated by Department of Pathology, SGH. Ethics approval was 































































Lymph node involvement 
None 8 8.4
1 to 3 20 20.2









2.16.3 Immunohistochemical staining of breast cancer tissues 
 Immuno-staining for TMA sections were performed on the Bond Max (Leica, 
Wetzlar, Germany) automated platform using E9 clone of antibody raised against MT. 
All the other reagents used in this procedure were purchased from Leica unless specified 
otherwise. Briefly, the TMA sections were first dewaxed and washed in ethanol and 
Bond wash solution respectively before heat activated epitope retrieval (HIER) with 
citrate buffer (pH 9.0) was performed for 20 min. Endogenous peroxidase activity was 
quenched by Peroxidase block and washed thrice before E9 antibody (Dako Corporation) 
was applied to the slides after diluting (1:100) with primary antibody diluent (Leica). 
Primary antibody was incubated for 15 min at room temperature and washed with Bond 
wash solution. The slides were further incubated with Polymer solution for 8 min and 
washing was repeated with Bond wash solution. Following a quick rinsed with de-ionized 
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water, Mixed DAB refine solution was incubated with the TMA sections for 10 min 
before washing. The slides were counter-stained with haematoxylin for 5 min before 
excess stain were rinsed off with de-ionized water and Bond wash solution subsequently. 
The processed slides were dehydrated through a series of alcohol and Histoclear before a 
coverslip was mounted for viewing under light microscope.       
 
2.16.4 Quantitation of immunohistochemical staining 
The stained sections were scanned with Scanscope scanner (Aperio, Vista, CA, 
USA) and viewed using the Aperio ImageScope software (Aperio) for scoring purposes. 
Intensity of staining and the corresponding percentage of immunopositivity were scored 
independently by one individual and verified by a pathologist, Dr Aye Aye Thike, from 
the Department of Pathology, SGH. The intensity of cytoplasmic and nuclear MT 
staining was scored as 0 (no detectable staining), 1+ (light staining), 2+ (moderate 
staining) and 3+ (strong staining).  
 
2.16.5 Statistical analysis 
The SPSS software Version 18.0 for Windows (SPSS, Chicago, IL, USA) was 
used for statistical analysis. Co-relation of MT-1/2 immunohistological staining was 
assessed with clinicopathological parameters and verified by Student‟s t-test and 





















































3.1 Morphological features of breast cancer cells 
 
 The breast cancer cells examined in this study included MCF-12A, MCF-7, ZR-




Figure 3.1 Morphology of breast cancer cells. Micrographs of various breast cancer 
cell lines of epithelial origins as observed under light microscopy. Bar represents 200 µm.   
 
MCF-12A is a non-tumuorigenic, immortalized cell line established from 
intraductal hyperplasia of a Caucasian female patient undergoing reduction 
mammoplasty. These adherent cells exhibit luminal epithelial morphology, expressing 
epithelial markers cytokeratin 8, 14 and 18 respectively (Paine et al, 1992). On the other 
hand, epithelial-shaped MCF-7 belongs to a class of ER- and PR- positive breast cancer 
cell lines demonstrating low invasive capabilities in vitro (Thompson et al, 1992; Tong et 
al, 1999). Likewise, ZR-75 breast cancer cells also exhibit ER and PR co-positivity and 
was considered non-invasive due to its inability to penetrate through collagen fibroblast 
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matrix (Thompson et al, 1992). Similarly, cancerous cells of T-47D lineage isolated from 
pleural effusion from a 54 year old patient by Keydar and colleagues (Keydar et al, 1979) 
also co-expressed hormonal receptors ER and PR. Artificial basement membrane assay 
confirmed the non-invasiveness of these cells after they failed to invade though collagen 
fibroblast matrix (Thompson et al, 1992) On the contrary, spindle-shaped MDA-MB 231 
breast cancer cells displayed an invasive phenotype compared to its counterparts as 
validated by chamber invasion and chemotaxis assays (Thompson et al, 1992). Carmerci 
et al attributed this aggressive phenotype to the ER negativity of the breast cancer cells 
(Carmeci et al, 1998). MDA-MB231 cells were also found to be PR negative as well. 
Generally, the aggressiveness of various breast cancer cell lines range from non-invasive 
MCF-7 and ZR-75, to mildly invasive T47D and highly metastatic MDA-MB231.       
        
3.2 Evaluation of MT isoforms in breast cancer cells 
 
 Real-time PCR quantification using isoform specific primers (Mididoddi et al, 
1996) revealed a diverse MT expression profile in the various types of transformed cells 
examined (Fig 3.2). Threshold cycle (Ct) values of individual MT isoforms were 
normalized against the hosusekeeping G3PDH gene and relative expression was 
calculated. Three MT isoforms, viz. MT-1F, 1X and 2A were commonly expressed in all 
the cell lines included in this study, with MT-2A displaying the highest level of 
expression. While transcripts representing MT-1A and MT-1E were detected in both 
MCF-12A and MDA-MB231 cells, MT-1B, 1H and 1G were notably absent. MT-3 and 
MT-4 were undetectable in this set of breast cancer cell sample, consistent with previous 
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reports of their specific expression in breast tumours and stratified epithelia exclusively 
(Gurel et al, 2003; Quaife et al, 1994).   
 
Figure 3.2 Quantitative expressions of MT-1 and MT-2 isoforms in various breast 
cancer cell lines. Using G3PDH gene for normalization, adjusted expression of MT 
isoforms were evaluated for the non-tumourigenic MCF-12A, non-invasive breast cancer 
cell MCF-7, ZR-75, T-47D and highly invasive MDA-MB231 respectively. Each column 
represents mean ΔCt values ± standard error mean (SEM) for individual MT isoform. A 
lower mean ΔCt value corresponded to a higher level of transcript expression.    
 
 
Figure 3.3 A typical melting curve analysis output. Each peak denotes the specificity 
of the primer pairs to form single amplicon. This validation step helps to identify primer 
dimerization during real-time PCR procedure that may confound quantification.  
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Specificity of the primers used in the quantitative PCR procedure were validated 
via melting curve analysis (Fig 3.3) and gel electrophoreisis (Fig 3.4), where singled 
banded amplicons were observed. 



















Figure 3.4 Expression profiles of functional MT isoforms in various lineages of 
breast cancer cells. Amplicons representative of each MT isoform were separated on a 
2% agarose gel and visualized under ultraviolet illumination. Legend, Lane M, DNA 
marker; Lane G, G3PDH (160 bp); Lane 1A, MT-1A (219 bp); Lane 1E, MT-1E (284 
bp); Lane 1F, MT-1F (232 bp); Lane 1X, MT-1X (151 bp); Lane 2A, MT-2A (259 bp).       
 
3.3 Immunocytochemistry of MT-1/2 expression in breast cancer cell lines 
 Using the E9 clone of antibody, immunostaining was performed on the luminal 
breast cancer cells. Positive MT-staining was observed in all the breast cancer cells, 
demonstrating both cytoplasmic and nuclear staining under the light microscope (Fig 
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3.5). MT staining was intense in all except ZR-75 cells, which portrayed weak and 
diffused staining. Incidentally, both MCF-12A and MDA-MB231 exhibited the most 
intensified MT staining, a consequence of higher overall MT isoforms expression 
endogenously compared to the rest of the cell lines evaluated. Previously, it was 
suggested that aggressiveness of the breast cancer cell is associated with the intensity of 
MT immuno-staining, whereby cell lines of lesser invasive potential (MCF-7, ZR-75 and 
T-47D) were lightly stained in contrast to metastatic MDA-MB231 cells (Tai et al, 2003). 
Negative control where the primary antibody was replaced by diluents showed minimal 
or no staining when DAB substrate was added.     
 
 
Figure 3.5 Light micrographs of MT immunocytochemistry in breast cancer cells. 
Various cancer cell lines displayed variable intensity of MT staining. Cells were 
counterstained with haematoxylin and cells in the negative control group were incubated 





3.4 Transient over-expression of MT-2A isoform in MCF-7 cells 
 As demonstrated in section 3.3, higher MT expression associated with aggressive 
phenotype of breast cancer cells, particularly in MDA-MB231. MT-2A isoform was 
found to have the highest expression in these breast cancer cell lines and previous studies 
by Jin et al (2002) and Tai et al (2003) have identified that MT-2A may be involved in 
cell proliferation and invasiveness of breast cancer.  
 
Figure 3.6 Transfection of MCF-7 cells with PXJ40 and 6633 vectors. (A) An 
amplicon of 183 bp was detected after PCR amplification, representative of MT-2A 
coding region. (B) Successfully transfected cells expressed EGFP as observed under 
fluorescent microscopy. (C) Real-time PCR validation of MT-2A expression 24hr post 
transfection (***, p-value <0.001). Lane M- DNA marker; Bar = 100 µm; columns-
means ± SEM, n=3.     
 
Henceforth, to evaluate these co-relationships, MT-2A gene was up-regulated in 
MCF-7 breast cancer cells, one of the cell lines that demonstrated low expression for this 
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isoform amongst the cell lines screened. The successful cloning of 183 bp coding 
sequence (CDS) region of MT-2A into PXJ40 expression vector (6633) and its subsequent 
transfection into MCF-7 led to ~185 fold up-regulation of MT-2A transgene by qPCR 
(Fig. 3.6 A and C) in comparison to PXJ40 control vector group. A transfection 
efficiency of ~32.7% was achieved by calculating the number of cells illuminated by 
EGFP expression.  
Due to the lack of a well-established Western Blot procedure to detect low 
molecular weight MT protein, determination of MT over-expression was verified using 
immunocytochemistry instead (Fig 3.7). The intensity of MT immunopositive staining 
was significantly up-regulated in cells transfected with 6633 MT-2A over-expressing 
plasmid (Fig 3.7C). To further quantify the immunostaining, five random views of each 
triplicate experiments were captured at 400X magnification under light microscope and 
the intensity of the staining were evaluated accordingly. Although staining appeared 
heterogenous and diffused, mean MT immunopositivity score for 6633 MT-
overexpressing treatment group (1.66) was compared to PXJ40 control vector transfected 













Figure 3.7 Immunocytochemical analysis of MT-2A transient over-expression. 
Intensity of MT immunoreactivity in (A) immunocytochemistry control (B) pXJ40 and 
(C) 6633 transfected cells as viewed under light microscope respectively 48hr post 
transfection. Nuclear staining was performed using haematoxylin. (D) Immunopositive 
scores of corresponding MT-1/2 staining were determined in pXJ40 and 6633 treated 
cells. Statistical analysis was performed using the Student‟s T-test (**, p-value <0.01). 
Bar = 50 µm; columns-means ± SEM.     
 
 
3.5 Generation of a clone stably transfected MCF-7 cells over-expressing MT-2A 
transgene 
 
 To obtain a homogenous population of cells constitutively over-expressing MT-
2A isoform, MCF-7 cells were selected using G418 antibiotics after successful cloning 
into pIRES2-EGFP mammalian expression system and delivered intracellularly via 
lipofection. Transformant cells co-expressed EGFP that emitted green fluorescence after 
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excitation at 480 nm (Fig 3.8 B). Only cells transfected with the plasmid carrying the 
MT-2A CDS DNA fragment (MT-2AOE) generated a 183 bp amplicon after qPCR 
amplification (Fig 3.8 A). Driven by the cytomegalovirus promoter, MT-2A transcript 
was up-regulated by ~ 76 fold compared to pIRES control group confirmed by real-time 
PCR.  
 
Figure 3.8 Stable transfection of MT-2A isoform in MCF-7. (A) A DNA fragment of 
183 bp which is representative of MT-2A coding region was exclusively observed in the 
MT2AOE transfected cells after real-time PCR amplification. (B) Successful 
transformants co-expressed EGFP under physiological conditions after G418 selection. 
(C) Real-time PCR validation of MT-2A expression 24hr post transfection (***, p-value 
<0.001). Lane M- DNA marker; Bar = 100 µm; columns-means ± SEM, n=3.     
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Since MCF-7 expressed MT-1F and MT-1X endogenously, expression levels of 
these two isoforms were investigated to evaluate if they were affected by the exogenous 
introduction of the MT-2AO/E expression vector. Both isoforms showed little or 
negligible compensatory effect even though up-regulation of MT-1X (~1.4 fold) was 
statistically significant (p-value <0.05) (Fig 3.9).  
 
Figure 3.9 Quantitative expressions of MT-1F and MT-1X isoforms in MT2AOE 
stable-transfected cells. Endogenous levels of MT-1F and MT-1X were marginally 
increased as determined by real-time PCR. Relative expression was calculated by 
comparing expression level of the two isoforms against G3PDH house-keeping gene and 
only MT-1X transcript was determined to be statistically up-regulated (*, p-value <0.05). 
Results are presented as means ± SEM of triplicate experiments.     
 
MT-1/2 protein levels were also up-regulated concomitantly as demonstrated by 
immunostaining, with MT2AOE cell population exhibiting 2-fold change over pIRES 
control group (Fig 3.10). MT2AOE cells (Fig. 3.10 C) homogenously displayed elevated 
DAB staining compared to their pIRES transfected counterparts (Fig 3.10 B) and this 
increased intensity of staining coincided with MT2AOE cells having higher overall 
immunopositive score (2.0 vs 1.0), whereby the highest possible score is 2 in a single 
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view with breast cancer cells demonstrating strong immuno-staining under 40X 
magnification (Fig. 3.10 D).  
 
Figure 3.10 Immunohistochemical profile of MT-1/2 staining in pIRES and 
MT2AOE stable transfected cell lines. Profound DAB staining was observed in (B) 
pIRES and (C) MT2AOE transfected cells after antibiotic selection. (A) Staining control 
cells displayed only haematoxylin staining after E9 antibody was substituted with 
blocking buffer instead for immunostaining procedure. (D) Immunopositive scores of 
corresponding MT-1/2 staining were evaluated in pIRES and MT2AOE cells and tested 
for statistical significance using the Student‟s T-test (***, p-value <0.001). Results are 
representative of means ± SEM of three independent experiments. Bar = 50 µm. 
 
3.6 MT-2A over-expression increased MCF-7 cancer cell proliferation      
 
 Over-expressing the MT-2A isoform led to increased cell growth in breast cancer 
cells confirmed by alarmaBlue cell viability and MTT cell proliferation assays 
respectively (Fig 3.11). Cell proliferation assay showed that MT2AOE cells exhibited a 
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growth advantage over the pIRES stable transfected cells over a duration of 72 h (p-value 
<0.001) (Fig 3.11 A). Growth curve analysis monitored using a non-toxic alarmaBlue cell 
viability assay mirrored the increased growth rate conferred by MT-2A over-expression 
(p-value <0.001) (Fig 3.11 B).   
 
Figure 3.11 Over-expression of MT-2A isoform enhanced cell proliferation in MCF-
7 breast cancers. (A) Formazan-based cell proliferation assay was employed to 
determine the growth rate in pIRES and MT2AOE stable transfected cell lines. Relative 
absorbance was determined by the difference between absorbance at 570nm with respect 
to the reference wavelength at 650nm. (B) Viability of breast cancer cells was assessed 
using alarmarBlue reagent over a 72 h period after G418 selection. Fluorescence signal 
from viable cells was measured after excitation at 570 nm and emission at 585 nm. 
Statistical analysis performed using two-way ANOVA determined that both sets of 
results were statistically significant (p-value <0.001). Results presented are indicative of 
triplicate experiments and bars represent standard error of means.  
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Figure 3.12 Western blot analyses of MEKs and ERKs in stable-transfected cell 
lines. (A) Protein expression of MEK5, MEK1, MEK 2, ERK 1 and ERK 2 were 
evaluated in pIRES and MT2AOE cells via immunoblotting with specific antibodies. β-
actin served as loading control. (B) Volumetric analysis of the band intensities of the 
corresponding blots. Results are representative of three independent experiments. Lane P, 
pIRES; Lane E, MT2AOE. 
 
Further evaluation was conducted to check for the involvement of MAPK 
signaling in this cell proliferative observation in ER-positive MCF-7 cells after MT-2A 
up-regulation. Expression levels of members involved in the pathway were checked with 
Western Blot using antibodies targeting extracellular signal regulated kinases ERK1and 
ERK2, as well as their upstream regulators ERK kinases MEK1 and MEK 2 together 
with MEK5 was evaluated. While immunoblotting did not detect any change in protein 
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expression for ERK 1, ERK 2, MEK1 and MEK 2, MEK 5 was found to be up-regulated 
after MT-2A over-expression (Fig 3.12).     
 
3.7 Effects of MT-2A over-expression on cell motility 
 In general, non-invasive MCF-7 cells demonstrated elevated migratory and 
invasive behavior after MT-2A up-regulation (Fig 3.13 and Fig 3.14). 
 
Figure 3.13 Over-expression of MT-2A isoform in MCF-7 cells promoted cell 
migration. (A) Parental MCF-7 was included to control for inherent migratory capability 
of these cells. (B) pIRES and (C) MT2AOE cells that had migrated through the 
polycarbonate inserts were stained with crystal violet. (D) Total number of cells that had 
migrated was counted before relative migration was determined using pIRES cells as 
baseline group. No significant difference was detected between MCF-7 and pIRES cells 
(p-value >0.05). One-way ANOVA test confirmed the statistical significance of the cell 
counts (***, p-value <0.001). Results shown are representative of triplicate experiments. 
Bar represented 100 µm.   
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Transwell migration assay employed demonstrated a remarkable increase in the 
migratory rate in breast cancer cells carrying the MT-2A transgene (Fig 3.13 C) over 
control vector treatment (Fig 3.13 B) and parental MCF-7 cells. This represented a 3.89 
fold (389.34 ± 9.85 % vs 100 ± 5.11 %) increase when comparison of migratory rate 
between MT2AOE cells and pIRES was made (Fig 3.13 D)(p-value < 0.001).   
 
Figure 3.14 Up-regulation of MT-2A isoform induced cell invasion in vitro. (A) 
Parental MCF-7 showed minimal intrinsic cell invasion after a 24 h incubation duration. 
(B and C) Stable-transfected MT2AOE cells acquired extensive invasive capability 
compared to pIRES vector control. (D) Total number of MT2AOE cells that had invaded 
through the membrane was significantly higher than baseline pIRES group, as well as 
MCF-7. n=3, mean ± SEM. One-way ANOVA test was performed and p-value was 
determined to be less than 0.001 (***). No significant difference was detected in 




Moreover, breast cancer cells also displayed concomitant invasiveness after MT-
2A elevation. MT2AOE cells illustrated a prominent increase in the number of which 
invaded through the Matrigel coated chamber after incubation (Fig 3.14 B and C). This 
invasive capability was enhanced by ~10.2 fold (1018.52 ± 53.67 % vs 100 ± 12.56%) 
compared to pIRES baseline group (Fig 3.14 D)(p-value <0.001). 
 
3.8 Down regulation of MT-2A isoform via RNA interference 
 To address the biological and functional significance of aberrant MT-2A 
expression, chemically synthesized siNEG, siAClam, siMT2A_1 and siMT2A_2 were 
purchased for validating the silencing of MT-2A transcripts in MCF-7 breast cancer cells. 
Figure 3.15 depicted the regions targeted by the two independent silencing duplexes 
directed against MT-2A isoform. Transfection efficiency was monitored using a Cy3-
labelled siRNA with a scrambled sequence (Fig 3.16 A and B). By counting the number 
of cells illuminated per view, transfection efficiency was determined as ~93.7%. Gene 
targeting siRNAs successfully knock-down positive control A/C lamin and MT-2A genes 
by 71.55 %, 91.36 % and 91.82 % using siAClamin, siMT2A_1and siMT2A_2 
respectively through real-time PCR quantification (Fig. 3.16 C).      
 
Figure 3.15 Graphical representation of MT-2A mRNA (NM_005953) and the 




Figure 3.16 Transfection and silencing efficiencies of MT-2A targeting siRNAs. (A) 
Transfection efficiency of the silencing protocol was validated by quantifying the 
distribution of cyanine 3 labelled siRNA in MCF-7 cells 24 h post transfection. (B) A 
magnified view of the inset in (A), showing that most of the siRNA accumulated in the 
cytosol to exert its silencing effect, where protein translation takes place within a 
mammalian cell. (C) Total RNA was extracted and converted to cDNA before analysis by 
quantitative real-time PCR. The housekeeping gene used for normalization was G3PDH. 
Silencing efficiencies of A/C lamin and MT-2A were measured 48 h post-transfection 
with siAClamin, siMT2A_1 and siMT2A_2 respectively in comparison with siNEG 






Figure 3.17 Expression level of MT-1X isoform was down-regulated after MT-2A 
silencing with siMT2A_1. MT-1X expression was decreased in siMT2A_1 transfected 
cells confirmed by real-time PCR. Relative expression was calculated by comparing 
expression level of MT-1X transcript against G3PDH house-keeping gene. Results are 
presented as means ± SEM of triplicate experiments and statistical significance was 
verified by one-way ANOVA (**, p-value <0.01).      
 
To check the specificities of siMT2A_1 and siMT2A_2, expression levels of other 
MT isoforms were analyzed via real-time PCR. While MT-1F expression was unaffected 
by both silencing duplexes, MT-1X isoform was down-regulated by siMT2A_1 by 66.21 
% (Fig 3.17). This was due to the high homology (95% or 19/20 bases) between a 
common region encoded within the coding sequences of MT-1X and MT-2A by which 
siMT2A_1 targets (Fig 3.18). However, siMT2A_1 was still employed for validation of 








CLUSTAL W (1.83) multiple sequence alignment 
 
 
MT2A            ATGGATCCCAACTGCTCCTGCGCCGCCGGTGACTCCTGCACCTGCGCCGGCTCCTGCAAA 60 
MT1X            ATGGACCCCAACTGCTCCTGCTCGCCTGTTGGCTCCTGTGCCTGTGCCGGCTCCTGCAAA 60 
                ***** *************** *  * * ** ******  **** *************** 
 
MT2A            TGCAAAGAGTGCAAATGCACCTCCTGCAAGAAAAGCTGCTGCTCCTGCTGCCCTGTGGGC 120 
MT1X            TGCAAAGAGTGCAAATGCACCTCCTGCAAGAAGAGCTGCTGCTCCTGCTGCCCTGTGGGC 120 
                ******************************** *************************** 
 
MT2A            TGTGCCAAGTGTGCCCAGGGCTGCATCTGCAAAGGGGCGTCGGACAAGTGCAGCTGCTGC 180 
MT1X            TGTGCCAAGTGTGCCCAGGGCTGCATCTGCAAAGGGACGTCAGACAAGTGCAGCTGCTGT 180 
                ************************************ **** *****************  
 
MT2A            GCCTGA 186 
MT1X            GCCTGA 186 
                ****** 
Figure 3.18 Comparison of coding regions between MT-1X and MT-2A isoforms by 
Clustal W. Sequence alignment of CDS regions between the two MT isoforms with 
mismatch bases demarcated in blue. DNA sequence highlighted in yellow is 
representative of the intended target region of siMT2A_1.  
 
 
3.9 MT-2A silenced cells show reduced protein expression via immunostaining 
Immunochemical analysis revealed that MT protein also showed concomitant 
down regulation after MT-2A silencing. Cells were incubated with blocking solution in 
place of E9 antibody to control for background staining is shown in Fig. 3.19 A. 
Prominent reduction was observed in immunopositive staining of  MT protein in MCF-7 
breast cancer cells (Fig 3.19 C and D) as compared with the siNegative-treated control 
(Fig 3.19 B). Lower immunopositivity scores were also recorded for MT-2A silenced 







Figure 3.19 Evaluation of MT protein expression by immunohistochemistry after 
MT-2A silencing. Immunohistological profile of MT-1/2 staining in MCF-7 breast 
cancer cells transfected with (B) siNEG, (C) siMT-2A_1 and (D) siMT2A_2 after 72 h. 
Immunostaining was less intense in MT-2A silenced cells (C and D). (A) Staining control 
demonstrated haematoxylin counterstaining with no or minimal non-specific brown 
colourization. (E) One-way ANOVA confirmed that the reduction in staining intensity 
associated with MT-2A silencing was statistical significant when siMT2A_1 and 
siMT2A_2 were compared with siNEG treated cells respectively (***, p-value <0.001). 




3.10 MT-2A silencing decreases cell viability and proliferation 
As quantified by MTT assay, fewer numbers of proliferating cells were observed 
after MT-2A down regulation (Fig. 3.20 A) in MCF-7 cell population.  
 
Figure 3.20 MT-2A silencing led to lower cell viability and proliferation in MCF-7 
cells. (A) Cells were less viable after MT-2A silencing demonstrated by tetrazolium based 
viability MTT assay 72h after transfection. Absorbance reading taken at 570nm 
wavelength is a surrogate measure for numbers of viable cells in each well. (B) After a 
four hour incubation, fluorescence intensity of the alamarBlue reagent recorded was 
directly proportional to number of viable cells per well.  Data shown are mean readings 
of triplicate experiments carried out for each data point. Error bars = standard error of 
means. Two-way ANOVA, p-value<0.05 
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Cell viability decreased to approximately 87% in both sub-populations in which 
MT-2A has been down-regulated using siMT2A_1 and siMT2A_2 respectively compared 
to control after 72h (p-value <0.05). Likewise, growth curve analysis also recorded 
significant cell proliferation with time in siNEG treated cells whereas MT-2A silencing 
limited cell growth in siMT2A_1 and siMT2A_2 transfected populations respectively 
(Fig 3.20 B).    
 
Figure 3.21 Down-regulation of MEK 5 was associated with decreased cell 
proliferation and viability after MT-2A silencing. (A) Cell lysates were examined by 
Western Blot quantification with antibodies specific towards MEK1, MEK 2, MEK5, 
ERK 1 and ERK 2 after respective siRNAs treatment. Equal loading was confirmed with 
β-actin and results shown are representative of three independent experiments. (B) 
Densitometric analysis of the corresponding MAPKs protein bands. Lane P, pIRES; Lane 
N, siNEG; Lane 1, siMT2A_1; Lane 2, siMT2A_2. 
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This slower growth rate observed in siMT2As treated cancer cells coincided with 
a decrease in MEK 5 expression as determined by Western blotting (Fig. 3.21). Band 
intensities for MEK 5 after siMT2A_1 and siMT2A_2 treatments were markedly reduced 
compared to control group while protein expression of other ERKs and MEKs remained 
relatively unchanged 72 h after the transfection procedure.   
 
3.11 Cell motility was affected in MCF-7 cells after MT-2A silencing  
 RNAi mediated down regulation of MT-2A attenuated the migratory and 
invasive capabilities of MCF-7 breast cancer cells (Fig 3.22 and 3.23). Migration rate of 
MCF-7 cells through Transwell membrane declined by 71.54 ± 3.90 % and 59.06 ± 5.45 
% in siMT2A_1 and siMT2A_2 transfected cells respectively (Fig 3.22 D) (p-value 
<0.01). Correspondingly, siMT2A_1 and siMT2A_2 treatments resulted in extensive 
reduction in the number of cell that successfully invaded through the Matrigel coated 
membrane compared to control (Fig 3.23 A, B and C). This drop represented a decline of 
67.37 ± 5.01 % and 57.85 ± 4.51 % in the number of invading cells in MCF-7 treated 
with siMT2A_1 and siMT2A_2 silencing duplexes respectively in comparison to siNEG 
baseline treatment. The quantitative analysis had a p-value of less than 0.01 as 
determined by one-way ANOVA. 




Figure 3.22 Suppression of MT-2A isoform in MCF-7 cells limited cell migration. 
MCF-7 cells transfected with siNEG (A), siMT2A_1 (B) and siMT2A_2 (C) exhibited 
varied migratory behaviors. Cells that passed through the polycarbonate inserts were 
stained with crystal violet to aid visualization. (D) Total number of migrated cells was 
quantified before relative migration was determined using siNEG treated cells as 
baseline. One-way ANOVA test confirmed the statistical significance of the cell counts 
(**, p-value <0.01). No statistically significance was noted between siMT2A_1 and 
siMT2A_2 silenced cells (p-value >0.05). Results shown are representative of triplicate 





Figure 3.23 Invasive potential was curtailed in MCF-7 cells following MT-2A knock-
down. Micrographs depicting MCF-7 cells pre-treated with (A) siNEG, (B) siMT2A_1 
and (C) siMT2A_2 siRNAs were analyzed on their abilities to penetrate a membranous 
barrier. (D) Assessment on their in vitro invasiveness was achieved by counting the total 
number of cells that had passed through the Matrigel inserts after 24 h. No significant 
difference was detected between siMT2A_1 and siMT2A_2 treated cells (p-value >0.05). 
One-way ANOVA test confirmed the statistical significance of the cell counts (**, p-
value <0.01). Results shown are representative of triplicate experiments. Bar represented 









3.12 Silencing of MT-2A gene induced the formation of cell-in-cell phenomenon 
 As viewed under the light microscope, a subpopulation (2.35 ± 0.07%) of MCF-7 
breast cancer cells was found to be enclosed within another cell in culture following MT-
2A silencing (Fig 3.24 A). Engulfing and internalized cells had lower MT expression in 
comparison to non-engulfing MCF-7 cells as evidenced by immunostaining (Fig 3.24 B). 
 
Figure 3.24 Examination of MCF-7 cells 72 hr after siMT2A_1 and siMT2A_2 
treatment under light microscopy. (A) Presence of cell-within-cell structures were 
indicated by white arrows in semi-thins fixed samples stained with methylene blue. (B) 
MT immunocytochemical staining demonstrating both engulfing cells and internalized 
cells (white arrow) displayed lower MT-1/2 protein expression as opposed to more 
intensified MT-staining exhibited by non-engulfing counterpart (black arrow) when E9 
antibody was employed. Bar represented 30 µm.  
 
 This phenomenon of an adherent breast cancer cell being interiorized into a 
neighbouring cell is verified by ultrastructural examination under transmission electron 
microscopy (Fig 3.25). A common fate for these “interiorized” cells was cell death as 
shown by the presence of large lysosomes in the cytoplasm of some siMT2A–treated 
cells (Fig 3.25 C and D).  
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Figure 3.25 Electron-micrographs of MCF-7 cells undergoing entosis after MT-2A 
silencing. Transmission electron microscopy showed the presence of cell-in-cell 
cytological features in siMT2A_1 (A) and siMT2A_2 (B) transfected cell populations. 
Internalized cell appears to undergo lysosomal degradation after siMT2A_1 (C) and 
siMT2A_2 introduction (D). No entosis was observed in untreated or siNegative treated 
cells. Scale bar= 5 μm.  
 
To further examine the  cyto-architecture of the internalized cell within the MT-
2A silenced cells, adherent junction which was recently described by Overholtzer et al. 
(2007) to be important for cell internalization, was selected as a marker for 
immunofluorescence microscopy (Overholtzer et al, 2007). Beta–catenin (green) and 
phalloidin (red) co-labeling revealed that adherent junction might also play an important 
role in this entotic sighting observed in MT-2A silenced cells, leading to its eventual cell 
death by lysosomal degradation (Fig 3.26).           
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Figure 3.26 Formation of adherent junction is important for cell cannibalism in 
MCF-7 cells mediated by MT-2A silencing. Down regulation of MT-2A isoform by 
siMT2A_1 (A) and siMT2A_2 (B) resulted in the manifestation of entotic structures 
(white arrows) by immunofluorescence microscopy. The interiorized cell is demarcated 
with an orange-yellow “ring” with fluorescent markers after engulfment and adherent 
junctions are important for the cell-in-cell architecture. (C) Cell underwent lysosomal cell 
death after internalization. Legend: Red-phalloidin, Green- β-catenin, Blue- DAPI, Scale 
bar= 30 μm. 
 
 
3.13 Silencing MT-2A isoform did not dysregulate expression of autophagy related 
genes and ROCK   
 The resemblance between the cellular process of autophagy and the cell-within-
cell cytofeature led to further investigation of autophagy related genes participating in the 
cell-eating phenomenon observed herein after MT-2A silencing. However, specific 
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primers targeting markers of autophagy such as Microtubule Associated Protein 1-LC3A 
and LC3B , autophagy related genes ATG5, ATG7 and ATG12 exhibited no significant 
fold change at the transcript level after real-time PCR validation to suggest the 
involvement of autophagy in this instance (p>0.05) (Fig 3.27). 
 
Figure 3.27 Expression of autophagy related genes after MT-2A silencing. (A) 
Quantitative PCR demonstrated that MT-2A knock-down did not affect gene expression 
of autophagy-related genes. Data are means ± SEM, p-value >0.05 as determined by one-
way ANOVA. (B) Gel electrophoreisis of amplicons representative of ATG5 (170 bp), 
ATG7 (151 bp), ATG12 (183 bp), LC3A (193 bp) and LC3B (194 bp). Graph legend, N-
siNeg, 1-siMT2A_1, 2-siMT2A_2 transfected samples. Gel legend, Lane M, DNA 
ladder; Lane 1, ATG5; Lane 2, ATG7; Lane 3, ATG12; Lane 4, LC3A; Lane 5, LC3B. 
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Interestingly, real-time PCR also revealed that the Rho-associated protein kinases 
ROCK1 and ROCK2 gene expression were not perturbed in MT-2A silenced samples,  
contrary to the observations reported by Overholtzer and colleagues, whereby ROCK 
were proposed to be key mediators of the “cell-in-cell” formation in MCF-7 cells 
(Overholtzer et al, 2007) (p>0.05) (Fig 3.28).  
 
Figure 3.28 ROCK1 and ROCK2 expression remained unchanged after MT-2A 
silencing. (A) Real-time PCR using cDNA converted from siNEg, siMT2A_1 and 
siMT2A_2 respectively showed no difference in expression of Rho-associated protein 
kinases at the transcript level, suggesting that cell-within-cell observation occurred 
independent of ROCK expression. Data are means ± SEM, p>0.05. (B) Amplicons 
representative of ROCK1 (224 bp) and ROCK2 (231 bp) following 45 cycle of real-time 
PCR cycling were visualized on 2% agarose gel stained with ethidium bromide. Graph 
legend N-siNeg, 1-siMT2A_1 and 2-siMT2A_2 transfected samples; Gel legend, Lane 
M, DNA ladder; Lane1, ROCK1; Lane 2, ROCK2. 
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3.14 Assessment of quality and integrity of RNA starting material for gene 
expression profiling 
 
 Total RNA isolated from MT-2A over-expressing and silenced cells were checked 
for their quality and integrity before they were used as starting material for microarray 
hybridization. Table 3.1 summarized the A260/A280 ratios and RNA Integrity Numbers 
(RIN) of the RNA samples employed for conversion and hybridization. Samples 
employed in this study had a minimum mean ratio of 2.03 ± 0.03 and a RIN of 9.2 ± 0.15.   
Pseudo gel images and electrophoregrams from Agilent Bioanalyzer 2100 depicted the 
characteristic 18S and 28S ribosomal RNA ensured that samples were not degraded and 
free from DNA contamination(Fig 3.29 and 3.30). Only samples that fulfilled the criteria 
were evaluated.  
 
Table 3.1 RNA purity and integrity of samples used for microarray study. 
Samples A260/A280 RIN 
 Mean (±SEM) Mean (±SEM) 
siNEG (n=3) 2.10 ± 0.01 9.4 ± 0.03 
siMT2A_1 (n=3) 2.03 ± 0.03 9.5 ± 0.03 
siMT2A_2 (n=3) 2.07 ± 0.003 9.2 ± 0.15 
pIRES (n=3) 2.07 ± 0.01 9.7 ± 0.03 






Figure 3.29 Gel image of RNA starting material for microarray hybridization. 
Samples from siNEG, siMT2A_1 (si2A1), siMT2A_2 (si2A2) transfected samples as 
well as pIRES and MT2AOE stable transfected cells demonstrated the characteristic 18S 






Figure 3.30 Evaluation of RNA integrity for samples used in genomic study. 
Electropherograms of total RNA isolated from siNEG, siMT2A_1 (si2A1), siMT2A_2 
(si2A2) transfected samples as well as pIRES and MT2AOE (OE2A) stable transfected 
cells demonstrated the characteristic peaks representative of 18S and 28S ribosomal 
subunits respectively using the Agilent Bioanalyzer.   
 
3.15 GeneChip high density oligonucleotide microarray analysis and data mining  
Selected RNA samples were converted to complementary RNA and labelled with 
biotin prior to hybridization in U133 2.0 plus gene chips. Staining, washing and scanning 
were performed on a Fluidics Station 450 and Affymetrix GeneChip Scanner 3000 after 
an overnight hybridization. Information on raw data images and raw signal intensities 
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were retrieved and processed by three different analytical algorithms, namely 
GeneSpring-RMA, PLIER and GCRMA. Individual software created a list of 
differentially expressed probesets according to filtering criteria of 1) at least a 2-fold 
change in gene expression accompanied by 2) a statistical significant p-value of less than 
0.05. In addition, these probesets must also show directional fold change concurrence 
with the two silencing duplexes used in this study. Briefly, 95 and 197 probesets were 
pulled out by GeneSpring-RMA filtering algorithm following MT-2A silencing and up-
regulation. Likewise, 66 (silencing) and 143 (over-expression) probesets were selected 
using the PLIER methodology. A final inspection with GCRMA programme fished out 
227 and 326 probesets determined to associate with MT-2A down and up regulation in 
MCF-7 cells respectively. Probesets within each algorithmic enclave were matched to 
seek out potential candidate genes for downstream validation. The relationship between 
the 3 analytical softwares utilized was mapped onto a Venn diagram and overlapping 
genes were highlighted in Figure 3.31. A unified list of 13 candidate genes demonstrating 
concurrent fold changes and screened from GeneSpring-RMA, PLIER and GCRMA was 
derived for real-time PCR verification. 
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Figure 3.31 Schematic representation of the microarray work flow and selection of 
candidate genes through utilization of GeneSpring-RMA, GCRMA and PLIER 
softwares.  Genes that demonstrated concordant fold change by this screening 
methodology were earmarked for downstream validation. Overlapping genes MAOB and 
UGT2A15 were found to be commonly identified by the analytical algorithms used. 





3.16 Hierarchical clustering of microarray expression data 
 Unsupervised sample clustering was employed to identify novel sample clusters 
and their associated gene signatures. Hierarchical clustering also allowed for the checking 
of the quality of the microarray data to determine if similar samples were clustered 
together and to identify unexpected clustering. Dendrograms shown in Figure 3.32 
illustrates the overall gene expression profile across all samples, highlighting the 
dissimilarity of in gene expression pattern between baseline group and treated samples.    
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Figure 3.32 Hierarchical clustering of differentially expressed genes after MT-2A 
manipulation in MCF-7 breast cancer cell. (A) Dendrograms representing gene 
clusters after MT-2A silencing with siMT2A_1 (Upper panel) and siMT2A_2 (Lower 
panel). (B) Clustering profiles of genes associated with MT-2A up-regulation. Genes that 
are highly similar are grouped closely together in within the clustering tree. Each row 
represents a gene whereas a column corresponds to a sample. Down regulation is 
represented by a blue colouration whereas a red marking denoted that a gene has a higher 
expression compared to the median (yellow).     
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3.17 Graphical summaries of cDNA microarray experiment 
Volcano plots are commonly employed to graphically represent the association 
between fold-change (≥ 2-fold) and statistical significance in genomic studies. Both 
filtering parameters were log transformed and scatter-plots representative of each gene 
were plotted. Genes that demonstrated statistically significant differential expression are 
highlighted in red. Volcano plots allow quick visual inspection on the distribution of 
genes as well as identification of genes that were highly regulated during genomic wide 
studies. From Figure 3.33, it was evident that more genes fell within the selection criteria 
in siMT2A_1 treatment in contrast to siMT2A_2 (Fig 3.33 A and B). On the other hand, 
MT-2A over-expression sorted out genes that exhibited higher fold-change compared to 
the MT-2A silenced samples (Fig 3.33 C). With a bigger pool of candidate genes to begin 
with, it was no coincidence that 12 of the 13 potential candidate genes filtered out were 
based on their ≥ 2-fold change in association with siMT2A_1 transfection compared to 
siMT2A_2. UGT1A was the only gene that exhibited a fold change of -2.14 after 
MT2A_2 transfection compared to a -1.11 fold change with siMT2A_1 treatment 
observed in microarray screening.        
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Figure 3.33 Volcano plots of candidate genes distribution after various MT-2A 
treatments in MCF-7 breast cancer cells.  Scatter plots representative of genes that 
demonstrated statistical significant differential gene expression in conjunction with 
siMT2A_1 (A) siMT2A_2 (B) and MT-2AOE (C) regimes. A red marking signifies that a 
gene has shown at least 2 fold-dysregulation with MT-2A manipulation supported a 
significance test of p-value <0.05. Non significant results were coloured in grey and 
results were plotted using log transformed values. Horizontal green line represents the 
statistical threshold whereas the two vertical ones refer to the positive and negative 
threshold with respect to fold changes.     
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3.18 Functional annotation of microarray expression data 
 As most data were sieved out by the GCRMA algorithm, the list of genes that 
exhibited differential gene expression after MT-2A silencing (Table 3.2) and over-
expression (Table 3.3), served as input data for classification using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (version 6.7) in an attempt 
to uncover potential biological relevance and interactions between MT-2A and its 
associated genes. These genes were functionally annotated and catergorized accordingly 
to Gene Ontology (GO) standardization. To add robustness, an EASE score output 
statistically measured the strength of associations of these genes along with GO terms by 
Fischer‟s Exact test programme that was inherent to DAVID bioinformatic database 
(Dennis et al, 2003; Huang et al, 2009).  
 The list of genes presented in Table 3.2 was determined by microarray analysis to 
be aberrantly expressed in MT-2A silenced samples. Many of these genes participated in 
breast tumourigenesis, including cell proliferation, cell motility and responses to 
hormonal stimulus. Candidate genes identified in Section 3.15 has been highlighted (in 
bold font) in the table to note their plausible involvement in these biological processes. 
 Similarly, the extensive gene list show cased in Table 3.3 In addition to cell 
motility and proliferation, data mining with DAVID also predicted MT-2A to regulate   
vascularization and angiogensis through its associated genes. A metal binding protein by 
nature, MT-2A has been suggested to mediate cation homeostasis and affect enzyme-
linked receptor protein signaling to contribute toward tumour progression in MCF-7 cell. 






ELF5 E74-like factor 5 (ets domain transcription factor) 2001 2.2742374 1.4198611
KITLG KIT ligand 4254 -2.3347623 -1.025269
BLZF1 basic leucine zipper nuclear factor 1 8548 -2.0117104 -1.0742593
BCAT1 branched chain aminotransferase 1, cytosolic 586 -2.1653183 -1.0608987
CDC25A cell division cycle 25 homolog A (S. pombe) 993 -2.3226936 -1.103545
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 -2.5028486 -1.9056188
FST follistatin 10468 3.728178 1.5909455
ENPEP glutamyl aminopeptidase (aminopeptidase A) 2028 2.3192575 2.048833
HSPD1 heat shock 60kDa protein 1 (chaperonin) pseudogene 5 3329 -2.8424387 -1.3804414
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2066 3.1816614 1.1263001
Regulation of Cell motion 
SP100 SP100 nuclear antigen 6672 -2.0925903 -2.3634923
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 -2.5028486 -1.9056188
F2RL1 coagulation factor II (thrombin) receptor-like 1 2150 -2.3859682 -1.2720108
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2066 3.1816614 1.1263001
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 4067 -2.0849645 -1.0321562
FST follistatin 10468 3.728178 1.5909455
VCL vinculin 7414 -2.140129 -1.1968046
Cell Migration 
KITLG KIT ligand 4254 -2.3347623 -1.025269
SP100 S100 calcium binding protein P 6672 -2.0925903 -2.3634923
Table 3.2 Highlight of genes that were differentially expressed after MT-2A  silencing grouped by their functions
Relative fold change





CCL5 chemokine (C-C motif) ligand 5 6352 -2.543016 -2.4946265
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 -2.5028486 -1.9056188
ENPEP glutamyl aminopeptidase (aminopeptidase A) 2028 2.3192575 2.048833
FST follistatin 10468 3.728178 1.5909455
PODXL podocalyxin-like 5420 2.0963488 1.5202415
PARP9 poly (ADP-ribose) polymerase family, member 9 83666 -2.6383493 -2.4541295
Response to Hormone Stimulus
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 10057 2.1392817 1.1184183
BTG2 BTG family, member 2 7832 2.2282357 1.2320007
TIMP3 TIMP metallopeptidase inhibitor 3 7078 2.2706 1.0068622
UGT1A UDP glucuronosyltransferase 1 family 54575 -1.0885541 -2.1821282
ADCY1 adenylate cyclase 1 (brain) 107 2.3087146 1.1654941
BCHE butyrylcholinesterase 590 2.2322657 1.0599841
CCL5 chemokine (C-C motif) ligand 5 6352 -2.543016 -2.4946265
4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 -1.0316356 -2.0217395
STAT1 signal transducer and activator of transcription 1, 91kDa 6772 -2.2053258 -1.904152
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 2066 3.1816614 1.1263001
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 4067 -2.0849645 -1.0321562
Cell Adhesion
KITLG KIT ligand 4254 -2.3347623 -1.025269
ANTXR1 anthrax toxin receptor 1 84168 2.566493 1.8251662
CDH18 cadherin 18, type 2 1016 4.785634 1.0710855
CDH26 cadherin-like 26 60437 4.026574 1.2982513
CCL5 chemokine (C-C motif) ligand 5 6352 -2.543016 -2.4946265
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 -2.5028486 -1.9056188
COL3A1 collagen, type III, alpha 1 1281 2.0529125 1.0986071
EFS embryonal Fyn-associated substrate 10278 2.186158 1.7632519





FLRT3 fibronectin leucine rich transmembrane protein 3 23767 2.336391 1.3335398
ITGB8 integrin, beta 8 3696 2.1582627 2.0717976
MTSS1 metastasis suppressor 1 9788 2.0718641 1.265192
VCL vinculin 7414 -2.140129 -1.1968046
Regulation of Cellular protein metabolic process
KITLG KIT ligand 4254 -2.3347623 -1.025269
TIMP3 TIMP metallopeptidase inhibitor 3 7078 2.2706 1.0068622
AGTR1 angiotensin II receptor, type 1 185 2.3640335 1.1891718
CLN8 ceroid-lipofuscinosis, neuronal 8 2055 2.3550394 1.6515127
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 -2.5028486 -1.9056188
4EBP2 eukaryotic translation initiation factor 4E binding protein 2 1979 -1.0316356 -2.0217395
MLL myeloid/lymphoid or mixed-lineage leukemia ( Drosophila) 4297 2.151518 1.6025922
QKI quaking homolog, KH domain RNA binding (mouse) 9444 -2.152621 -1.2347541
SPTBN2 spectrin, beta, non-erythrocytic 2 6712 2.437175 1.5438992
LYN v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 4067 -2.0849645 -1.0321562








Gene Symbol Gene Name ENTREZ Gene ID Relative fold change
Cell motion 
KLF7 Kruppel-like factor 7 (ubiquitous) 8609 -2.0128865
ARHGEF7 Rho guanine nucleotide exchange factor (GEF) 7 8874 2.047434
BMP7 bone morphogenetic protein 7 655 -2.363622
BMPR1B bone morphogenetic protein receptor, type IB 658 -2.7484076
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 2.5134487
CXCR4 chemokine (C-X-C motif) receptor 4 7852 2.8965409
DCLK1 doublecortin-like kinase 1 9201 -6.0648
FST follistatin 10468 -2.3497732
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 5168 -2.11333
DNALI1 dynein, axonemal, light intermediate chain 1 7802 -2.1287577
KIF5C kinesin family member 5C 3800 -2.0377162
NRP1 neuropilin 1 8829 2.0868094
PLAT plasminogen activator, tissue 5327 2.9576814
SEMA3B
sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3B 7869 2.341322
Slit2 slit homolog 2 (Drosophila) 9353 -2.1276548
VIM vimentin 7431 -2.2919686
Blood vessel development
UGT1A UDP glucuronosyltransferase 1 family 54575 2.310052
UGT2B15 UDP glucuronosyltransferase 2 family, polypeptide B15 7366 -2.8012104
ACOX2 acyl-Coenzyme A oxidase 2, branched chain 8309 -5.833891
ADM adrenomedullin 133 -2.3638031
AKR1C1
aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-
alpha (3-alpha)-hydroxysteroid dehydrogenase) 1645 -2.0035148





Gene Symbol Gene Name ENTREZ Gene ID Relative fold change
AKR1C2
aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III) 1646 -2.0568855
NR1H4 nuclear receptor subfamily 1, group H, member 4 9971 -2.596404
SORL1 sortilin-related receptor, L(DLR class) A repeats-containing 6653 2.0491278
Vasculature development/Angiogenesis
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 2.5134487
CXCL17 chemokine (C-X-C motif) ligand 17 284340 -2.5466704
CXCR4 chemokine (C-X-C motif) receptor 4 7852 2.8965409
COL3A1 collagen, type III, alpha 1 1281 -3.1189165
EREG epiregulin 2069 3.565907
HEY1 hairy/enhancer-of-split related with YRPW motif 1 23462 -2.053097
NRP1 neuropilin 1 8829 2.0868094
PLAT plasminogen activator, tissue 5327 2.9576814
Slit2 slit homolog 2 (Drosophila) 9353 -2.1276548
Enzyme Linked receptor protein signaling pathway
REPS2 RALBP1 associated Eps domain containing 2 9185 -2.8191159
BMP7 bone morphogenetic protein 7 655 -2.363622
BMPR1B bone morphogenetic protein receptor, type IB 658 -2.7484076
COL3A1 collagen, type III, alpha 1 1281 -3.1189165
EREG epiregulin 2069 3.565907
FLT3 fms-related tyrosine kinase 3 2322 -2.7840405
FST follistatin 10468 -2.3497732
IGF1R insulin-like growth factor 1 receptor 3480 -2.3403287
NRP1 neuropilin 1 8829 2.0868094
PLAT plasminogen activator, tissue 5327 2.9576814
Response to metal ions
AQP3 aquaporin 3 (Gill blood group) 360 -2.768933
CA2 carbonic anhydrase II 760 -2.9752352
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Gene Symbol Gene Name ENTREZ Gene ID Relative fold change
GRIA2 glutamate receptor, ionotropic, AMPA 2 2891 -32.43147
MT1H metallothionein 1H 4496 3.523642
MT1X metallothionein 1X 4501 2.0814166
TNFRSF11B tumor necrosis factor receptor superfamily, member 11b 4982 -2.7431166
Regulation of locomotion
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 2.5134487
CXCR4 chemokine (C-X-C motif) receptor 4 7852 2.8965409
ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 5168 -2.11333
FST follistatin 10468 -2.3497732
IGF1R insulin-like growth factor 1 receptor 3480 -2.3403287
IGFBP5 insulin-like growth factor binding protein 5 3488 -6.2093163
Slit2 slit homolog 2 (Drosophila) 9353 -2.1276548
TRIP6 thyroid hormone receptor interactor 6 7205 3.2125087
Regulation of Cell Proliferation 
ADM adrenomedullin 133 -2.3638031
AGTR1 angiotensin II receptor, type 1 185 5.0914826
BMP7 bone morphogenetic protein 7 655 -2.363622
CDCA7 cell division cycle associated 7 83879 -19.690437
CUL4A cullin 4A 8451 2.6971943
CDK6 cyclin-dependent kinase 6 1021 -2.9728708
FST follistatin 10468 -2.3497732
EREG epiregulin 2069 3.565907
FLT3 fms-related tyrosine kinase 3 2322 -2.7840405
FRK fyn-related kinase 2444 2.3330374
HOXC10 homeobox C10 3226 2.0345132
IGF1R insulin-like growth factor 1 receptor 3480 -2.3403287
IGFBP5 insulin-like growth factor binding protein 5 3488 -6.2093163
MITF microphthalmia-associated transcription factor 4286 -2.2597451
NPY5R neuropeptide Y receptor Y5 4889 2.2270434
NRP1 neuropilin 1 8829 2.0868094  
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Gene Symbol Gene Name ENTREZ Gene ID Relative fold change
PTHLH parathyroid hormone-like hormone 5744 6.7971063
RUNX2 runt-related transcription factor 2 860 4.8240027
Di, tri valent inorganic cation homeostasis
ADM adrenomedullin 133 -2.3638031
AGTR1 angiotensin II receptor, type 1 185 5.0914826
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 6387 2.5134487
CXCR4 chemokine (C-X-C motif) receptor 4 7852 2.8965409
MT1H metallothionein 1H 4496 3.523642
MT2A metallothionein 2A 4502 4.2921734
NPY1R neuropeptide Y receptor Y1 4886 3.17487
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3.19 Validation of microarray results by quantitative real-time PCR 
 Reliability of the microarray data was validated by quantitative PCR using 
specific primers targeting the genes of interest. A total of 13 genes altered by MT-2A 
manipulation were chosen for downstream verification. Figure 3.34 illustrated the 
comparison of fold changes of these candidate genes calculated from real-time PCR 




Figure 3.34 Real-time verification of MT-2A associated genes from microarray 
analysis. cDNA converted from MT-2A silenced RNA samples used in microarray 
hybridization was deployed as template for qPCR amplification. Fold changes were 
calculated after gene expression was normalized against G3PDH house-keeping gene in 
real-time PCR. Concordant genes were determined to be statistically regulated by one-
way ANOVA (p-value <0.05). Results are presented as means ± SEM of triplicate 
experiments. # denotes the dissonant pair of result. 2A1- siMT2A_1 and 2A2- siMT2A_2 
treated samples respectively. 
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 Both interleukin 1 receptor accessory protein (IL1RAP) and keratin 13 (KRT 13) 
appeared to demonstrate discordant fold changes between the two validation 
methodologies and were henceforth omitted from further evaluation. Figure 3.35 detailed 
the expression profile of the candidate genes with respect to MT-2A up-regulation. 
Surprisingly, UDP-glucuronosyltranferase 2B15 (UGT2A15), neurobeachin (NBEA) and 
E74-like transcription factor 5 (ELF5) did not exhibit concurring fold change in MT-2A 
over-expressed cells notwithstanding previous agreement with MT-2A silencing. 
Likewise, non-concordant genes were subsequently excluded from downstream 
validation, leading to an eventual list of 7 genes comprising of butyrylcholinesterase 
(BCHE), monoamine oxidase B (MAOB), follistatin (FST), branched chain amino-acid 
transaminase 1 (BCAT1), chemokine (C-X-C motif) ligand 12 (CXCL12), type III 
collagen, alpha 1  (COL3A1), kallikrein-related peptidase 12 (KLK12) and UDP-
glucuronosyltranferase 1A (UGT1A).  
Figure 3.36 summarizes the fold changes of these genes in accordance with MT-
2A silencing and over-expression. Specificity of the primers used was confirmed through 
gel electrophoreisis utilizing real-time PCR products which manifested single band 
amplicons (Fig 3.36 B). From Table 3.4 it is evident that these candidate genes were 
more profoundly regulated in siMT2A_1 transfected sample in comparison to siMT2A_2 
counterpart with the exception of UGT1A. A possibility underlying this observation could 
be additional down regulation of MT-1X isoform targeted by this silencing duplex. 
Interestingly, MT2AOE also exhibited elevated level of MT-1X after transfection, 
leading to the suggestion a plausible synergistic effect between the two MT isoform that 
resulted in the discovery of these genes.  
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Figure 3.35 Validation of candidate genes from microarray analysis using cDNA 
from MT-2A over-expressing cells. Real-time PCR computed fold changes of candidate 
genes were compared with corresponding fold changes determined by microarray 
analysis. Discordant results were omitted from down stream validation, indicated by #. 
Genes were determined to be statistically regulated by one-way ANOVA (p-value <0.05). 
Results are presented as means ± SEM of triplicate experiments. 2AOE refers to cDNA 
samples extracted from MT-2A over-expressing cells and differential gene expression 





Figure 3.36 Summary of fold changes of candidate genes as determined by real-time 
PCR. (A) An overview of finalized candidate genes and their respective fold changes in  
respond to MT-2A silencing and up-regulation. (B) Gel electrophoreisis of amplicons 
representative of candidate genes. Legend for graph, 1- siMT2A_1, 2-siMT2A_2 and O-
MT2AOE. Legend for gel, Lane M, DNA ladder; Lane 1, BCHE (167 bp); Lane 2, 
MAOB (158 bp);; Lane 3, FST (218 bp); Lane 4, BCAT1(150 bp);; Lane 5, CXCL12 (225 
bp);   Lane 6, COL3A1 (114 bp); Lane 7, KLK12(165 bp); Lane 8, UGT1A (175 bp);. 
Results are presented are representative of three independent experiments. One-way 







Table 3.4 Summary of fold changes  
 
 
3.20 Effects of MT silencing in MT2AOE stable transfected cell line 
 To re-affirm relationship of the candidate genes with MT, silencing was 
performed using siMT2A_1 only as it targets the CDS sequence of MT-2A isoform that 
was cloned into the expression vector. Results showed that MT-2A expression was 
profoundly down-regulated by ~92.68 % after siMT2A_1 transfection by qPCR (Fig 3.37 
A) (p<0.001). Similarly, candidate genes also demonstrated reciprocal fold changes in 
relation to silencing by siMT2A_1 duplex (Fig 3.37 B). Only UGT1A did not 
demonstrate any significant fold change, consistent with earlier result (Fig 3.36 A) that its 
regulation was associated to silencing effect with siMT2A_2 and therefore excluded for 
further examination. As siMT2A_1 also targets the CDS sequence of MT-1X due to high 
homology, this reciprocal gene regulation shown only by the remaining genes (previously 
demonstrated to be siMT2A_1 biased) after siMT2A_1 transfection supported the notion 
of plausible synergism between MT-2A and MT-1X isoforms in breast cancer cells.  
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Figure 3.37 Evaluation of MT silencing with siMT2A_1 in MT2AOE cells. (A) Real-
time PCR confirmed the down regulation of MT-2A isoform at 48 h post transfection 
with siMT2A_1. (B) MT associated genes demonstrated reciprocal fold changes in 
accordance with siMT2A_1 introduction. Results are presented are mean ± SEM and 
indicative of three separate experiments. pIRES was included to indicate basal expression 
of respective genes. OE- MT2AOE cells, P-pIRES, E- siNEG transfected MT2AOE 






3.21 MT-1/2 protein in MT over-expressing cells displayed concomitant down 
regulation after siMT2A_1 transfection 
 Following transfection, protein expression of MT evaluated 72 h later 
demonstrated overall decreased immunostaining in MT2AOE cell population treated with 
siMT2A_1 (Fig 3.38).  
 
Figure 3.38 Immunohistological profile of MT-1/2 staining in MT2AOE cells after 
siMT2A_1 silencing. DAB staining was observed in (A) pIRES control (B) siNEG 
transfected MT2AOE control and (C) siMT2A_1 transfected MT2AOE cells. Staining 
intensity was markedly reduced in (C) 72 h post silencing. (D) Immunopositive scores of 
corresponding MT-1/2 staining were evaluated and one-way ANOVA confirmed 
statistical significance of staining intensities evaluation (**,p-value <0.01). Results are 
representative of means ± SEM of three independent experiments. Bar = 50 µm. 
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Evaluation of staining intensity concurred that siMT2A_1 silencing reduced MT 
staining intensity by ~ 2 fold (1.92 vs 0.92) in MT2AOE cells compared with siNEG 
treatment (Fig 3.38 D). 
 
3.22 Silencing of MT inhibited the growth advantage in MT2AOE cells 
 Cell viability essays in MT2AOE cells confirmed that cell proliferation 
was inhibited by the introduction of siMT2A_1 (Fig 3.39). A fewer number of viable 
cells was noted in MT2AOE cells transfected with siMT2A_1, with a reduction of 35.6% 
and 28.5% observed through the use of formazan based MTT and alamarBlue assays 




Figure 3.39 Reduction in cell proliferation was observed in MT2AOE cells after 
silencing with siMT2A_1. siMT2A_1 treated MT2AOE cells became less viable as 
demonstrated by MTT assay (A) for up to 72h after transfection. This inhibitory effect  
on cell proliferation was confirmed by alamarBlue cell viability assessment (B) after  
fluorescence intensity representative of the live cells were measured. pIRES cells were 
included to demonstrate basal cell proliferative rate after G418 selection. Data shown are 
mean readings of triplicate experiments carried out for each data point. Error bars = 






3.23 Assessment of cell motility in MT2AOE cells after MT silencing  
Following the transfection of siMT2A_1, cell motility and invasion were notably 
curtailed in MT over-expressing cells compared to siNEG treated counterparts (Figure 
3.40 and 3.41).  
 
Figure 3.40 Down-regulation of MT-1X and 2A isoforms by siMT2A_1 in MT2AOE 
cells restricted cell migration. pIRES stabled transfected  demonstrated endogenous 
migratory rate after G418 selection (A).  Stable transfected cell line over expressing MT 
was transfected with siNEG (B) and siMT2A_1 (C) respectively. siMT2A_1 treated cells 
exhibited limited migratory capability in contrast to siNEG . (D) Total number of 
migrated cells was quantified and one-way ANOVA test confirmed the statistical 
significance of the cell counts (**, p-value <0.01, ***, p-value <0.001). Results shown 
are representative of triplicate experiments. Bar represented 100 µm. OE denotes 
MT2AOE stable transfected cell line. 
 
Relative cell migration and cell invasion declined by ~ 2.01 fold (100.00 ± 4.69 % 
vs 49.54 ± 4.58 %) and ~ 1.96 fold (100.00 ± 6.10 % vs 51.03 ± 2.28 %) respectively in 
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MT2AOE cells after number of cell that penetrated the Transwell and Matrigel inserts 
was  determined 72 h post transfection (Fig 3.40 D and 3.41 D).  
   
 
Figure 3.41 Invasive potential was curtailed in MCF-7 cells following MT down 
regulation. Assessment on the respective in vitro invasiveness of pIRES (A) siNEG 
transfected MT2AOE (B) and siMT2A_1 transfected MT2AOE cancer cells was 
achieved by quantifying cells that had passed through the Matrigel inserts (D) Cells that 
passed through the membranous barrier were stained with crystal violet to aid 
visualization. One-way ANOVA test confirmed the statistical significance of the cell 
counts (**, p-value <0.01). Results shown are representative of triplicate experiments. 
Bar represented 100 µm. OE refers to MT2AOE cell line. 
 
3.24 Western blot analysis of FST protein expression after MT-2A manipulation 
  To gain further insight on the relationships between candidate genes and observed 
phenotypes, FST was selected for downstream verification. As indicated in Table 3.2 and 
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3.3, FST was identified by DAVID to regulate cell proliferation and cell motility. Current 
literature reported that FST expression led to the induction of apoptosis in R30C 
mammary carcinoma cells and its down regulation increased migratory and invasive 
potentials in PC-3 prostate cancer cells (Krneta et al, 2006; Ye et al, 2007).  Therefore, 
validation of FST protein expression was performed to confirm its association after MT-
2A manipulation as illustrated in Figure 3.42. . Immuno blot revealed the up-regulation of 
FST protein in MCF-7 cells after transfection by siMT2A_1 and siMT2A_2 respectively 
(Fig 3.42 A, upper panel). Densitometric analysis corroborated that FST expression had 
increased by ~1.71 fold and ~1.38 fold respectively (Fig 3.42 A, lower panel). 
Conversely, lower level of FST protein was detected in MT2AOE cells, whereby protein 
expression decreased by ~2.24 fold compared to pIRES control cells (Fig 3.42 B). On the 
other hand, silencing by siMT2A_1 also rescued the protein expression of FST in 
corresponding cell line, restoring FST expression by ~ 1.84 fold compared to siNEG 
control (Fig 3.42 C). No detectable difference in band intensity was noted between 
protein samples extracted from pIRES and MT2AOE cells transfected with siMT2A_1 







Figure 3.42 FST protein expression was affected by MT-2A manipulation. Western 
blotting depicting FST protein expression after (A) siNEG, siMT2A_1 and siMT2A_2 
transfection, (B) pIRES and MT2AOE stable transfected cells and (C) siNEG and 
siMT2A_1 tranfected MT2AOE cells (upper panel).  Densitometric analysis of the band 
intensities of the corresponding blots are shown in the lower panel. Results are indicative 
of three independent experiments. One-way ANOVA test and t-test, *, p-value <0.05, **, 
p-value <0.01,***, p-value <0.001. Legend, Lane N-siNEG, Lane1-siMT2A_1, Lane 2-
siMT2A_2, p-pIRES, E-MT2AOE, EN-MT2AOE transfected with siNEG, E2A- 





3.25 Assessment of FST silencing in MCF-7 breast cancer cells  
 
 Pre-designed siRNAs targeting FST was employed to down regulate its 
expression in MCF-7 breast cancer cells. Silencing efficiency was evaluated at the 
transcript level using real-time PCR.  
 
 
Figure 3.43 Validation of FST gene and protein expression after silencing. (A) Using 
SMARTpool siRNA targeted against FST, real-time PCR verified that FST gene 
expression was successfully down-regulated (upper panel). Amplicons representative of 
G3PDH and FST was resolved on 2% agarose gel showing single band DNA fragments 
of 160 bp and 218 bp respectively, confirming the specificity of the primers used (lower 
panel). (B) Western blot quantification (upper panel) and densitometric analysis (lower 
panel) revealed lower FST protein expression 72 h after siFST lipofection. Results shown 
are representative of three independent experiments and statistical analysis was 
performed using Student‟s t-test, **, p-value <0.01. Legend, Lane M- DNA ladder, 
Lane1-G3PDH, Lane 2-FST, Lane N- protein samples extracted from MCF-7 cell 
transfected with control scrambled siRNA or siNEG, Lane F- protein samples extracted 
from MCF-7 cell transfected with FST targeting siRNA duplexes. 
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FST expression was suppressed up to 84.8% as determined by qPCR (Fig. 3.43 
A). Likewise, FST protein expression was concomitantly down-regulated 72 h post 
silencing. Densitometric analysis of band intensities too recorded a ~2.83 fold drop in 
FST expression compared to control siNEG treatment group (Fig 3.43 B).  
 
3.26 Silencing FST did not affect expression of MT and its associated genes 
 Silencing of FST did not dysregulate gene expressions of MT- 1X and MT-2A 
isoforms along with MT-associated genes as determined by real-time PCR (Fig 3. 44). 
This result validates that FST might lies downstream of MT signaling.  
 
Figure 3.44 Gene expression of MT and its related genes was not perturbed by FST 
silencing. Quantitative PCR validated that FST knock-down did not affect gene 
expression of MT and its associated genes. Data are means ± SEM, n=3, p-value >0.05 as 







3.27 Cell proliferation profile of MCF-7 was unaltered after FST silencing  
 
 To ascertain if observed growth advantage after MT over-expression was a result 
of FST down-regulation, cell viability assessment was conducted after FST silencing 
contrary to expectation. The ability of MT to promote cell proliferation in breast cancer 
cells demonstrated previously was not mediated through FST. This was evidently 
demonstrated in Figure 3.45, where MTT and alamarBlue assays did not register a 
discernable increase in cell proliferation between siNEG and siFST treated cells. 
Coincidentally, MEK5 protein expression too remained unchanged by Western blot 
analysis after siFST silencing, suggesting that this MAPK regulating kinase possibly 




Figure 3.45 Effect of FST silencing on growth of cancer cells in vitro. Anchorage- 
dependent cell proliferation of MCF-7 cancers cells was determined by (A) formazan 
based MTT assay and (B) alamarBlue cell viability assay. No detectable difference was 
noted between the two siRNA treatments. Data are means ± SEM, p-value >0.05 as 
determined by two-way ANOVA. 
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Figure 3.46 FST silencing did not affect MEK 5 protein expression. (A) 
Immunoblotting demonstrated that the expression level of MEK 5, along with other 
MEKs and ERKs was unaffected by FST down regulation. Equal amount of protein was 
loaded per lane as determined by β–actin band intensity and results presented are 
representative of three separate experiments. (B) Relative optical densities of protein 
bands corresponding to various members of the MAPK family.  
 
3.28 Suppression of FST enhanced the migratory and invasive potential of breast 
cancer cells in vitro 
 Silencing of the FST gene has been demonstrated to profoundly increase cell 
motility of MCF-7 cells (Figs 3.47 and 3.48). Higher numbers of MCF-7 cells was 
observed to have migrated through the polycarbonate membrane in siFST transfected 
cells compared to parental and siNEG controls (Fig 3.47 A, B and C). A similar sighting 
was also recorded when more FST silenced cells were stained by crystal violet after 
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successfully penetrating through the Matrigel barrier following an overnight incubation in 
comparison to control treatments (Fig 3.48 A, B and C). Compared to siNEG treatment, 
cell migration and invasion improved by ~3.64 fold (363.88 ± 8.88 % vs 100.00 ± 8.65 
%) and ~ 3.82 fold (382.14 ± 27.72 % vs 100.00 ± 14.05 %) respectively after siFST 
transfection (Fig 3.47 D and 3.48 D). These data confirmed that FST silencing induced 
non-invasive MCF-7 cells to acquire migratory and invasive behaviors similar to those 
observed in MT over-expressing cells, suggesting that the metastatic phenotypic 
manifestations were effected through FST signaling.    
 
Figure 3.47 FST silenced cells exhibited migratory behavior. MCF-7 cell (A) and their 
siNEG treated counterparts (B) showed similar level of cell migration whereas siFST 
transfection substantially enhanced the migratory capability of this non-invasive breast 
cancer cell line. (D) Total number of crystal violet stained cells was quantified and 




Figure 3.48 FST silencing promoted invasiveness of MCF-7 cell in vitro. (A) Basal 
MCF-7 cells demonstrating minimal intrinsic cell invasion after 24 h incubation duration. 
(B) siNEG transfected cells showed similar invasiveness to parental MCF-7. (C) Down 
regulation of FST profoundly increased the number of cells gaining passage through the 
Matrigel inserts (D) Relative cell invasion was significantly up-regulated by FST 
silencing after cell count was evaluated. Data are presented as mean ± SEM. One-way 
ANOVA statistical test confirmed p-value was less than 0.001 (***). Bar represented 100 
µm. 
 
3.29 FST silencing regulated gene expressions of bone morphogenetic protein 7 and 
its receptor   
 Bone morphogenetic protein 7 (BMP-7) and one of its receptor sub-unit (BMPR-
1B), both downstream targets of FST signaling,  were found to be significantly down 




Figure 3.49 Gene expression profiles of BMPR-1B and BMP-7 in breast cancer cells 
after various treatments. (A) Histogram of depicting the expression levels of BMPR-1B 
and BMP-7 after MT silencing (green), MT over-expression (red) and FST silencing 
(blue) by quantitative PCR. (B) Amplicons after real-time PCR amplification were 
resolved on a 2% agarose gel to demonstrate the specificity of the primers utilized. Data 
are means ± SEM, n=3, p-value >0.05 as determined by one-way ANOVA. Legend, 
graph, 1B-BMPR-1B, B7-BMP-7; gel, Lane M- DNA ladder, Lane GAP-G3PDH (160 
bp), Lane 1B- BMPR-1B (184 bp) and Lane B7- BMP-7 (250 bp) 
 
Functional classification by DAVID outlined their plausible role in mediating cell 
motility led to the investigation of their expression in MT manipulated samples, as well 
as, FST silenced cDNA. While real-time PCR verified that BMP-7 and BMPR-1B 
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transcripts tend to be reciprocally regulated by MT over-expression and silencing, a more 
profound decrease in their respective gene expressions was recorded after FST silencing 
seemed to suggest that the former observations were likely to be mediated through FST 
instead (Fig 3.49 A). 
 
 
3.30 Higher MT-2A mRNA expression is associated with the percentage of 
tumourigenic cells and cancer staging in breast cancer tissues 
 
 Using a panel of pre-normalized human cDNA array sample from breast cancer 
patients, elevated level of MT-2A transcript was found to be associated with the 
percentage (> 80%) of tumourigenic cells found within the cancerous tissue from which 
the RNA samples were isolated from via real-time PCR quantification (Fig 3.50 A). 
Higher MT-2A expression also correlated positively with breast cancer staging status, 
with tumour samples from stage 3 and 4 patients recording higher expression level for 








Figure 3.50 Evaluation of MT-2A gene expression using cDNA from breast cancer 
patients. Quantitative PCR measured the expression level of the MT-2A isoform in a 
cDNA array representative of 48 patients. (A) High level of MT-2A transcript was 
positively associated with a higher percentage of tumourigenic cells identified within the 
tumour samples isolated. (B) Patients diagnosed with high stage tumours (3 and 4) were 
determined to have higher expression for MT-2A compared to lower stage ones (1 and 2). 





3.31 MT expression in breast cancer tissues 
 Out of the 99 invasive ductal carcinomas cases studied, MT immunopositivity 
was detected in 97 (97.97%) tumours examined. Only 2 cases did not manifest MT 
staining in neither cytoplasm nor nucleus after immunohistological procedure was 
performed. Under the microscope, MT immunostaining was observed in cancerous 
epithelial cells, as well as, few myoepithelial cells that were present in residual benign 
acini surrounding the tumour. MT exhibits both nuclear and cytoplasmic localization 
without preponderance of staining pattern. For this patient cohort, a mean nuclear 
percentage positive staining of 50.8% (range 0-100%) and a mean cytoplasmic 
percentage positive staining of 74.2% (range 0-100%) were documented. The intensity of 
nuclear and cytoplasmic MT immunostaining was categorized into weak, moderate and 
strong respectively as depicted in Figures 3.51 and 3.52 for association studies with 
clinicopathological parameters.  
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Figure 3.51 Categorization of MT intensity scoring in the nucleus. (A) A showcase of 
0 (no staining) and 1+ (weak staining, black arrow) staining intensity. (B) An example of 
+2 (moderate staining) has been demarcated by white arrowheads. (C) Intensively stained 
nucleus (+3, strong staining) by MT immunohistochemistry is indicated by green 




Figure 3.52 Categorization of MT intensity scoring in the cytoplasm. (A) A 
representation of faint or negative staining (score 0) for cytoplasmic MT. Weak (1+) and 
moderate (2+) staining intensities for MT were exemplified in (B) and (C) respectively. 
(D) Tissue section demonstrating intensified staining for MT (3+, strong staining). 











3.32 Clinicopathological significance of MT expression in invasive ductal carcinoma 
 High level of MT-1/2 protein expression was found to correlate with presence of 
associated DCIS component within the cancerous tissue examined. From Tables 3.5 and 
3.6, higher nuclear and cytoplasmic immunopositivity also suggested a positive 
association with the extent of the associated DICS observed (p=0.007 and p=0.001). 
Significant correlations were also determined between increasing levels of cytoplasmic 
MT expression with lymph node involvement, as well as, histological grades in invasive 
ductal carcinoma (p= 0.025 and p=0.039) (Table 3.6). On the other hand, MT expression 
was not associated with patients‟ race and age, staging, HER2 and hormonal receptor 
















Table 3.5 Correlation of clinicopathological relevance with mean nuclear percentage 
positive MT expression in invasive ductal carcinoma (n=99) 
 
Lower Bound Upper Bound 
Associated DCIS
None 13 36.15 16.76 55.55 .007**
Minimal 46 48.15 39.29 57.01
Extensive 18 71.15 61.51 80.80
Unavailable 22 - - -
Lymph node involvement
0 8 22.33 16.81 31.29 .183
1 to 3 20 38.25 23.96 52.54
4 to 9 35 42.33 25.53 59.14
> 10 21 60.00 36.83 83.17
Unavailable 15 - - -
Race
Chinese 78 49.68 42.93 56.42 .607
Malay 8 62.50 38.23 86.77
Indian 1 70.00 . .
Others 11 47.73 26.36 69.10
Unavailable 1 - - -
Age
≤ 55 years 42 46.31 37.95 54.67 .208
> 55 years 56 54.02 45.50 62.54
Unavailable 1 - - -
Histological grades
1 3 58.33 29.79 76.45 .105
2 27 65.89 46.66 77.12
3 64 75.56 54.08 86.05
Unavailable 5 - - -
Staging (1 vs 2AB vs 3AC)
1 14 44.64 29.43 59.85 .770
2A & 2B 39 45.00 36.14 53.86
3A & 3C 31 49.68 37.79 61.56
Unavailable 15 - - -
ER
Negative 44 51.02 41.18 60.87 .856
Positive 52 49.90 42.12 57.68
Unavailable 3 - - -
PR
Negative 47 50.53 41.10 59.96 .971
Positive 49 50.31 42.28 58.33
Unavailable 3 - - -
HER2
Negative 47 52.79 45.57 60.00 .145
Positive 49 42.60 31.01 54.19
Unavailable 3 - - -





Table 3.6 Correlation of clinicopathological relevance with mean cytoplasmic 
percentage positive MT expression in invasive ductal carcinoma (n=99) 
 
Lower Bound Upper Bound 
Associated DCIS
None 13 44.23 19.26 69.20 .001**
Minimal 46 74.78 65.98 83.58
Extensive 18 87.00 74.76 99.24
Unavailable 22 - - -
Lymph node involvement
0 8 28.55 20.85 36.24 .025*
1 to 3 20 55.00 35.96 74.04
4 to 9 35 64.67 46.08 83.25
> 10 21 92.00 86.89 97.11
Unavailable 15 - - -
Race
Chinese 78 72.44 65.25 79.62 .734
Malay 8 82.50 60.61 104.39
Indian 1 95.00 . .
Others 11 76.82 53.53 100.10
Unavailable 1 - - -
Age
≤ 55 years 42 71.90 61.59 82.22 .575
> 55 years 56 75.54 67.38 83.69
Unavailable 1 - - -
Histological grades
1 3 43.33 35.83 68.38 .034*
2 27 72.52 60.74 86.30
3 64 88.67 75.68 94.67
Unavailable 5 - - -
Staging (1 vs 2AB vs 3AC)
1 14 75.00 54.49 95.51 .913
2A & 2B 39 71.03 60.53 81.52
3A & 3C 31 70.65 58.34 82.95
Unavailable 15 - - -
ER
Negative 44 72.16 61.98 82.33 .665
Positive 52 75.00 66.51 83.49
Unavailable 3 - - -
PR
Negative 47 73.40 63.87 82.94 .930
Positive 49 73.98 64.97 82.99
Unavailable 3 - - -
HER2
Negative 47 76.71 69.46 83.97 .097
Positive 49 64.40 50.15 78.65
Unavailable 3 - - -




















































Mammoth efforts have been made in an attempt to understand the etiology of 
breast neoplasia. Breast cancer is multi-factorial disease manifestation of altered cell 
physiology and homeostasis. Biomedical research has gravitated towards a genetic origin 
in carcinogenesis, leading to a surge in experimental effort to uncover oncogenes 
responsible for this life threatening disease. Several lines of evidence has shown that  MT 
expression drives cell multiplication, disrupts apoptotic cell death and mitotic cycle, 
predicts chemoresistance and is an indicator of prognosis in carcinoma of the mammary 
gland (Abdel-Mageed & Agrawal, 1997; Sens et al, 2001; Jin et al, 2002; Lim et al, 
2009;  Yap et al, 2009). Numerous studies performed in unmasking the roles of MT in 
breast carcinogenesis have hitherto yielded little information on the mechanistic 
involvement of MT.      
In this study, real-time PCR has verified that MT-1F, MT-1X, MT-2A isoforms 
were expressed in all the cell lines evaluated, with the MT-2A gene showing the highest 
expression. Meanwhile, the MDA-MB231 invasive breast cancer cell line demonstrated 
highest level of expression for MT-1E isoform amongst the cell lines compared. While 
MT-1E expression is commonly associated with ER negative cells with a more aggressive 
phenotype, it is intriguing to witness its presence in MCF-12A cells (Friedline et al, 
1998; Jin et al, 2000). This cell line is widely employed for comparison in breast cancer 
in vitro studies and is commonly labelled as non-tumorigenic (Ling et al, 2009; Reddy et 
al, 2009; Castro-Sanchez et al, 2010; Soto-Guzman et al, 2010). The role of MCF-12A as 
a baseline group for normalization of MT conducted in many studies has been questioned  
( Theocharis et al, 2003; Theocharis et al, 2004). It was also observed that both MT-1A 
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and 1F isoforms showed low expression levels, suggesting that they may not be the 
dominant isoforms important for breast oncogenic transformation.    
In this present study, functional assays were performed to investigate the 
capabilities of MT to influence cell propagation and motility, processes heavily linked to 
tumourigenesis (Hanahan & Weinberg, 2000). To identify molecular partners involved in 
MT signaling, genomic analysis was conducted using samples extracted from cancer cells 
which experienced MT silencing and over-expression respectively.  
Genomic analysis unraveled a set of MT regulated genes and plausibly, a possible 
synergistic effect between MT-1X and MT-2A in MCF-7 breast cancer cells. From 
volcano plot analyses, it evident that distribution of candidate genes from siMT2A_1 and 
MT2AOE treatments which affect the expression levels of MT-1X and 2A isoforms 
concurrently shared similarity compared to siMT2A_2 treated samples, which is MT-2A 
specific. Moreover, candidate genes verified in this study appeared to be more profoundly 
regulated in siMT2A_1 silenced cells compared to siMT2A_2 treatment as evidenced by 
qPCR and immuno-blot analyses respectively. Given the high DNA sequence homology 
between these two evolutionary conserved MT isoforms, it is highly possible that they 
might co-operate endogenously to promote breast carcinogenesis. With the exception of 
MT-1E, MT-1X has the second highest expression level in all breast cancer cell lines 
screened, signifying its importance towards tumour development.  Furthermore, these 
two genes appeared concomitantly regulated in events of cellular stress and neurological 
disorders ( Chung et al, 2006a; Chung et al, 2006b; Choi et al, 2008; Teyssier et al, 
2010).    
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4.1 MT expression enhances breast cancer cell proliferation 
Uncontrolled proliferation is often needed to initiate and promote tumourigenesis 
(Vermeulen et al, 2003). In normal cells, cell division is tightly regulated, only to be 
triggered in the presence of mitogens before they emerged from their quiescent state into 
an active proliferative state (Hanahan & Weinberg, 2000). To circumvent this 
dependency on growth signals, neoplastic cells devised strategies such as autocrine 
stimulation, evasion of cell death and anti-growth regulations to achieved limitless 
replicative capacity ( Yarden & Ullrich, 1988; Medema & Bos, 1993; Weinberg, 1995; 
Datto et al, 1997; Foley & Eisenman, 1999; Ostrakhovitch et al, 2006; Wu et al, 2008b; 
Maiuri et al, 2009; Proskuryakov & Gabai, 2010).  
The literature has provided evidence that MT expression is intricately linked to 
cell proliferation in ductal carcinoma ( Oyama et al, 1996; Jin et al, 2002). Up-regulation 
of MT has been documented in cancerous luminal tissue to be predictive for a higher 
histological grade accompanied by an increased mitotic index. This relationship between 
elevated MT expression and mitogenic response was further validated by Jin and her 
colleagues through an MT co-localization study with Ki-67 nuclear antigen(a 
proliferation marker) using double-immunofluorescence staining, whereas in situ 
hybridization identified MT-2A as the culpable isoform underlying this phenomeneon (Jin 
et al, 2002). While the rationale for anomalous expression of MT in cancerous luminal 
cells remains largely elusive, it is not difficult to see how tumour cells could benefit from 
overexpression of this protein. At the molecular level, MT has been proven to be pivotal 
in promoting neoplastic cell growth through its interacting partners. This includes a host 
of genes that control vital cellular activities such as cell proliferation, apoptosis and cell 
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cycle. MT was experimentally determined to bind to p50 subunit of nuclear factor κB 
(NFκB) and kinase domain of protein kinase Cµ (PKCµ) to drive cellular growth in 
cancers. While MT could co-operate with NFκB to transactivate gene expression for 
proliferation, MT binding is also known to regulate the kinase activity of PKCµ (Abdel-
Mageed & Agrawal, 1998; Rao et al, 2003). Other growth promoting partners of MT 
include MAPK signaling related Rab3A GTPase and transcription factor IIIa responsible 
for downstream 5S RNA transcription (Zeng et al, 1991b; Huang et al, 2004; Zhang et al, 
2004; Knipp et al, 2005). Many of these interactions center on the biochemistry of Zn 
bound MT (Zn-MT), where the requirement for this trace element is critical to their 
structural stability, enzymatic action and DNA recognition through zinc fingers (Abdel-
Mageed & Agrawal, 1998; Cherian et al, 2003). 
 To exert their growth advantage over somatic cells, malignant cells have 
developed impaired cellular defence that has limited their progression. When Abdel-
Mageed and Agrawal (1997) first demonstrated induction of growth suppression and 
apoptosis in breast cancer cells after MT-2A silencing with antisense oligonucleotides, 
they observed a concomitant up-regulation of c-fos and p53 gene expression. However, 
these effects were ameliorated when MT expression was up-regulated, suggesting its role 
in the disruption of apoptotic cell death and cell cycle arrest.   Ostrakhovitch et al later 
discovered that metal free MT (apo-MT) could bind and compete with p53 for Zn ion. 
The formation of MT-p53 complex compromised the conformation of wild type p53 and 
prevented its binding to DNA targets (Ostrakhovitch et al, 2006). Previously, 
translocation of cytoplasmic MT into the nucleus was reported to be cell cycle dependent 
and recent work by Lim and her colleagues supported this rationale whereby MT-2A 
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over-expression may lift the blockade mediated by ATM and cdc25A and allow breast 
cancer cell to progress from G1 to S phase (Lim et al, 2009).    
Cell proliferation assays have re-affirmed MT‟s contribution towards 
enhancement of proliferation in MCF-7 cells. In this study, cell viability was appreciably 
decreased in MT silenced cells whereas cell number underwent a profound up-regulation 
after MT over-expression. Conversely, transfection with siMT2A_1 in cells stably over-
expressing MT reversed this pro-proliferative effect demonstrated through MTT and 
alamarBlue assays. Western blot attributed this MT-related surge in cancer cell number to 
be an effect of MAPK kinase 5 (MEK5) protein up-regulation. Mitogen activated protein 
kinase (MAPK) pathway plays a crucial role in breast cancer development, mediating 
events such as neoplastic transformation, invasion and metastasis, therapeutic resistance, 
as well as cell survival and cell death (Janda et al, 2002; Pinkas & Leder, 2002; Harada et 
al, 2004; Song et al, 2007). Four dominant MAPK pathways has been suggested by 
Whyte et al to be regulating these breast oncogenic milestones, where MEK5/ERK5 axis 
represents a unique class of MAPK signaling that was previously demonstrated to 
perform non-redundant functions compared to the classical MEK1/2-ERK1/2 pathway in 
breast cancers (Whyte et al, 2009). ERK5 is a specific substrate of MEK5 
phosphorylation, whereby synchronized action in this pair of kinases has been cited to 
promote vasculogenesis and angiogenesis, cell survival and mitosis, invasion and 
metastasis in cancer biology (Mehta et al, 2003; Hayashi et al, 2004; Pi et al, 2004; 
McCracken et al, 2008; Zhou et al, 2008). MEK5 overexpression in breast and prostate 
malignancies has been well documented, where it specifically works in tandem with 
ERK5 to affect growth rate in neoplasia by facilitating entry into the S-phase of the 
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mitotic cell cycle (Weldon et al, 2002; Mehta et al, 2003; Song et al, 2004; McCracken et 
al, 2008). In addition, activation of MEK5/ERK5 kinases also prevented apoptotic 
occurrence in MDA-MB231 breast cancer cells in order to fulfill overall proliferative 
agenda (Li et al, 2008).   
Previous reports suggested that MEK5 was a subject of atypical protein kinase C 
(aPKCs) regulation, whereby these aPCKs have been annotated to participate in cell 
growth and proliferation (Diaz-Meco & Moscat, 2001). These aPKCs share many 
similarities with conventional PKCs, including an evolutionary conserved C1 zinc 
binding domain. Rao et al first demonstrated the binding of recombinant MT-2A protein 
to PKCµ via its kinase and C1 domains respectively (Rao et al, 2003). Through this 
interaction, the formation of MT-2A-PKCµ complex allows MT-2A to regulate its kinase 
activity. Similarly, such a relationship could exist for MT and aPKCs that could 
culminate in MEK5 activation, leading to the elevated cell proliferation observed after 
MT over-expression and vice-versa. Downstream effectors of MEK5-ERK5 signaling 
include Forkhead box O3A (FoxO3A), Cyclin D1 (CCND 1) and Bcl-2 antagonist of cell 
death (BAD). The MEK5/ERK5 signaling cascade promotes cell survival through 
indirect phosphorylation of FoxO3A, leading to its translocation to the cytoplasm only to 
be sequestered upon 14-3-3 binding to attenuate the action of apoptosis inducing Fas 
ligand (FasL) (Wang et al, 2006). Cell survival was further sustained when ERK5 target 
p90 ribosomal S6 kinase (RSK) phosphorylated and triggered prosurvival Ca
2+
/cAMP 
response element binding protein (CREB) to transcriptionally repress the expression of 
BH3-only member BAD and prevent apoptosis induction (Finegan et al, 2009). 
Alternatively, MEK5/ERK5 activation could propel cellular growth by targeting CREB 
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protein to initiate the transcription of Cyclin D1 (CCND1) to promote G1 transition into 
S phase of mitosis in MCF-7 cells (Mulloy et al, 2003).     
To better understand the mechanism underlying MT expression and accelerated 
cell growth, cDNA microarray analysis isolated genes that displayed differential gene 
expression with MT manipulation and had an effect on tumourigeninc growth. Human 
follistatin (FST) was singled out by the DAVID bioinformatics database to be capable of 
regulating cell proliferation and hence selected for further evaluation. FST belongs to the 
transforming growth factor β (TGF- β) superfamily. This class of polypeptides is heavily 
involved in processes dictating cell physiology such as cell proliferation, differentiation 
and apoptosis (Chen et al, 2002). FST was first identified as an inhibitor of follicle 
stimulating hormone in ovarian follicular fluid. To date, its suppressive capabilities 
extend to other members of the TGF-β family, including activin and bone morphogenetic 
proteins (BMP), where their interactions have come under the scrutiny of many 
oncologists (de Winter et al, 1996; Botchkarev & Sharov, 2004; Harrison et al, 2005). 
Surprisingly, silencing of FST did not elevate cell proliferative rate in MCF-7 as 
expected.  MTT and alamarBlue assays did not register discernable difference in growth 
rate between treatment and control group. Similar observations were reported by Ogino et 
al and Ye et al, whereby dysregulation of FST had no effect on cell proliferation in lung 
and prostate cancer cell lines in vitro (Ye et al, 2007; Ogino et al, 2008). One possibility 
could be due to the lack of exogenous stimulation by growth factors. From literature 
available, FST seems to influence cell growth through its interaction with its binding 
partners, which include Activin A and BMP-7 (Chen et al, 2002; Botchkarev & Sharov, 
2004;Seder et al, 2009). In this present study, lower FST expression was accompanied by 
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a decrease of BMP-7 by plausible feedback mechanism (Ye et al, 2007). BMP-7 was 
previously shown to inhibit p38 MAPK activated proliferation of breast cancers cells in 
an estrogen dependent manner (Takahashi et al, 2008). Furthermore, expression levels of 
MEK1, MEK2, ERK1 and ERK2 remained constant throughout this study led to 
speculation that the increase in MCF-7 cell number observed here is likely to be regulated 
through MEK5/ERK5 activation by MT and occurred independent of FST. It appears that 
MEK5/ERK5 signaling might be the dominant MAPK pathway activated here in this 
study although the involvement of p38 and c-Jun N-terminal kinase (JNK) remains to be 
validated.  
MT up-regulation also suppressed the transcript expression of BCHE, MAOB and 
KLK12. This could be a counter measure acquired by breast cancer cells to defend against 
the proliferative constraints exerted by these genes. Together with acetylcholinesterase 
(ACHE), butyrylcholinesterase (BCHE) is responsible for the break down of 
acetylcholine neurotransmitters in the cholinergic synapse to terminate its stimulatory 
action (Massoulie et al, 1993). Growing evidence has shifted the focus on the non-
cholinergic functions that BCHE performs in tumour progression, causing its altered 
phenotype and expression level in carcinomas of the breast, brain and lungs (Small et al, 
1996; Johnson & Moore, 2000; Ruiz-Espejo et al, 2002; Bernardi et al, 2010). These 
include modulation of cell adhesion and proliferation in neuroblastomas and sporadic 
breast cancers respectively (Johnson & Moore, 2000; Bernardi et al, 2010). Expression of 
BCHE in final stage of mitosis has been postulated to drive cell towards postmitotic 
differentiation, thereby preventing cancer cells from re-entering the cell cycle (Layer & 
Willbold, 1995). Extra neuro-regulatory roles of monoamine oxidase B (MAOB), an 
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enzyme responsible for the catabolism of neuroactive amine has been suggested to 
contribute towards carcinogenesis (Shih & Thompson, 1999). A gene commonly 
associated with Parkinsonism and Norrie Disease, recent work by Launay et al suggested 
that 5-hydroxytryptamine (5-HT) induced MAOB reduction due to cigarette smoking 
appears to pre-dispose smokers to lung cancers (Launay et al, 2009; Shih & Thompson, 
1999; Youdim & Bakhle, 2006). Deregulation of MAOB expression also promoted the 
differentiation of Caco-2 colorectal cancer cells, resulting in its silencing via DNA 
methylation and transcriptional repression (Wong et al, 2003). In addition, inhibiting the 
activity of this mitochondrial enzyme could also preclude tumourigenic cells from 
oxidative stress and eventual death arising from the Fenton reaction (Youdim & Bakhle, 
2006).  
Likewise, Kallikrein-related peptidases 12 (KLK12) belonging to a family of 
serine proteases were altered. Expression and proteolytic activities of this group of 15 
isozymes were reported to be commonly dysregulated in tumours (Borgono & 
Diamandis, 2004). Due to their protein cleaving activity, human KLKs are expressed in 
their zymogen state and requires autolytic cleavage for activation, usually by other 
members within the KLK family, and hence postulated to form an activation cascade 
(Yoon et al, 2007). In breast cancers, KLK10 and KLK12 were determined to be down-
regulated in malignant tumours and cell lines (Liu et al, 1996; Yousef et al, 2000; Luo et 
al, 2001a; Luo et al, 2001b). While little is known about KLK12, this isoform probably 
shares a similar tumour suppressing role like its KLK10 counterpart, which experienced 
subdued level of protein expression in breast neoplasia (Liu et al, 1996). In this study, 
higher MT expression, consistent with a more malignant phenotype, was shown to 
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decrease the level of KLK12 transcript expression in MCF-7 cells. Breast cancer cells 
could potentiate tumour growth by removing potential inhibitory threat shown by the 
closely related KLK10 isozyme which was observed to limit anchorage-independent 
growth in MDA-MB231 metastatic breast cancer cells (Goyal et al, 1998).    
In contrast, chemokine CXCL12 and branch chain amino- acid transaminase 
(BCAT1) exhibited concomitant up-regulation in MCF-7 cells stably over-expressing 
MT. Chemokines are small molecular weight proteins that are capable of initiating 
divergent signaling pathways when they bind to their receptor targets. Inherently, the 
chemokine-receptor interaction can orchestrate a variety of responses ranging from 
immunologic and inflammatory responses such as leukocyte trafficking, cell survival/ 
proliferation, adhesion, haematopoiesis and angiogenesis (Sung et al, 2008). As such the 
CXCL12/CXCR4 axis is frequently manipulated to facilitate tumour progression in 
instances of breast and skin cancers (Muller et al, 2001). Neovascularization is a 
prerequisite for primary tumour growth and these cytokine-like CXCL12 proteins could 
recruit and mobilize haematopoietic, endothelial and smooth muscle precursor cells to 
angiogenic niches within the neoplastic mass (Petit et al, 2007). When CXCL12 binds to 
its target CXCR4, a G-protein coupled receptor (GPCR), triggering of the downstream 
signaling cascade can promote cell survival through the inactivation of Bcl-2 related 
protein, BAD, by phosphoinositide 3 kinase (PI3K) activated serine/threonine kinase 
(AKT) phosphorylation (Suzuki et al, 2001). Teicher and Fricker too proposed an 
increase in transcriptional activity of genes might alter gene expression survival-related 
genes and cell cycle progression following CXCL12 stimulation (Teicher & Fricker, 
2010).  
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Up-regulation of the cytosolic form of BCAT1 has been validated in many types 
of human malignancies that usually predict unfavourable outcomes (Ben-Yosef et al, 
1998; Yoshikawa et al, 2006; Zhou et al, 2007; de Bont et al, 2008; Ju et al, 2009). 
Similarly, over-expression of BCAT1 was cited in a group of nasopharyngeal carcinoma 
(NPC) patients to promote tumour growth after RNAi mediated down regulation in NPC 
cells blocked its proliferation (Zhou et al, 2007). Not surprisingly, BCAT1 is an 
important enzyme for amino acid metabolism and is responsible for the synthesis of L-
isoleucine, L-leucine and L-valine essential for cell growth (Naylor & Shows, 1980). 
However, findings by Burns and her co-workers posited a dichotomous function of 
BCAT1 in regulating cell division after in situ hybridization and Northern blot 
highlighted the plausibility of this amino acid transferase to promote cell proliferation 
and terminal differentiation in adrenal and ovarian tumours (Burns et al, 2003). 
Moreover, an inverse relationship between levels of BCAT1 expression with G1 to S 
phase transition in yeast has previously been reported (Schuldiner et al, 1996). While the 
roles of BCAT1 cell proliferation remains obscure, the possibility of these observed 
phenotypes to be a result of c-Myc signaling known to paradoxically promotion cell 
proliferation and death in cancers, could not be ruled out (Schuldiner et al, 1996; 
Yoshikawa et al, 2006).    
The roles played by candidate genes discussed are in agreement with the cell 
proliferative effect of elevated MT expression in breast cancer cells. Although the 
functional aspect of BCAT1 in regulating cell growth awaits further clarification, results 
from this study favour the hypothesis that it promotes clonal expansion in MCF-7 cells in 
association with MT. Further testing will be required to validate if these genes function 
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synergistically to contribute towards the hyper proliferative observation that high level of 
MT advocates in ductal carcinoma. Figure 4.1 provides an overview of their individual 
contributions towards the added growth advantage observed after amplified gene 
expression of MT in breast cancer cells.   
 
 
Figure 4.1 Postulated Pathways involving MT and its associated genes in the 





4.2 MT expression potentiates cell motility and metastasis in breast cancers   
 As the tumourigenic mass enlarges in size, neoplastic cells compete with normal 
cells in the surrounding tissues for space and nutrients. This might evoke a subset of cell 
to move out of the primary tumour and begin to invade adjacent tissue and subsequently 
distant anatomical sites, spawning secondary tumor (Weigelt et al, 2005; Weinberg, 
2007). These distant settlement of cancer cells or metastases are responsible for majority 
of cancer related morbidity and mortality (Talmadge & Fidler, 2010). Dissemination of 
tumour cells from site of origin to discontiguous organs is a multistep process which 
Stephen Paget proposed to follow a “seed and soil” hypothesis more than 120 years ago. 
Successful metastases are dependent on the interaction between progenitor metastatic cell 
(seed) and host organ microenvironment (soil) (Langley & Fidler, 2007). 
 Cell migration plays an important role towards initiation of cancer invasion and 
metastasis. Leslie Shaw has previously demonstrated a direct implication with regards to 
in vitro cell motility on invasive behavior in vivo (Shaw, 2005). Cell motility is a 
complex process combining polarization and extension of pseudopodia, cell attachment 
and detachment in conjunction with cytoskeletal rearrangement (Oelz et al, 2008; Ke et 
al, 2010; Parsons et al, 2010). Recent studies showed MT was capable of regulating cell 
migration in smooth muscle cells, keratinocytes and leukocytes (Yin et al, 2005; 
Morellini et al, 2008; Zbinden et al, 2010). Interestingly, a separate study by Wu et al 
identified MT-1E as novel positive regulator of cell migratory activities in human bladder 
cancer (Wu et al, 2008a). These reports suggest that MT may have a significant role in 
promoting cell motility, particularly in cancers. Furthermore, a high level of MT protein 
expression has been implicated in facilitating tumour invasive capacity and lymph node 
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metastases in breast carcinoma, as well as squamous cell carcinoma from the oral cavity 
together with head and neck regions (Dutsch-Wicherek et al, 2005; Lee et al, 2008; 
Szelachowska et al, 2009). Similarly, a combination of high MT and low p27 immuno-
expression was noted in set of gastric cancer patient with nodal metastasis (Galizia et al, 
2006). These immunohistological findings using patient samples point towards a 
correlation between high MT expression with nodal metastasis. In addition, MT produced 
by tumour associated fibroblast could co-operate with receptor binding cancer antigen 
expressed on Siso cells (RCAS1) and Vimentin (Vim) to re-sculpture the tumour 
microenvironment and facilitate the spread of cancer ( Popiela et al, 2006a; Popiela et al, 
2006b; Dutsch-Wicherek, 2010). Using gene specific primers with qPCR and reverse 
transcriptase PCR, Tai et al postulated that the MT-2A isoform might regulate the 
invasiveness of breast cancer cells, reasoning that reverting to the myoepithelial 
phenotype could confer the ability to express MMPs, tenascin and β4–integrin for 
stromal invasion (Tai et al, 2003).    
 Results from Transwell migration and in vitro Matrigel invasion assays confirmed 
the acquired cell motility associated with MT over-expression in adherent MCF-7 breast 
cancer cell line. This is a clear indication that MT has capability to induce and enhance 
migratory and invasive potential in neoplastic cell, consistent with general consensus 
cited herein. MEK5 was earlier shown to be regulated by MT expression via 
immunoblotting had a part to play in regulating cell proliferation in this study through its 
downstream kinase ERK5. This interaction proved to be important in controlling the 
expression of MMP-9 in prostate cancer, which is capable of degrading the ECM and 
compromised cellular adhesion (Mehta et al, 2003). The same authors emphasized that 
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specific activation of ERK5 by MEK5 led to an increase in AP-1 translation which 
consequently induced and activated the protein expression of this ECM remodeling 
protease. MMP-9 hyperactivity has been speculated to augment metastatic potential in 
many tumour types, including breast cancer (Sehgal et al, 1998; Stack et al, 1998; 
Scorilas et al, 2001). 
Studies showed some of MT related candidate genes might participate in the 
development towards an invasive and metastatic phenotype in cancers. The DAVID 
analysis underlined the involvement of FST in the regulation of cell motility in breast 
cancer cells. In this study, FST was experimentally verified to be regulated by MT 
expression. Eichberger and his co-workers have successfully elucidated the specific 
activation of FST gene expression by GLI2 transcription factor (Eichberger et al, 2008). 
Trace elemental Zn is an essential component of Zn fingers formation in GLI2 protein for 
DNA binding to elicit its transactivational function. The same cation is also required for 
structural stability of MT, where a competition might exist between the increased level of 
apo-MT (Zn free MT) and GLI2 without exogenous Zn supplementation in MT2AOE 
cells. Being a central regulator of intracellular Zn concentration, MT could have higher 
affinity towards the divalent cation and depleted its intracellular availability, henceforth 
disrupting and destabilizing the functions and stability of a few transcription factors 
reported previously (Zeng et al, 1991a; Zeng et al, 1991b; Meplan et al, 2000). This 
could lead to the rapid proteosomal degradation of GLI2, lowering the level of FST 
expression observed. Silencing MT in parental MCF-7 and MT2AOE cells reversed this 
suppressive observation, indicating that the possible chelation of Zn by MT was crucial in 
determining the level of FST expression.     
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Silencing of FST transcript expression using specific siRNA confirmed the 
acquired cell motility in MT2AOE cells that stably over-express MT was in part due to 
FST signaling. FST is a known antagonist of BMP-7 and real-time PCR demonstrated 
down-regulation of BMP-7 along with one of its receptor subunit BMPR-1B after FST 
silencing (Botchkarev & Sharov, 2004). The same phenomenon was observed by Ye and 
colleagues, who later discovered a concomitant increase in cell motility in PC-3 prostate 
cancer cells as result of reduced BMP-7 expression (Ye et al, 2007). A plausible feedback 
mechanism was suggested by the same group to be the underlying rationale for decreased 
levels of FST, BMP-7 and BMPR-1B observed. In this current set of experiments, lower 
level of BMP-7 expression too coincided with enhanced cell migratory and invasive 
potential in MT over-expressing cell supporting its role as a suppressor of epithelial to 
mesenchymal transition (EMT) (Na et al, 2009). EMT is an important event during 
embryonic development that has been adopted by cancer cells to promote metastasis, 
where epithelial cells become fibroblast-like to achieve local invasion and distal organ 
colonization ( Thiery, 2002; Huber et al, 2005; Yang et al, 2006). When BMP-7 binds its 
receptor comprising of heterodimerization of type I (BMPR-1A, BMPR-1B) and type II 
(ALK2) subunits, it is capable of signaling through the ALK2 component to reverse the 
process of EMT and markedly decreased mesenchymal marker expression such as Slug, 
Snail, SMA, and TWIST in metastatic melanoma cells (Botchkarev & Sharov, 2004; Na et 
al, 2009). As a result, migratory and invasive activities were abolished due to exogenous 
BMP-7 introduction. Romero and her co-workers also noted a similar observation when 
BMP-7 interacted with ALK2 in prostate cancer cell, leading to phosphorylation of 
endoglin which was demonstrated to curtail overall cell migration (Romero et al, 2010). 
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This effect operated independent of the canonized SMAD pathway activation cascade 
(Botchkarev & Sharov, 2004; Chen et al, 2004; Alarmo & Kallioniemi, 2010). While 
ALK2 did not exhibit significant fold change to be detected by genomic screening in the 
present study, a decrease in BMPR-1B will generally lower the amount of functional 
receptors available to elicit the effect of BMP-7 signaling, coupled to reduced BMP-7 
expression by FST antagonism. Outcomes of BMP-7 signaling were previously reported 
to be both anti-tumourogenic and protumourigenic (Tu et al, 2003). Botchkarev and 
Sharov speculated that the specificity BMP-7 related pathway was due to coupling 
partners of BMP-7 receptors and the sequential manner by which they heterodimerize 
(Botchkarev & Sharov, 2004). This may hold key to the downstream effectors that were 
activated and account for the varied responses reported thus far.      
Two reports have also identified the capability of COL3A1 to influence cell 
motility of cancerous cells in breast and lung malignancies (Yang et al, 2004; Sun et al, 
2010). Collagens belong to a family of natural occurring protein that constitutes the 
organization of the extracellular matrix component. In human, there are more than 19 
sub-types of collagens encoded by no less than 35 genes (Vuorio & de Crombrugghe, 
1990). An important component of arterial walls, type III collagen is encoded by 
COL3A1 gene, whereby a mutation in this gene underlies the molecular etiology of 
vascular Ehlers-Danlos syndrome (Germain & Herrera-Guzman, 2004; Germain, 2007). 
Abnormal level of COL3A1 expression has been reported in lung adenocarcinoma, B-cell 
lymphoma and invasive ductal carcinoma (Sakhinia et al, 2007; Turashvili et al, 2007; 
Sun et al, 2010). Roles in angiogenesis and cell adhesion are some of the oncogenic 
attributes associated with the dysregulation of COL3A1 in cancer progression (Yang et al, 
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2004; Timur et al, 2005;). Sun et al has highlighted the suppressive effects of caffine and 
its derivatives on metastasis in transformed mammary epithelial cells to be related to 
COL3A1 up-regulation while a similar inhibition on cell invasiveness was observed in 
lung cancers along with other collagen isotypes.  
 With reference to Paget‟s hypothesis, CXCL12 expression seems to be a crucial 
determinant (soil) to which the metastatic cell (seed) chose to colonize. Expression of 
CXCL12 chemoattractant directs the homing of tumour cells to the bone marrow micro-
environment to enhance their proliferation and survival as it offers sanctuary for them to 
develop (Meads et al, 2008). Other studies also demonstrated the chemotactic response of 
CXCL12/CXCR4 combination in breast cancer culminating in lymph node and lung 
metastases (Muller et al, 2001; Cabioglu et al, 2005). Chemotaxis experienced by breast 
cancer cells were likely to be the aftermath resulting from activating phosphorylation of 
focal adhesion component such as focal adhesion kinase (FAK), paxillin and proline-rich 
kinase 2 (PyK-2) (Wang et al, 2000; Zhang et al, 2001). Muller et al found a transient 
surge in filamentous actin polymerization after stimulation with exogenous CXCL12, a 
critical precondition for cell motility and migration (Muller et al, 2001). Previously, MT 
was reported to mediate leukocytes migration across a concentration gradient via GPCR 
activation (Yin et al, 2005). Taken together, it is likely that the cell trafficking 
consequence observed through MT could be effect through CXCL12/CXCR4 signaling.  
  Back in 2006, Yoshikawa et al identified BCAT1 as a potential candidate gene 
subjected to polysaccharide K anti-neoplastic regulation and proposed this enzyme to be 
a reliable marker for distant metastasis in colorectal cancer (Yoshikawa et al, 2006). 
Immunohistochemistry with BCAT1 specific antibody suggest a positive co-relation with 
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distant metastasis and intensity of immunostaining with patient samples. A separate study 
also ascertained the reliability of BCAT1 as a potential biomarker of metastasis when its 
up-regulated expression was validated in the cerebrospinal fluids of medulloblastoma 
patients (de Bont et al, 2008). Both sets of experimental outcomes reinforced the notion 
that anomalous level of BCAT1 might be implicated in the development of tumour 
metastases. More data are required to validate its functions and binding partners that 
contributed towards the dissemination of breast cancers. 
 Coherently, the combined effort of these MT linked genes facilitated the acquired 
motility in breast cancer cells as a consequence of MT up-regulation. As FST silencing 
has suggested that these genes could function independently, much remains to be seen as 
to how MT could coordinate activities of these proteins to operate cohesively so as to 
achieve the common goal of enhanced invasive and metastatic potential. While the exact 
mechanism remains unclear, it is possible that MT could regulate the expressions KLK12, 
MAOB, BCHE, COL3A1, CXCL12 and BCAT1 at the transcription level through its 
interaction with unknown members of the transcriptional machinery. Postulated 
mechanisms involving the respective candidate genes towards the promotion of the MT-









Figure 4.2 Schematic representation of the postulated pathways involving MT and 
its candidate genes towards regulation of cell proliferation and motility in MCF-7 
cells.
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4.3 Significance of cell-in-cell formation in adherent MCF-7 after MT-2A silencing 
 
Cell-eating-cell is a process that constantly takes place within the tissue 
microenvironment. While cell engulfment is not uncommon, it is relatively exclusive to 
phagocytic cells engaging pathogenic and host cells respectively in a heterogeneous 
manner during bacterial infection and events of cell death (Ip et al, 2009; Overholtzer & 
Brugge, 2008; Tsolaki, 2009). The eventual outcome is a cell-within-cell manifestation 
which was first coined by Humble et al as emperipoleisis (Humble et al, 1956). As early 
as 1925, Warren Lewis documented an intriguing occurrence of the cell-in-cell phenotype 
when he observed large mononuclear white cells living within identical host cells in frogs 
(Lewis, 1925). Similar observations were reported by others in a homotypic fashion in 
various types of cancerous cells from lung, breast, skin, bladder and lower genital tract 
(Abodief et al, 2006; Brouwer et al, 1984; Fais, 2007; Kojima et al, 1998; Ng et al, 
2003).   
For a long time, researchers have attempted to elucidate the molecular mechanism 
and significance of the cell-in-cell formation and this has led to the inception of 
synonymous terms such cytophagocytosis, cannibalism, and much recently, entosis 
(Humble et al, 1956; Overholtzer & Brugge, 2008). In non-disease state, the 
physiological significance of a cell being internalized into another cell as suggested by 
Overholtzer et al included the maturation and differentiation of thymocytes and B cells 
within thymic nurse cells and follicular dendritic hosts respectively. Factors that led to 
the occurrence of this cell-in-cell phenomenon in a tumourigenic environment and its 
function remain largely unknown.  
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A common sighting amongst pathologists, it was not until 2007 that a pathway 
governing this cell-invading-cell event in matrix independent breast cancer cells was 
proposed. In the report, Joan Brugge and her colleagues described a new cell 
internalization process where a live epithelial cell could be engulfed by a neighboring 
host cell (Overholtzer et al, 2007). They termed this process “entosis”, which is derived 
from the Greek word entos, which means “inside”, “into” or “within”. Using a host of 
microscopy techniques, the authors demonstrated that human mammary epithelial MCF-
10A cells in suspension cultures could internalize into or invade neighboring cells. They 
further observed that the process involved cadherins and formation of adherent junctions. 
Other than MCF-10A cells, four out of nine tumor cell lines (including MCF-7 breast 
cancer cells) were observed to have the propensity to undergo entosis following matrix 
detachment. A similar observation was made in cultures of human small cell carcinoma 
of the lung more than two decades ago by Brouwer and colleagues who called the 
phenomenon “cannibalism” (Brouwer et al, 1984). In both instances, the majority of the 
interiorized cells underwent cell death eventually, even to the extent of causing 
autodestruction of all cells within the culture. 
Likewise, light and transmission electron microscopy also revealed the presence 
of “a cell within another cell” cytological feature, a hallmark of entosis as defined by 
Brugge and co-workers, following successful silencing of the MT-2A gene and down-
regulation of the MT protein (Overholtzer et al, 2007). Interestingly, degradation of the 
residing cell by a lysosome was also observed. Internalized cells have been previously 
documented to predominantly die although some may be released back into the culture 
(Overholtzer et al, 2007). Generally, cell death is known to occur by either necrosis or 
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apoptosis. Hallmarks for apoptosis include prominent nuclear changes such as chromatin 
condensation and nuclear fragmentation which are absent in necrotic cell death. Recently, 
there has also been an emerging interest in autophagy (which is characterized by the 
presence of autophagic vacuoles) as a survival mechanism and yet at the same time, an 
alternative form of cell death under certain circumstances (Wu et al, 2008b).
 
However, 
alteration in autophagy-associated genes was not detected following silencing of the MT-
2A gene, ruling out the possibility of an autophagic cell death event causing the cell-in-
cell manifestation reported here. Moreover, it was also reported that the fate of entotic 
cells is predominantly non-apoptotic cell death mediated by lysosomes which concurred 
with our experimental findings (Overholtzer et al, 2007). Alamarblue and MTT assays 
demonstrated decreased cell viability following MT-2A silencing, whereby death of these 
MT-2A silenced cells was largely attributable to apoptosis (Lim et al, 2009). Surprisingly, 
this study further showed a subset of these cells (2%) has chosen the entotic way to die 
instead. Entosis along with apoptosis could possibly be tumor suppressor mechanisms as 
both processes promote elimination of cancer cells (White, 2007). 
Entosis was reported to be dependent on the activity of Rho and its downstream 
effector ROCK (Overholtzer et al, 2007). Actin polymerization coupled with myosin II 
activity which could mediate cell internalization are known to be regulated by Rho 
signaling. However, ROCK gene transcripts did not appear to be dysregulated in MT-2A-
silenced MCF-7 breast cancer cells, suggesting the presence of an alternative mechanistic 
pathway for entosis in MT-2A-silenced cells. While adherent junctions appears to be 
involved in cell-in-cell formation evidenced by immunofluoroscent staining, it is still not 
clear how MT-2A interacts with other cytoskeletal components to induce the cell “eating” 
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and “invading” process. One possibility is through the interaction of MT-2A protein with 
cations, thereby regulating cation homeostasis. MT is known to bind zinc and copper ions 
endogenously and the MT-2A isoform could in turn facilitate the formation of the cell-in-
cell phenotype, a notion supported by Xia and colleagues, who suggested that 




 may be crucial to affect actin 
polymerization in filopodia and cytoskeletal re-modeling in entosis and emperipoleisis 
(Xia et al, 2008).  
The „cell-eats-cell‟ phenomenon in anchorage-dependent cells probably mirrors 
cell cannibalism found in primary breast cancer and other tumors more closely than that 
seen in suspension cell cultures, as multi-layered cells in tissues are interconnected with 
one another (Abodief et al, 2006; Overholtzer et al, 2007). Entosis has been proposed as 
a suppressive mechanism which limits tumor growth. The observation that down-
regulation of the MT protein, which is known to enhance cell proliferation and inhibit 
apoptosis, induces entosis supports this perception. A further understanding of the 
biological process of entosis may provide novel therapeutic approaches in the fight 
against cancer. 
 
4.4 Clinico-pathological significance of MT expression in invasive ductal carcinoma  
 Results from in vitro experiments conducted in this study clearly indicated the 
capability of MT to influence cell proliferation and motility in MCF-7 breast cancer cells. 
To demonstrate the clinical significance of these findings, MT expression was determined 
in samples obtained from breast cancer patients. Through the use of gene specific 
primers, MT-2A transcript expression was assessed in cDNA samples representative of a 
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cohort of 48 female patients with ductal carcinoma of Caucasian ethnicity. Quantitative 
PCR validation showed a direct association between higher MT-2A expression and the 
percentage of tumorigenic cells present in the biopsy sample from which the RNA was 
extracted from. The anomalous expression of MT in the ductal cells was postulated to be 
a hallmark of neoplastic transformation (Schmid et al, 1993). MT-2A was previously 
described to be the most abundant MT isoform expressed in breast cancers with 
demonstrated abilities to promote cell proliferation and inhibit apoptosis (Abdel-Mageed 
& Agrawal, 1997; Jin et al, 2002; Tai et al, 2003). Taken together, it is not surprising that 
cancerous cells could exploit these traits of MT-2A to their benefit and therefore, 
explaining its up-regulated expression in majority of the cells within the neoplastic 
lesion. In addition, tumour promoting capability of MT-2A was further illustrated when 
elevated level of MT-2A was found to co-relate with increased tumour staging. To the 
author‟s knowledge, this is the first instance where MT-2A exhibited statistically 
significantly association with breast cancer staging, an indicator of cancer severity, 
suggesting the importance of this isoform towards metastatic development in breast 
cancers. Besides, high level of MT-2A expression might predict an unfavourable 
prognosis in patients with Stage 3 and 4 disease.    
Expression of MT was also evaluated with various clinicopathological parameters 
in breast cancer tissue in the current study. Using the E9 clone antibody, 
immunohistological analyses revealed that intensity of MT immuno-staining was 
validated to co-relate with associated DCIS parameter. High overall (nuclear and 
cytoplasmic) MT immunoreactivity was consistently associated with the extent of DCIS 
component within the heterogenous malignant lesion. Widely perceived to be the 
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precursor of invasive ductal carcinoma, significance of these non-invasive components of 
cancerous tissue should not be overlooked (Wiechmann & Kuerer, 2008). A study 
conducted by Evans et al concluded that DCIS with high histological grade accompanied 
by profuse necrosis has higher tendency to develop into IDC compared to those with 
well-differentiated cytonuclear morphorphological traits (Evans et al, 2001). Given its 
protective nature, MT-2A over-expression might confer these transformed cells resistance 
against apoptotic cell death and growth advantage in the early stages of breast 
carcinogenesis (Abdel-Mageed & Agrawal, 1997; Abdel-Mageed & Agrawal, 1998; Jin 
et al, 2002). This could prolong their survival while awaiting microevolution to take 
place for them to proceed to the next phase of oncogenesis (Hanahan & Weinberg, 2000). 
 Increased cytoplasmic MT staining was observed to separately associate with 
higher histological grades and extent of lymph node involvement. Consistent with 
previous observations, MT immunopositivity and tumour grade demonstrated a 
significant co-linear association (Jin et al, 2002; Yap et al, 2009). Mitotic index, a 
determinant of the Nottingham Combined Histological Grading system, was routinely 
used as a marker for cell proliferation in paraffin embedded tissue section under light 
microscopy following haematoxylin and eosin staining (van Diest et al, 2004; Elston, 
2005). The present study identified novel MT interaction with genes that were capable of 
conferring proliferative advantage to breast cancers cells of epithelial origins. As outlined 
in Figure 4.1, manipulating MT expression could allow cancer cells to break free from 
inhibitory mechanisms to achieve a hyper proliferative state through its associated genes 
such as BCHE, MAOB, MEK5, CXCL12 and BCAT1. In MT driven tumour cell 
propagation, pro-proliferative events such as transition between G1 and S phase and 
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synthesis of amino acid precursors could be complemented by concurrent prohibition on 
cell death and differentiation machineries to achieve this proliferative outcome. On the 
other hand, intensified MT cytoplasmic content was observed to be positively associated 
with lymph node metastasis. Previously, Yin et al noticed the ability of MT to influence 
the migratory pattern of leukocytes through a concentration gradient, highlighting its 
capability to direct cell trafficking (Yin et al, 2005). Herein this study, genome wide 
analysis unveiled MT regulated genes that might participate in mediating this 
chemoattracting phenomenon, particularly the CXCL12/CXCR4 axis that has been cited 
for guiding nodal metastasis in human breast cancer (Cabioglu et al, 2005). Over-
expression of MEK5 could induce the increased secretion of MMP-9 to degrade ECM 
and compromised cell adhesion (McCawley & Matrisian, 2000; Mehta et al, 2003). In 
addition, perturbation to inhibitory effects of BMP7 and COL3A1 could aid cell 
migratory movement in metastatic progenitor cells, polarizing them towards 
intravasation. Pathways positing MT mediated breast cancer metastases have been 
depicted in Figure 4.2.  
Intriguingly, MT immunostaining did not manifest a significant relationship with 
cancer staging illustrated using human breast cancer gene expression cDNA panel. The 
incapability of E9 antibody to differentiate between MT-1 and MT-2 isoforms during 
immunohistochemical analyses might have masked the association that could be MT-2A 
specific. MT expression was consistently observed to be independent of patients‟ age and 
tumour size (Bay et al, 2006; Yap et al, 2009). Absence of the inverse relationship 
between ER content with MT expression was evidently due to the use of the E9 antibody 
as the effect appeared to be MT-1E specific (Friedline et al, 1998; Jin et al, 2000). In this 
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study, MT immuno-expression also showed no association with patients‟ ethnicity, PR, 
HER2 and local recurrence.             
From this study, aberrant MT expression seems to play delineated functions in 
different phases of breast cancer development. While elevated levels of MT expression 
noted in the pre-invasive DCIS was inclined to gear transformed cell towards 
uncontrolled propagation, increased MT expression in invasive ductal carcinoma could 
prime malignant cells towards metastasis. Furthermore, association of MT expression 
with histological grades and lymph node metastasis highlights the ability to predict 
disease outcome (Ignatiadis & Sotiriou, 2008). The results corroborate some of the in 
vitro findings and could substantiate the potential of MT to be a biomarker of tumour 

















































5. Conclusion and future studies 
Breast cancer is fast growing disease in many countries. As the level of awareness 
for this mammary gland disorder is raised globally, more women are stepping forward to 
go for routine mammogram screening, implying a foreseeable surge in the number of 
breast cancer cases detected. Although the outcome need not be fatal, the physical, 
psychological and financial impacts inflicted extend beyond the patient. Better 
understanding of this illness will equip healthcare workers with knowledge to combat it 
and provide a glimmer of hope for breast tumour stricken females. From the perspective 
of MT, novel findings from this study will provide the groundwork for better 
understanding of breast carcinogenesis.  
In conclusion, this is the first study to show a possible synergism between MT-1X 
and MT-2A isoforms in breast cancer development through genomic analysis. Although 
the functional significance of MT in cell proliferation and migration/metastasis has been 
clearly demonstrated, assessements could be conducted to further validate the influence 
of MT on breast cancer cell viability through entosis.  This could be achieve through 
immunofluorescent staining for lysosomal cell death markers such as membranal protein 
LAMP1 and capthesin B protease, as well as a secondary assay to validate attenuated cell 
proliferation through BrdU incorporation. Moreover, involvement of ROCK could be 
further evaluated through Western blot analysis using specific antibodies targeting this 
class of kinases. This study has also elucidated putative mechanisms by which aberrant 
MT expression could contribute towards the aggressiveness of breast cancers, re-iterating 
its role in breast cancer progression. MT could possibly potentiate the invasiveness and 
metastatic capability of breast cancer cells through the involvement of MEK5, COL3A1, 
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CXCL12, FST and BCAT1. At the tissue level, the association of MT with enhanced 
proliferation was reflected by an elevated mitotic index and increased metastatic potential 
by the positive correlation with lymph node metastasis.   
 
. Further validations are required to confirm the complementary role of MT-1X in 
this co-operative effort to promote ductal carcinoma progression, perhaps through the 
employment of isoform specific methodologies such as siRNAs silencing and in situ 
hybridization given the incompetency of the E9 antibody used. Downstream validation 
could be performed on the remaining candidate genes isolated from cDNA microarray to 
reaffirm their concerted effort, if any, in promoting MT induced cell proliferation and 
motility observed in this study. Through these associated genes, it will be interesting to 
investigate if anomalous MT expression affects vasculogenesis and angiogensis in breast 
cancer given the ability to recruit leukocytes reported in earlier studies. Much of the 
functionality of MT lies in its biochemistry to regulate intracellular disposability of zinc. 
Future work involving the depletion of zinc in vitro could be conducted to verify its 
importance in regulating MT-affected genes discussed in this study and how a 
combinatory therapeutic strategy could be implemented by down regulating MT 
expression and Zn supplementation to reinstate the tumour suppressing functions 
previously abolished as a result of MT up-regulation.   
 Studies involving animal models could be employed to determine the pro-
carcinogenic functions of MT towards breast cancer in vivo. Transgenic mice with altered 
MT expression could be generated to portray the systemic anomalies occurred during 
oncogenesis. Finally, MT-transfectant cells could also be introduced into suitable animal 
surrogates to model the motility of these cells and their consequential interactions with 
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key components such as ECM and the vascular systems to culminate in regional/nodal 
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